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Abstract 
 
Hereditary hemochromatosis (HH) is the most common genetic iron-overload disease 
among Caucasians, classically associated with the p.C282Y mutation in the HFE gene, 
localized at the Major Histocompatibility Complex (MHC) region in chromosome 6. 
Immunological abnormalities have been consistently observed in HH patients, namely a 
phenotype of low CD8+ T-lymphocyte numbers associated with a more severe iron-overload. 
The genetic transmission of this low CD8 trait was first associated with the inheritance of 
certain HLA alleles markers and more recently, with a SNP microhaplotype named A-A-T, in 
the context of a strong linkage disequilibrium in the region between HLA and HFE. The 
physiological mechanism how CD8+ T lymphocytes can act as clinical modifiers of disease 
susceptibility in HH was still unsolved. 
The main objectives of this thesis were: i) to study the genetic contribution of the 
MHC-class I region to the setting of CD8+ T- lymphocyte numbers and ii) to perform a 
functional approach by addressing the iron handling ability of these cells and the involvement 
of other lymphocyte proteins in cellular/systemic iron homeostasis.  
We first tested the predictive value of MHC markers on CD8 and iron phenotypes with 
studies of genotype/phenotype associations in different geographically distant HH 
populations (Porto, Portugal; Alabama, USA and Nord- Trøndelag, Norway). This study 
revealed that the microhaplotype A-A-T cannot be used as a universal predictive marker 
neither for the iron phenotype nor for the low CD8 phenotype. Moreover, the most common 
HLA haplotypes A*01-B*08 or A*03-B*07 showed different conservation patterns among the 
three populations revealing different recombination histories which reflect on the different 
genotype-phenotype associations. Because HH patients from Porto displayed the strongest 
genotype association with the low CD8 trait, this population was chosen to further 
characterize the haplotype structure in HH. Results from a high density mapping covering 63 
markers along the HLA-HFE region revealed the existence of two major haplotype groups 
(AA and CG group haplotypes) with distinct conservation patterns in both HH patients and 
controls, suggesting a selective stronger recombination suppression in AA haplotype group, 
which, in the case of HH associated chromosomes, includes the classical ancestral HLA 
A*03-B*07 haplotype. The inheritance of the HH ancestral haplotype in homozygosity 
seemed to be most strongly associated with the low CD8 phenotype supporting the 
hypothesis of a still unidentified major quantitative trait locus for that particular phenotype in 
this region. 
Regarding the mechanisms how CD8+ T cells may modify systemic iron levels, we 
evaluated the in vitro response of lymphocytes to changes in ferric-citrate (as non-transferrin- 
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bound iron, NTBI) and the NTBI retention ability of peripheral blood mononuclear cells 
(PBMCs) isolated from HH patients and from normal controls. We were able to prove that 
peripheral T lymphocytes take up and retain high levels of NTBI, preferentially the Fe3Cit3 
oligomeric species. In HH patients, the retention capacity of PBMCs was significantly 
correlated with the iron re-accumulation patterns after intensive treatment. In terms of CD8+ T 
cell gene expression, results obtained in both animal and human models of HH support a 
direct effect of HFE on the transcriptional profile of CD8+ T lymphocytes. Results from the 
transcriptional profile of CD8+ T lymphocytes in HH patients suggest that the HFE defect 
affects the homeostatic equilibrium of central and effector memory cells. In the animal model, 
HFE deficiency induced the up-regulation of several genes clustered in the functional 
categories of lymphocytes activation/differentiation pathways. The most significant result was 
obtained with the higher expression of calgranulin S100a9, a result further confirmed in HH 
patients at the gene and protein levels. 
In summary, the results obtained in the context of this thesis constitute an important 
step forward in the characterization of lymphocyte abnormalities in HH. At the genomic level, 
they reveal novel aspects of haplotype conservation that may help explain differences among 
distinct populations regarding the impact on CD8 and iron phenotypes. At the functional 
level, not only they reveal novel aspects of disease heterogeneity possibly explained by 
different NTBI retention capacity of PBMCs, but also bring into light the importance of 
S100a9 as a new molecular player interacting with HFE in CD8 lymphocyte function. 
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Resumo 
A Hemocromatose Hereditária (HH) é a doença genética de sobrecarga de ferro mais 
comum na população caucasiana, classicamente associada à mutação p.C282Y no gene 
HFE, localizado no cromossoma 6 na região do Complexo Principal de Histocompatibilidade. 
Os doentes com HH apresentam frequentemente várias anomalias imunológicas, tais como 
um fenótipo de baixo número de linfócitos CD8+ T no sangue associado a uma maior 
sobrecarga sistémica de ferro. A transmissão genética deste fenótipo (baixo número de 
linfócitos CD8+ T) foi inicialmente associado à heritabilidade de certos alelos HLA e mais 
recentemente de um outro marcador genético muito conservado na região entre os genes 
HLA e HFE, composto por 3 SNP e denominado como microhaplótipo A-A-T. O mecanismo 
pelo qual os linfócitos CD8+ T actuam como modificadores clínicos de susceptibilidade à 
doença na HH ainda estava por decifrar. 
Os principais objectivos desta tese foram os seguintes: i) estudar a contribuição 
genética da região do MHC classe I para a definição do números de linfócitos CD8+ T e ii) 
realizar uma abordagem mais funcional testando a capacidade de aquisição e modulação do 
ferro pelos linfócitos CD8+T assim como a identificação de outras proteínas expressas por 
estas células envolvidas na homeostasia do ferro a nível celular e sistémico. 
No campo da genética dos linfócitos, testámos o valor preditivo dos marcadores do 
MHC associados ao número de linfócitos e à sobrecarga sistémica de ferro através de 
estudos de associação genótipo/fenótipo em diferentes populações de doentes HH 
geograficamente distantes (Porto, Portugal; Alabama, EUA e Nord-Trøndelag, Noruega). 
Este estudo revelou que o microhaplótipo A-A-T não pode ser usado como um marcador 
preditivo universal nem para o fenótipo de ferro nem para o fenótipo de número baixo de 
linfócitos CD8+ T. Observámos que os haplótipos mais frequentes HLA-A*01-B*08 ou HLA-
A*03-B*07 apresentaram diferentes padrões de conservação entre as três populações, 
revelando diferentes histórias de recombinação que se refletem em diferentes associações 
genótipo-fenótipo. A população de doentes de HH da região do Porto conserva uma maior 
associação dos marcadores genéticos ao fenótipo de números baixos de linfócitos e por 
este motivo a sua estrutura haplotípica foi caracterizada de forma mais pormenorizada. O 
mapeamento genético de 63 marcadores ao longo da região HLA-HFE revelou a existência 
de dois grandes grupos de haplótipos (definidos por AA e GC) com padrões de conservação 
diferentes, tanto nos doentes com HH como nos controlos, sugerindo uma supressão de 
recombinação selectiva mais forte no grupo AA que inclui o haplótipo clássico ancestral da 
HH, o HLA A*03-B*07. A herança do haplótipo ancestral HH em homozigotia revela uma 
forte associação com o fenótipo de baixo número de CD8+ T apoiando a hipótese de que um 
locus responsável pela transmissão quantitativa desse fenótipo se encontra nesta região. 
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Relativamente ao estudo funcional no qual se pretendeu elucidar a forma como as 
células CD8+ T podem modificar os níveis de sistémicos de ferro, foi avaliada a resposta in 
vitro destas células à incubação com citrato de ferro (como fonte de ferro não-ligado à 
transferrina- NTBI) e a capacidade de retenção desta forma de NTBI pelas células 
mononucleares de sangue periférico (PBMCs) isoladas a partir de doentes com HH e de 
controlos. Os resultados provaram que os linfócitos T periféricos são capazes de captar e 
reter elevados níveis de NTBI, e identificámos a espécie oligomérica Fe3Cit3 como a 
molécula que os linfócitos internalizam preferencialmente. Em doentes com HH, a 
capacidade de retenção dos PBMC foi significativamente correlacionada com o perfil de re-
acumulação de ferro após o tratamento intensivo. Os resultados da análise da expressão 
génica nas células CD8+ T por microarray, em modelos animais e humanos de HH, suporta 
um efeito directo do HFE sobre o perfil de transcrição dos linfócitos CD8+.T. Os resultados 
da análise da expressão génica dos linfócitos CD8+ T de doentes com HH sugerem que a 
deficiência no HFE afecta o equilíbrio homeostático das células de memória central e 
efetoras. No modelo animal, a ausência de HFE resultou numa expressão diferencial de 
vários genes funcionalmente agrupados em vias de activação/ diferenciação de linfócitos. O 
gene com maior diferença na expressão entre os animais deficientes no HFE em relação 
aos controlos foi a calgranulina S100A9, que se encontrou sobre-expressa na ausência de 
HFE, um resultado confirmado nos doentes com HH ao nível do mRNA e da proteína. 
Em resumo, os resultados obtidos no contexto desta tese fornecem informações 
relevantes na exposição das anomalias nos linfócitos em doentes com HH. No campo da 
genética, foram relevados novos aspectos relativos à conservação dos haplótipos ancestrais 
que podem ajudar a explicar as diferenças encontradas na associação ao fenótipo de 
número baixo de linfócitos CD8+ T e sobrecarga de ferro entre as diferentes populações. Os 
estudos funcionais proporcionaram avanços no conhecimento da interacção dos linfócitos 
com o NTBI, revelaram a existência de diferenças na capacidade de retenção de NTBI pelos 
PBMC dos doentes com HH que podem explicar alguma da heterogeneidade clínica, e 
encontrámos uma ligação nova entre a molécula S100A9 e o HFE com potencial interacção 
na modelação da função dos linfócitos CD8+ T. 
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Iron and the immune system: hanging hands through 
history 
 
“Neither prevailing nor emerging dogmas see the 
circulation of the blood or the metabolism of iron as a 
motivating force for the development of a complex system 
of surveillance. While searching for evidence for this view, I 
came to be interested in iron as a target of surveillance by 
the immune system” 
 
Maria de Sousa, 1989 [1]  
 
Introductory remarks on the growth of knowledge of a subject are usually good 
opportunities to trace paths and highlight hallmarks considered most important for the field 
advance in a determined perspective. The interest on the relationship between iron and the 
immune system traces back to the seventies, last century (de Sousa, 1978) [2, 3], and since 
then it evolved encompassing the growing knowledge on the cellular and molecular players 
involved in iron homeostasis, in particular in the clinical model of Hereditary 
Hemochromatosis. The strong link between iron metabolism and the immune system has 
been the subject of several reviews devoted to this topic [4-7] but it is generally forgotten in 
historical reviews within the iron biology field [8, 9]. In this context, the first chapter of this 
thesis revisits a recent review on relevant historical marks in the iron biology field [8] adding 
and highlighting the concurrent hallmarks which brought together the iron biology and the 
immunology fields. A chronologic list of the selected major historical achievements is given in 
Table 1, where hemochromatosis hallmarks are highlighted in grey, and more specific 
immune related contributions are highlighted in green. 
 
The first description of an iron related disease, although not recognised as such, was 
made by Lange in 1554, when he described a frequent disease among young woman who to 
him appeared to be “sadly pallid”. The disease phenotype was a pale appearance and a 
disturbed mental state that he believed to be caused by the “filthy blood of the menses" that 
was being absorbed and moved to the head and so the patient become foolish and delirious 
[10]. In 1615 this condition was called by Jean Varandal as “chlorosis” due to the “greenish-
yellow” colour of the skin [11] but it was only identified as an iron deficient hipochromic 
anemia in 1936 [12], a long time lapse after the first measurements of iron in the blood in 
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1713 [13], or the introduction of the first red cell count in 1852 and the first 
haemoglobinometer devise in 1876 [14]. 
The term “hemochromatosis” (“hemo” for blood, “chromate” for color and “osis” for 
disease) was first used by the German pathologist Friedrich Daniel Von Recklinghausen in a 
short report published in 1889 where he reported a case of “bronze stain” in organs such as 
liver, pancreas and skin at an autopsy [15]. This term hemochromatosis was later applied to 
all cases of iron overload associated with organ damage, and assumed to be the case of the 
disease syndrome of “bronze cirrhosis and diabetes” previously described by Trousseau 
back in 1865 [16]. In 1935, Joseph Sheldon suggested that the multi-visceral nature of the 
iron overload syndrome resulted from an inherited metabolic defect [17]. In 1950 the iron-
overload patients started to be treated through phlebotomies (bloodletting) [18]. A huge 
advance on the identification of the putative gene for Hereditary Hemochromatosis (HH) was 
achieved in 1975 when Marcel Simon linked the HH syndrome with particular HLA-A and B 
alleles, placing the major histocompatibility complex region at chromosome 6 as a hotspot to 
look for the disease causing gene [19]. This link of an iron related disease with the genetic 
region involved in the immune system regulation constituted a good argument to suspect that 
the disease could be somehow immune related. At the same time, and based on her studies 
of lymphoid cell positioning demonstrating that lymphocytes migrate to areas of iron 
accumulation [2], De Sousa advanced in 1978 the postulate that the immunological system 
should have a role in monitoring tissue iron toxicity [3]. The impact of iron on the immune 
system also started at this time to be a subject of great interest after the demonstration of the 
immuno-suppressive effect of blood transfusions [20]. Altogether, evidences for this cross-
talk between iron and the cells of the immune system and the association of HH with the 
MHC, all led to concentrate efforts on the search for immunological abnormalities in HH 
patients. The first description by Reimão et al in 1991 [21] of abnormalities in the relative 
proportions of T lymphocyte subsets in HH patients related to the severity of iron overload, 
and the following demonstration that this disproportion was specifically due to defects in the 
CD8+ T cell pool [22], constituted the starting point to approach the reverse question, i.e., to 
look for iron metabolism abnormalities in experimental models of primary T lymphocyte 
immune deficiencies. As a result, the first experimental model of hemochromatosis was 
described by De Sousa and co-workers in 1994 with the study of mice depleted of the the β2 
microglobulin gene (β2m (-/-)) which were shown to develop a severe liver iron overload 
mimicking the human HH disease [23, 24]. Because it codes for an anchor protein essential 
for MHC-Class I expression at the cell membrane, β2m ablation leads to an almost complete 
depletion of CD8+ T cells [25, 26]. As extrapolated from the human model, CD8+ depletion 
could be therefore the cause for the induced iron overload. Two years later, in 1996, Feder et 
al. cloned the HFE gene (originally designated as HLA-H) where a single mutation (p.C282Y) 
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was found in the vast majority of HH patients [27]. This finding naturally removed the impact 
of the β2m(-/-) model as a proof of concept for the involvement of CD8+ T cells as modifiers of 
iron overload, because HFE, as a non-classical MHC Class I protein, also requires the 
presence of β2m to be expressed at the cell surface. This question was clarified, however, 
when Santos et al. demonstrated that mice deficient for both β2m and Rag1 (a recombinase 
activator gene required for normal B and T development) had an even more severe 
phenotype of iron overload with heart fibrosis [28]. For the following years CD8+ T 
lymphocyte abnormalities in HH were consistently found and characterized in the peripheral 
blood [22, 29-32] and in the liver [33], where low numbers were associated with a higher 
hepatic damage [33], and novel mouse models were generated with selective immune 
deficiencies to confirm the impact of lymphocytes as modifiers of iron overload [28, 34, 35]. 
The discovery of HFE was perhaps, the single research event that most significantly 
contributed to initiate the “molecular era” of hemochromatosis. From that time on, discoveries 
of novel molecular players came to explain many other rare forms of HH providing 
substantial new knowledge on the complex regulation of systemic iron homeostasis [36]. 
These findings turned the beginning of the XXI century a very exciting time for the history of 
iron biology. In 2000 the liver-expressed antimicrobial protein called hepcidin was discovered 
[37] and it was found to be downregulated in the Hfe knockout mice (Hfe-/-) [38]. After the 
description of the ferroportin and its involvement in cellular iron export, the functional 
regulation of ferroportin expression by hepcidin was established in 2005 by Nemeth and 
Kaplan [39]. Hepcidin is now generally recognised as the master regulator of systemic iron 
levels through regulation of cellular iron export. The more recent demonstration that in vitro 
activated T cells also express hepcidin in response to the exposure to transferrin-bound and 
non-transferrin bound iron support, for the first time, a functional role for T lymphocytes in 
response to iron [40]. 
A great contribution in the immuno-genetic perspective was the demonstration, in 
studies performed in HH families, that a low CD8 phenotype is genetically transmitted in 
linkage with other MHC genes namely HLA suggesting, for the first time, the existence of a 
putative genetic trait located at the MHC region implicated in the transmission of CD8 
numbers in linkage with the p.C282Y mutation [41-44]. Moving from the genetic associations 
to the functional interactions between HFE and MHC Class I proteins, an important study 
was performed by Almeida et al in 2005 first advancing the hypothesis that the mutated HFE 
interfered with the classical MHC class I presentation route [45]. 
Although HH offers the best model to address the complex interactions between iron 
metabolism and the immune system, in many other immune related conditions iron has been 
placed at the centre namely infection [46], inflammation [47] and cancer [48]. A long way 
track is still needed, however, to fully understand all the mechanisms involved in the 
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regulation of local and systemic iron homeostasis in these conditions as well as the clinical 
implications of iron homeostasis disturbances in those disorders. Most strikingly, the putative 
role of HFE in immune related conditions beyond iron overload has been remarkably 
neglected. 
 
Table 1 Time of the most important achievements in the hemochromatosis and iron 
metabolism 
Year Discovery Researchers 
1554 First description of “chlorosis” Lange [10] 
1713 Human blood show to contain iron Lemery & Geolfroy [13] 
1865 A case of “bronze diabetes and cirrhosis” is described Trousseau [16] 
1871/1882 Hypertrophic pigmentary cirrhosis and diabetes 
Troisier-Hanot & Chauffard 
[49] 
1889 
The term “hemochromatosis” is created to describe bronze-colored 
organs and tissues at autopsy 
Von Recklinghausen [15] 
1935 
Hemochromatosis is hypothesized to be hereditary and related to iron 
metabolism 
Sheldon [17] 
1937 The first iron protein (ferritin) is identified and crystalized Laufberger [50] 
1937 First study on the role of intestinal absorption in iron metabolism Widdowson & McCance [51] 
1939 Effect of iron in inflammatory joint disease Hiyeda [47] 
1946 An iron-binding protein (transferrin) is identified in human plasma Schade & Caroline [52] 
1950 Bloodletting reported as a treatment for hemochromatosis Davis&Arrowsmith [18] 
1950 Liver biopsy reported as a tool for diagnosing hemochromatosis Davids & Laurens [53] 
1951 First report of juvenile hemochromatosis 
Plattner, Nussbaumer & 
Rywlin [54] 
1951 Radioiron studies of intestinal absorption in hemochromatosis Alper & Bothwell [55] 
1955 First comprehension review on hemochromatosis Finch & Finch [56] 
1961 
Hemochromatosis as a variant of alcoholic cirrhosis and nutritional 
siderosis 
MacDonald [57] 
1963 
Intestinal iron absorption shown to be regulated at the enterocyte/blood 
interface 
Crosby [58] 
1969 Phlebotomy reported to improve survival in hemochromatosis  Williams & Sherlock [59] 
1975 
Hemochromatosis is shown to be a hereditary autosomal recessive HLA-
linked disease 
Simon [19] 
1976 First description of the transcriptional control of ferritin Zahringer & Munro [60] 
1978 Iron binding proteins add a role in the control of lymphoid cell migration De Sousa [2] 
1978 
Postulated role for the Immunological system in the surveillance of  
tissue iron toxicity 
De Sousa [3] 
1978 Demonstration of the immuno-suppressive effect of blood transfusions  Keown & Deschamps [20] 
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1978 Iron as a determining factor for microbial cell growth Weinberg [46] 
1980 
Iron & cancer: transformed cells acquire the capacity to bind iron through 
the expression of surface transferrin receptors 
Faulk [48]  
1983 
First description and characterization of iron-mediated oxidative damage 
in hemochromatosis 
Bacon & Recknagel [61] 
1985 
Survival and causes of death reported in a large series of 
hemochromatosis patients  
Niederau & Strohmeyer [62] 
1987 “Iron responsive elements” are found in the mRNA of ferritin 
Aziz & Munro - Hentze & 
Klausner [63, 64] 
1988 
First large population screening study using blood iron measures in HLA-
linked hemochromatosis 
Edwards & Kushner [65] 
1989 
Defective iron retention by reticuloendothelial macrophages is described 
in hemochromatosis 
Fillet [66] 
1989 
Generation of the immunological deficient mice model (β2-microglobulin 
knockout) that lack peripheral CD8 T cells 
Koller and Zijlstra [25, 26] 
1991 
Increased iron absorption in hemochromatosis linked to increased 
mucosal iron transfer to the plasma 
McLaren [67] 
1991 
Immunological abnormalities in HH patients: decrease CD4/CD8 rations 
of circulating T lymphocytes 
Reimão [21] 
1994 A novel correlation between CD8
+
 lymphocytes and iron overload Porto [23] 
1994 
CD8
+
 T-cell deficient mice (β2-microglobulin knockout mice ) develop a 
severe hepatic iron overload: the first mouse model of Hereditary 
Hemochromatosis 
De Sousa & Santos [23, 24] 
1996 
Identification of the gene mutated in HLA-linked hemochromatosis : HFE 
(a non.classical MHC Class I protein) 
Feder & Wolf [27] 
1997 
Divalent metal transporter 1 (DMT1)- the first mammalian 
transmembrane iron transporter is identified 
Fleming & Andrews-Gunshin 
& Hedlger  [68, 69] 
1999 
Description of non-HFE related hemochromatosis in adults (later 
identified as ferroportin disease) 
Pietrangelo [36] 
1999 Identification of transferrin-receptor 2 (TfR2) gene Kawabata [70] 
2000 Description of TfR2-associated hemochromatosis 
Camaschella & Gasparini 
[71] 
2000 Description of liver-expressed antimicrobial protein (hepcidin) in human Krause & Adermann [37] 
2000 Description of ferroportin1 (MTP-1; IREG-1) gene 
Abboud & Hailie-Donovan & 
Zon [72-74] 
2001 Description of ferroportin-associated iron overload (“ferroportin disease”) Montosi & Pietrangelo [75] 
2001 Hepcidin expression in the liver is linked to iron Pigeon & Loreal [76] 
2002 Decreased hepcidin levels in HFE null mice Ahmad & Fleming [38] 
2000-06 Documentation of the penetrance of HFE-associated hemochromatosis 
Kushner-Beutler-Olynyk-
Powell [77-80] 
2003 Description of hepcidin-associated hemochromatosis Roetto & Camaschella [81] 
2003 
Decreased hepcidin expression documented in human HFE-related 
hemochromatosis 
Bridle & Andreson-Gehrke & 
Stremmel [82, 83] 
2004 HJV gene isolated and HJV-related hemochromatosis reported Papanikolaou [84] 
2004 
Genetic transmission of Low CD8 numbers phenotype is associated  
with HLA-HFE haplotype 
Cruz [41]  
2005 C282Y mutation of HFE influences MHC class I presentation pathway Almeida [45] 
2005 
Hepcidin is shown to cause FPN1 degradation in vitro: a model for 
regulation of iron homeostasis in vivo 
Nemeth & Kaplan [85] 
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2004-06 Low progression rate of HFE-related hemochromatosis is documented 
Olynyk-Anderson & 
Nordestgaard-Allen [86-88] 
2006 HJV/BMP signaling shown to regulate hepcidin and iron metabolism Babbit &Lin [89] 
2006 A model for iron sensing based on HFE/TfR2 is proposed Goswami & Andrews [90] 
2009 ER stress controls hepcidin expression and iron metabolism in vivo Vecchi & Pietrangelo [91] 
2009 BMP6 shown to be the key endogenous regulator of iron metabolism 
Andriopoulos, Corrandi, Xia 
& Babitt-Meynard &Roth [92, 
93] 
2009 BMP6 signalling shown to be impaired  in HFE null mice 
Corradini &Babitt-Kautz 
&Roth [94, 95] 
2010 
Activated T lymphocytes express hepcidin in response to transferrin-
bound iron and non-transferrin bound iron 
Pinto [40] 
Adapted from Pietrangelo et al 2010 [8] 
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Normal Iron Homeostasis 
A healthy adult normally keeps in his body a total of 3 to 4g of iron. Since there is no 
excretory mechanism for iron, daily losses are mostly due to sweat and epithelial 
desquamation of skin, intestine and genitourinary track. In men these iron losses are of 
approximately of 1mg, but in women, due to menstruation, pregnancy and lactation, these 
losses may reach up to 2mg a day. In order to compensate for these physiological iron 
losses, 1-2mg of iron is absorbed from a normal diet which may contain 15mg of iron [96]. 
In general, the systemic iron homeostasis in humans can be monitored by the 
transferrin saturation levels. Plasma transferrin is normally about 30% saturated with iron. A 
transferrin saturation <16% indicates iron deficiency, whereas a saturation >50% can be a 
sign of iron overload. Under constant rates of transferrin production and catabolism, the 
transferrin saturation is influenced by: i) the amount of iron absorbed from the diet, ii) the 
amount of iron utilized by the bone marrow (mostly for erythropoiesis) and other tissues, and 
iii) and the amount of iron recycled and released by splenic macrophages [97]. 
The major players and mechanisms regulating systemic iron homeostasis classically 
consider four major compartments (involving particular cell types): the uptake compartment 
(enterocytes), the functional compartment (erythroid precursors and other proliferating cell 
pools), the recycling compartment (spleen macrophages) and the storage compartment 
(hepatocytes and macrophages) (Fig.1). 
The uptake of iron from the diet is mostly performed at the brush border of duodenal 
enterocytes. There are two sources of dietary iron: heme and non-heme iron, the first being 
absorbed more efficiently. Heme iron is estimated to contribute to 10–15% of total iron intake 
in meat-eating populations but because heme iron is much more efficiently absorbed, it could 
contribute to up 40% of total absorbed iron [98, 99]. Inorganic iron is less well absorbed than 
heme iron and is affected by both body iron status and by dietary enhancers (such as 
ascorbic acid) and inhibitors (for example: phytic acid, tannic and chlorogenic acids and soy 
protein) [98, 99]. Inorganic iron, mostly Fe(III), is very insoluble so in order to move across 
the enterocyte brush border membrane through the iron transporter divalent metal-ion 
transporter 1 (DMT1) it has to be reduced to Fe(II) by the duodenal cytochrome B (Dcytb) 
reductase and possibly by others reductases. Enterocyte iron is exported to the blood via 
ferroportin 1 (FPN1), also known as solute carrier family 40 member 1 (SLC40A1) which is 
the only known iron exporter in mammals. With expression on the basolateral membrane of 
enterocyte, FPN1 acts in partnership with the ferroxidase hephaestin that oxidizes exported 
ferrous iron to Fe(III) for binding to plasma transferrin [100]. After being exported by the 
enterocytes, iron circulates in plasma bound to the glycoprotein transferrin which has two 
high-affinity binding sites for Fe(III). Transferrin-binding maintains Fe(III) in a safe soluble 
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form, and is the major source of iron to cells that express the membrane receptor (transferrin 
receptor, TfR1) whose complex is internalized by endocytosis in order to fulfil cellular iron 
needs [97]. Non-transferrin-bound iron (NTBI) species begins to be present in the circulation 
and to be accumulated in parenchymal cells leading to organ damage even before transferrin 
becomes fully saturated [101, 102]. NTBI is bonded with low molecular weight ligands such 
as ATP, AMP, citrate, phosphate, lactate, acetate, carbohydrates and amino acids as well as 
albumin [102-104]. 
The functional compartment involves mainly the erythroid precursors that use 75% of 
the systemic iron fraction to incorporate the heme group, responsible for oxygen transport. 
These cells acquire transferrin-bound iron via TfR1, but it is also proposed that these cells 
can take up ferritin that macrophages release in erythroblastic islands [105]. Iron is also an 
essential nutrient for many cellular functions such as: energy production in the mitochondria, 
DNA synthesis and the production of myoglobin in the muscles. It is also a co-factor of 
several iron-requiring metalloenzymes such as catalase, hydrogenase or aconitase [106]. 
The majority of the iron found inside the cell (95-97%) is bound to transferrin and ferritin 
[107]. However, a free labile iron pool (LIP) fraction that corresponds to 3-5% of total iron 
content can also be found inside the cells. This LIP is mostly low–molecular weight 
chelatable iron, either Fe(II) or Fe(III), associated with a variety of ligands such as: citrate, 
phosphate, carbohydrates, nucleotides and nucleosides among others. This labile iron pool 
is the major source of oxidative stress by participating in the Haber-Weis-Fenton’s reactions 
that originates free radicals that cause damage to all macromolecules (lipids, proteins and 
DNA) [108]. The amount of iron that is not used can be either stored inside ferritin, or can be 
exported by FPN1 [109]. 
The recycling compartment is composed by the reticuloendothelial system (spleen 
and liver macrophages) that recycle every day 20–25 mg of iron from the turnover of 
senescent erythrocytes. This recycled fraction of iron is the main source for functional iron 
needs. Senescent red blood cells are phagocytosed and iron is transported from the 
phagocytic vesicles to the cytosol by NRAMP1 (natural resistance-associated macrophages 
protein 1) that is a DMT1 homolog transporter [110]. Export of ferrous iron from 
macrophages occurs via FPN1 which interacts with ceruloplasmin (a multicopper oxidase) 
which oxidases Fe(II) to Fe(III) for loading onto transferrin [97]. Since the amount of plasma 
iron is just over 10% of the amount used daily, this implicates that plasma iron is turned over 
many times each day. Under normal conditions, 80%–90% of the recycled iron is reused for 
hemoglobin synthesis [111]. The remaining 10%–20% of the recycled iron is stored inside 
the macrophage as ferritin. 
Like the reticuloendothelial cells, hepatocytes are also an important site of iron 
storage in the form of ferritin. Hepatocytes are the major storage compartment for iron; they 
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become particularly important when the iron-binding capacity of plasma transferrin is 
exceeded as they can rapidly clear the NTBI species formed from circulation. The identity of 
the hepatocyte NTBI uptake system is not known, DMT1 was pointed as important NTBI 
transporter [112, 113] however, hepatocytes can accumulate iron in the absence of DMT1 
[114]. Therefore, other potential candidates include: the L-type voltage-dependent Ca2+ 
channels [115, 116], and the already identified for their ability to transport other metal ions, 
the Zip-14 [117]. Most importantly, hepatocytes play a central role in iron homeostasis as the 
site of regulated production of the hormone hepcidin. Hepcidin is the master regulator of 
systemic iron levels. It orchestrates systemic iron fluxes and controls plasma iron levels by 
binding to FPN1 on the surface of iron-releasing cells, triggering its internalization and 
degradation and therefore reducing iron transfer to transferrin [85]. Systemic hepcidin levels 
regulate the amount of iron that is exported into circulation by the enterocytes, therefore its 
expression gives feedback of systemic iron status for regulation of dietary iron absorption. 
 
 
 
In terms of cellular iron homeostasis, the uptake and storage of cellular iron is 
regulated by a post-transcriptional mechanism involving mRNA-protein interactions – the 
IRE/IRP system. Iron responsive elements (IRE) are 30 nucleotide cis-regulatory structures 
present in the 3’ or 5’ untranslated region (UTR) of mRNAs, that code for iron metabolism 
proteins. Iron regulatory proteins 1 and 2 (IRP1 and IRP2) are cytoplasmatic and belong to 
Fig. 1 Iron distribution in the adult human body and the four major compartments 
involved in the processes of iron uptake, storage, recycling and functional involved in 
iron homeostasis with the principal cellular players. 
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the protein family of Fe-S cluster isomerases. The IRE-IRP regulatory system is based in the 
ability of cytosolic IRP to affect the stability of a previously synthesized mRNA, or to alter the 
efficiency with which a given transcript is translated [118-121]. 
 
 
Fig.2 Regulation of cellular iron metabolism: the IRE/IRP system. 
 
Under iron-deficient conditions, IRP1 is free to bind to IREs. If IRP-1 binds to the 5′ 
UTRs of target mRNAs it inhibits their translation (such as ferritin and ferroportin mRNAs), 
whereas IRP interaction with multiple 3′ UTR IREs results in increased mRNA stability (such 
of the TfR1). As a consequence, TfR1-mediated iron uptake increases and the iron storage 
in ferritin and export via ferroportin decrease, thus LIP content increases in order to fulfil the 
cell iron needs [97]. Under iron-loaded conditions, IRP1 is inactivated by assembling 4Fe/S 
cluster at the IRE-binding site that confers aconitase activity to the holoprotein. IRP1 and 
IRP2 are then signalled by the FBXL5 iron-sensing F-box protein and recruits the SKP1-
CUL1 E3 ligase complex that promotes IRP ubiquitination and degradation by the 
proteasome (Fig.2). 
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Hereditary hemochromatosis: an iron-overload disorder 
Hereditary hemochromatosis (HH), classically associated with the p.C282Y mutation 
in HFE, is an autosomal recessive disease that predisposes patients to an increased 
intestinal iron absorption and iron export from macrophages, resulting in progressive tissue 
iron overload which leads to irreversible organ damage if not treated timely. The pancreas, 
skin, joints and mostly the liver are the main target sites for iron deposition which leads to 
organ failure through production of oxidant species. Early symptoms are non-specific such as 
fatigue, arthralgia, malaise, abdominal pain, etc. The principal severe clinical manifestations 
associated with iron overload are: liver cirrhosis, hepatocellular carcinoma, diabetes and 
arthritis. These consequences can be avoided if HH patients are early detected and start a 
therapeutic phlebotomy treatment. Early diagnosis, i.e., before the onset of irreversible organ 
damage, and prompt initiation of iron-depletion therapy prevents irreversible organ damage, 
and increases the survival of patients with hemochromatosis [122]. A proper follow-up of 
circulating iron parameters, such the serum ferritin levels (that reflect the iron stores) and the 
transferrin saturation (that indicates the amount of potential NTBI in circulation), aimed at 
keeping them at normal levels, offers these patients a life expectancy similar to that of a 
normal population. 
An early diagnosis of HH may be difficult if only based on its clinical context, without 
any familiar related history. To confirm an iron-overload condition, measures of some 
biochemical blood parameters are highly informative although not 100% specific. Transferrin 
saturation above 50% in females or 60% in males is abnormal and suggestive of HH, 
although other liver pathologies have to be discarded such as alcohol or viral liver disease. 
The serum ferritin concentration is usually a good marker of body iron stores although 
increased levels are also observed in inflammatory conditions and in hepatocellular necrosis. 
Once there is a strong suspicion of HH, i.e., in the presence of suggestive biochemical 
abnormalities not explained by other conditions, a genetic diagnosis should be done, based 
on the detection of the p.C282Y mutation in HFE.  
 
HFE: the gene and its mutations  
The HFE gene codes for a 343 residue type I transmembrane glycoprotein 
homologous to Class I MHC molecules (it shares 37% of sequence identity with the HLA-A2). 
HFE has three extracellular domains analogous of α1, α2 and α3 domains of a MHC-I 
immunoglobulin (Fig.3). In contrast with the classic MHC-class I molecules, the α1 and α2 
domains are not-polymorphic and too narrow to accommodate a short peptide. Given this 
structural limitation, HFE is believed not to present antigens to T-lymphocytes. As with any 
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other MHC-I classical protein, HFE folding occurs in the endoplasmatic reticulum (ER), 
where its α3 domain interacts with the Class I light chain β2-microglobulin (β2m). The 
correctly folded protein leaves the ER and is presented at the cell membrane. HFE is 
predominantly expressed at duodenum, liver, pancreas, placenta, kidney, reticulo-
macrophagic system and ovary, while in colon, leukocytes, brain and lung the expression is 
low. Two common missense mutations were originally described by Feder et al, in the HFE 
gene; the p.C282Y and the p.H63D. The p.C282Y mutation is a single-base substitution of a 
guanidine to an adenine at nucleotide 845, resulting to the substitution of a tyrosine for a 
cysteine at amino-acid 282. This mutation provokes the disruption of the α3 domain 
intrachain disulfide bond with β2m (Fig.3) and so the molecule cannot migrate to cell surface 
and stays trapped in the ER following proteasomal degradation. The p.H63D mutation is a 
substitution of a cytosine to a guanidine at nucleotide 187, resulting in a substitution of an 
aspartate for a histidine at amino-acid 63. This mutation occurs in α1 domain and does not 
affect the ER folding, migration and presentation of the protein at cell membrane although it 
can slightly change the affinity of transferrin to its receptor [27]. According to the most recent 
clinical guidelines (EASL 2010), only the p.C282Y mutation in homozygosity confirms the 
diagnosis of HFE related HH [123]. The role of p.H63D as a risk factor for iron overload is still 
debated [124, 125]. 
 
Fig. 3 HFE molecular structure (non-classical MHC Class I 
molecule) with the HH associated mutations represented in red. 
 
HFE: the molecular functions in iron homeostasis 
Hepcidin expression is normally up-regulated by dietary or parenteral iron loading 
[76], in order to systemically feedback the enterocytes to limit intestinal iron absorption. In 
HH, this mechanism fails. In some patients the hepcidin levels may be at normal levels but 
they are still inadequately low for the amount of iron load [126, 127] and they do not respond, 
with increasing hepcidin levels, after an acute oral iron challenges [126]. Because this 
expected up-regulation of hepcidin in response to iron loading is impaired in patients with 
HH, HFE is expected to be involved in the regulation of hepcidin expression. 
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HFE has been suggested be an “iron-sensor” acting by switching between two 
sensors of the Tf-Fe levels, TfR1, and TfR2, on the plasma membrane of hepatocytes [90]. 
This model is supported by the following findings: HFE binds to TfR1 competing with Tf-Fe 
for the receptor binding site. By contrast, TfR2 can bind both HFE and Tf-Fe simultaneously 
[128]. The HFE–TfR1 functional interaction gained new insight from experimental mouse 
models generated either to promote or abolish this complex. The results from mice with 
constitutive expression of HFE-TfR1 complex were very similar to the HFE-deficient mice 
who show low hepcidin production and systemic iron overload suggesting that the TfR1 
sequesters HFE to prevent its participation in hepcidin activation. Conversely, mutations that 
abolish the HFE-TfR1 interaction or mice with increased HFE levels display iron deficiency 
due elevated hepcidin expression [129]. Hepcidin activation by holotransferrin requires both 
HFE and TfR2 [130]. Altogether, the described observations support a model in which high 
concentrations of Tf-Fe2 displace HFE from TfR1 to promote its interaction with TfR2, which 
is further stabilized by increased Tf-Fe2 binding to the lower-affinity TfR2. More recently 
another partner was added to HFE-TfR2complex, the hemojuvelin (HJV). The HJV protein 
acts as a BMP (Bone morphogenic protein) co-receptor, thereby activating hepcidin 
transcription via the BMP-SMAD signaling cascade. BMP6, which is activated by increased 
iron levels, is the endogenous ligand for HJV [92, 93]. Moreover, the BMP/SMAD signaling 
pathway is impaired in HH as well as in Hfe-knockout mice, suggesting a crucial role of HFE 
in BMP/SMAD signalling [131]. 
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T-Lymphocytes Homeostasis 
The ability to maintain T cell homeostasis allowed vertebrate organisms to produce 
an effective immune response. In order to maintain that immune responsiveness, distinct 
lymphocytes populations with different immune functions must also be maintained in 
equilibrium [132]. The lymphocytes TCRαβ are originated from lymphoid progenitor cells, 
haematopoietic stem cells originating from the bone marrow that home to the thymus. In the 
thymus a complex process of maturation it will occur which involves the recognition of MHC 
Class I molecules by the T cell receptors (TCR) and the submission to positive and negative 
selection which result in the production of CD4+ or CD8+ single-positive T lymphocytes [133]. 
From the thymus, single positive T lymphocytes migrate in a naïve state to the peripheral 
organs, where they circulate between the secondary lymphoid organs and the blood [134]. 
The pool of T-cells that present in the periphery consists of naïve CD4+ and CD8+ T cells, 
central memory (CM) and effector-memory (EM) subpopulations, each occupying a specific 
homeostatic niche [135]. CD4+ Treg and TH17 CD4+ effector T cells constitute an 
independent pool of cells occupying separate homeostatic niches [136, 137]. 
The peripheral T cell population is conserved at very constant numbers. The numbers 
of naïve T cells at the periphery is dependent on the stimulation of T cells through their 
TCRs. When peripheral major histocompatibility complex (MHC) class I or class II expression 
is absent, T cells are unable to survive due the lack of TCR-mediated T cell stimulation [138]. 
Also, induction of TCR deletion results in the disappearance of peripheral T cells, showing 
that T cells need to receive signals through their TCR to support their survival in the 
periphery [136]. Naïve T lymphocytes travel to T-cell areas of secondary lymphoid organs in 
search of antigen presented by dendritic cells [139, 140]. Once activated, they start to 
proliferate and give origin to effector cells that can migrate to B-cell areas or to inflamed 
tissues [141, 142]. A fraction of primed T lymphocytes persists as circulating memory cells 
that can confer protection and give, upon secondary challenge, a qualitatively different and 
quantitatively enhanced response [143, 144]. 
 
The differentiation process of T lymphocytes 
 
When peripheral naïve T cells return to lymph nodes, they first roll on high endothelial 
venules using CD62L (L-Selectin). This allows the chemokine receptor CCR7 to engage its 
ligand SLC (secondary lymphoid-tissue chemokine), which is displayed by endothelial cells 
[145]. The CCR7–SLC interaction activates integrins that promote firm adhesion and 
transmigration of the T cells into the lymph node [146, 147]. In contrast to naïve T cells, 
memory/effector cells migrate mostly through peripheral tissues [148]. This migration allows 
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a quicker response and is controlled by the expression of different sets of integrins and 
chemokine receptors [139, 149]. Some memory T cells must also reach the lymph nodes 
when they need to trigger a secondary proliferative response. The two types of memory 
response might depend on subsets of memory T cells produced with distinct homing and 
effector capacities. Because CCR7 and CD62L are essential for lymphocyte migration to 
lymph nodes [139, 150], the co-expression of these receptors helps to distinguish a 
supposed subset of memory T cells that home to lymph nodes. Human naïve and memory T 
cells can be identified by the reciprocal expression of the CD45RA or CD45R0 isoforms 
[151]. Staining of peripheral blood T cells with antibodies to CD45RA and CCR7 revealed 
three subsets of CD4+ and CD8+ cells: one naive CD45RA+CCR7+; and two memory subsets, 
CD45RA-CCR7+ and CD45RA-CCR7-. Both naïve and CCR7+ memory cells expressed high 
levels of CD62L, whereas the CCR7- memory cells expressed CD62L to a lower and variable 
extent. Within CD8+ T cells, an extra subset of CD45RA+CCR7- cells can be identified. In 
addition, the two CCR7+ subsets expressed high levels of CD62L, whereas most of the cells 
among the two CCR7- subsets lacked CD62L (Fig.4). The expression of the receptors 
responsible for lymph-node-homing on a distinct subset of memory CD4+ and CD8+ T cells 
points out different functions [135]. 
 
Fig. 4 T-Lymphocyte phenotype (Naïve, Effector, Central memory and Effector memory) 
with some cell membrane markers expressed accordingly the specific differentiation state.  
 
T cell activation and gene expression profile of activation 
 
Naïve T lymphocytes that survive to the apoptosis process become memory or 
effector T cells through a differentiation process that involves alteration in expression of 
membrane receptors and/or intracellular cytokines. After activation, the receptors that are 
expressed work as differentiation markers such cytokine receptors and growth factors, for 
example: α chain of IL-2 receptor (CD25), β chain of IL-12 receptor, the transferrin receptor 
(CD71) and the insulin receptor (CD220). Most of these receptors are involved in the cell 
cycle control and nutrient transport to fulfil the needs of the cell in its division process. While 
some of these receptors are immediately expressed after activation (for example, CD69 and 
CD25) others are expressed days after activation (for example CD71). Some other receptors 
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decrease or even abolish their expression after activation, an example of these are: CD62L 
integrin, CCR7+ receptor and the ζ TCR chain. During the activation and expansion process, 
naïve T lymphocytes stop expressing at different stages of the differentiation process the 
CD62L, CCR7 and CD28 receptors giving rise to effector or memory T cells (Figure 4) [152, 
153]. 
Another very specific and heterogeneous TCRαβ lymphocyte subset of either CD4 or 
CD8 activated cells is defined by the expression of IL-2 receptor α chain (CD25) and the 
transcription factor Foxp3 and are called as regulatory or Treg cells. The Treg lymphocytes 
are able to suppress the immunological response mediated by other T cells and can be 
divided in two major groups: the natural and the inductive or adaptive Treg. The natural Treg 
are CD4+CD25+ (characterized by protein expression of CTLA-4 and Glucocorticoid induced 
TNF receptor, GITR) and are produced in the thymus under specific signals. The adaptive 
Treg can be CD4+CD25+, CD8+CD25+ or CD8+CD28- and are produced in the thymus but 
differentiate at the periphery under certain stimulatory factors such as IL-10 and TGF-β [154]. 
 
Final remarks on the homeostatic control of CD8+ T lymphocyte 
subsets at the periphery 
 
As discussed above, multiple regulatory mechanisms operate for the maintenance of 
T cell numbers and functions under a strict homeostatic equilibrium. These mechanisms are 
known to operate in an independent manner for the different subsets of naïve or memory 
effector T lymphocytes [155]. While naïve T cells persist mainly as long-lived resting cells, 
memory cell survival depends on their constant self-renewal by triggering and cell division at 
the periphery [156]. The types of interactions implicated in these processes are naturally 
complex and differ according to the cell type. Focusing on CD8+ T lymphocytes, the cell 
population implicated in hereditary hemochromatosis [22, 29-32], it is now well described that 
they go through successive effector phases, inflammatory and cytotoxic, with potentially 
different T cell properties [157, 158]. Notably, the survival and expansion of CD8+ T memory 
cells, in contrast to naïve cells, is not restricted to TCR-MHC-peptide interactions but needs 
only a nonspecific MHC class I interaction in the absence of antigen [159, 160]. 
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Hereditary hemochromatosis: an immunological 
disorder 
HFE: linkage to other MHC-class I genes  
The major histocompatibility complex (MHC) has been studied for more than 60 
years, and its early history is well documented [161]. Serological typing revealed 
associations between the MHC and many interesting immune phenotypes long before the 
cloning of class I and class II genes and determination of the structures of their encoded 
proteins. The MHC genetic region was first suggested as a possible region to look for a 
hereditary hemochromatosis (HH) gene by Simon et al because of the high frequency of 
HLA-A3 allele found among patients [162]. The most informative data about the genetic 
transmission of the syndrome was obtained through family studies that allowed to confirm the 
autosomal recessive disease inheritance in linkage with the HLA region. The disease 
associated gene should be therefore localized in the short arm of chromosome 6. Linkage 
analyses with several markers within the MHC region, helped to define a conserved 
haplotype, the HLA-A*03-B*07, as the most commonly associated with the disease in all 
populations studied, and this was assumed, as the founder chromosome, in spite of its high 
conservation, suggesting a very recent age for the p.C282Y mutation. In 1996, Feder et al. 
sequenced by positional cloning the MHC class I- region between HLA-A and the D6S276 
gene marker and, by further linkage-disequilibrium and full haplotype analysis, identified a 
250-kilobase region located more than three megabases telomeric from the major 
histocompatibility complex on chromosome 6 that was identical by descent in 85 percent of 
HH patients. Because it was a MHC class I related gene, they first named as HLA-H. The 
name of the gene was changed because there was a different pseudogene already named 
as HLA-H and so the hemochromatosis gene was renamed by the HUGO Genome database 
Nomenclature Committee as HFE that means High Fe (iron) (Fig.5).  
 
Fig. 5 Physical map of the MHC region with the distance between the HLA-A markers and HFE gene 
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After the general and global use of the genetic tests for detection of the most common 
HFE mutations, larger genetic studies were performed and the allele frequencies data of 
distinct populations became available. It became evident that the p.C282Y mutation is highly 
common in most European descent populations but it is almost absent in non-Caucasian 
populations from Africa. Within Europe the p.C282Y allele (Adenine (A)) frequency ranges 
from 0.013 to 0.140 with a north–south gradient. The highest frequencies are observed in 
populations from Ireland, United Kingdom and Brittany, and in Scandinavian populations. 
This high incidence in the northern populations support the proposed origins for the spread of 
the hemochromatosis mutation, the first by Simon suggesting that it was a unique and recent 
event originated in a Celtic population with a subsequent spreading by population migration, 
and the later suggested by Milman where arguing that the Viking conquests and migrations 
could have played a more significant role in the spread of the mutation [163]. 
 
Table 2 Allele frequency of the nucleotide at 845 position of HFE gene (Guanine – wild-
type or Adenosine - C282Y mutation) and respective genotype in different world 
populations. Information was obtained from the 1000 Genomes project [164]  
Population Allele frequency (count) Genotype frequency (count) 
1000GENOMES: ALL 
G: 0.987 (4945) G|G: 0.976 (2443) 
A: 0.013 (63) A|A: 0.001 (2) 
 
A|G: 0.024 (59) 
1000GENOMES: AFRICAN 
G: 0.998 (1319) G|G: 0.995 (658) 
A: 0.002 (3) A|G: 0.005 (3) 
1000GENOMES: AMERICAN 
G: 0.978 (679) G|G: 0.960 (333) 
A: 0.022 (15) A|A: 0.003 (1) 
 A|G: 0.037 (13) 
1000GENOMES: EAST ASIAN G: 1.000 (1008) G|G: 1.000 (504) 
1000GENOMES: SOUTH ASIAN 
G: 0.998 (976) G|G: 0.996 (487) 
A: 0.002 (2) A|G: 0.004 (2) 
1000GENOMES: EUROPE 
G: 0.957 (963) G|G: 0.917 (461) 
A: 0.043 (43) A|A: 0.002 (1) 
 A|G: 0.082 (41) 
 
The recent age for the p.C282Y mutation is supported not only by its restricted ethnic 
distribution (only European derived populations) but also by the extreme conservation of an 
ancestral haplotype spanning 4Mb at the MHC region. Initial linkage studies, using several 
polymorphic markers, estimated that the ancestral mutation may have originated between 62 
and 69 generations ago but other estimations based on recombination rates suggested that 
mutation is older (126 to 250 generations). Such a young age for the p.C282Y mutation 
contrasts with the very high allele frequency observed among European derived populations, 
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suggesting an increase in frequency due to a positive selective pressure where the p.C282Y 
may have conferred some advantage or could have been hitchhiked associated with other 
advantageous MHC gene alleles, given the strong linkage disequilibrium found in the region 
[165]. 
Although the frequency of the p.C282Y mutation in most European derived 
populations is very high (about 5-200) the proportion of patients with a fully developed 
phenotype found in clinical practise seems to be very low. Most homozygotes for the 
p.C282Y mutation of HFE show a common biochemical phenotype characterized by high 
transferrin saturation, as shown in family studies where homozygous relatives displayed this 
iron overload phenotype, yet they were still asymptomatic. The question remains whether 
under-diagnosis of HH results from the non-specific nature of early symptoms or incomplete 
penetrance of p.C282Y mutation. Family screening has proved to be highly effective in early 
case detection and disease prevention. Large population screening programs, however, 
revealed that the clinical penetrance of HH is very low. Beutler et al reported that the disease 
penetrance should be of less than 1% [79], a screening study in an Australian population 
showed that 50% of detected homozygous had clinical features of hemochromatosis and 
25% had hepatic fibrosis or cirrhosis [166]. A population screening in Norway, revealed that 
only 10% of detected homozygous subjects displayed hepatic fibrosis or cirrhosis [167]. In a 
multiethnic screening study of Hemochromatosis and iron-overload disorder, 99771 
participants collected blood samples and tested for transferrin saturation, serum ferritin, and 
p.C282Y and p.H63D mutations of the HFE gene [168]. The results revealed different 
prevalences of p.C282Y homozygotes among different populations: non-Hispanic whites 
(0.44%), Native Americans (0.11%), Hispanics (0.027%), Africans (0.014%), Pacific 
Islanders (0.012%), or Asians (0.000039%). Among the p.C282Y homozygous participants 
(227) in whom iron overload condition had not been diagnosed, serum ferritin levels were 
greater than 300 ng/ml in 78 of 89 (87%) men and greater than 200 ng/ml in 79 of 138 (57%) 
women. Serum ferritin levels above 1000 ng/ml, which is associated with a high risk of liver 
fibrosis [169], were detected in 364 participants undiagnosed for iron overload (29 were 
p.C282Y homozygotes). Among men, p.C282Y homozygotes and compound heterozygotes 
were more likely to report a history of liver disease than were participants without HFE 
mutations. However, the question of prevalence, penetrance and natural progression of 
clinical hemochromatosis is difficult to address because of the huge clinical heterogeneity 
found among HH patients. It can vary from a simple biochemical abnormality to a severe 
iron-overload with organ damage. The reasons for that heterogeneity are not fully 
understood. The discovery of novel modifiers of the clinical expression of type I HH may give 
new insights about the systemic regulation of iron homeostasis and could also explain the 
different disease susceptibilities among different populations. Among these, immunological 
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abnormalities have been consistently observed in HH patients, which will be next described 
in more detail. 
 
Immunological abnormalities in HH  
The genetic and biologic context of the hemochromatosis gene, HFE, is the MHC 
complex which is an extended gene cluster of extreme importance by the immunological 
functions they encode. In fact, HFE was first described as an aberrant MHC Class I like 
protein, when discovered by Feder et al, in 1996 [27]. The mechanism how could this protein 
contribute to iron overload was not obvious at all. The first hypothesis advanced at the time 
was that the protein could interact indirectly through association with components of the 
immunological system, an idea supported by previous observations by Arosa et al. on the 
functional interaction between the immunological system and iron metabolism [170]. 
The postulate that the immunological system could have a role in monitoring tissue 
iron toxicity, as part of its surveillance function, was first advanced by De Sousa in 1978, 
based on her observations on lymphocyte traffic and positioning [2]. It was implicit in that 
postulate that the adaptive system and its circulating components participate in the 
recognition and binding of metals as a protective device against metal toxicity and the 
preferential use of indispensable metals such as iron or zinc by bacteria or transformed cells. 
This motivated a series of studies of lymphocytes expression and function in 
hemochromatosis patients. Both these and further studies in animal models contributed to 
support and strengthen the notion of an inextricable link between iron and the immunological 
system. 
The finding of abnormalities in the relative proportions of the two major T lymphocytes 
populations (CD4+ and CD8+ T cells) in HH patients [21], and the observation of an iron 
overload similar to HH in the β2m knockout mice lacking MHC class I and CD8 T 
lymphocytes preceded the discovery of HH gene [23]. Reimão and co-workers had shown 
that patients with high CD4/CD8 rations (>2.9) display a faster re-entry of iron into the serum 
transferrin pool after intensive phlebotomy treatment, reaching abnormal transferrin 
saturation values (>60%) more rapidly than patients with normal CD4/CD8 rations 
(approximately 1) [21]. A significantly inverse correlation was found with the numbers of 
CD8+ T cells, and not with CD4+ T cells, and the amount of iron mobilized by phlebotomy 
treatment [22, 30]. These CD4/CD8 rations and the relative or absolute numbers of CD4+ and 
CD8+ T-cell populations were not altered by the treatment [22, 32]. In 2001, those low 
numbers of peripheral CD8+ T cells were also associated with low number of those cells in 
the liver, being directly associated with the iron hepatic tissue amount [33]. Other groups 
recapitulated these findings namely the low CD8+ T cell numbers associations with certain 
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HLA haplotypes and with a more severe iron overload [171]. Functional specific 
abnormalities have been previously described in CD8+ T lymphocytes from HH patients 
namely, a defective lymphocyte-specific tyrosine kinase (p56lck) activity, decreased cytotoxic 
activity, an increased number of CD8+ T cells lacking CD28 co-stimulatory molecule and an 
high percentage of cells in an activated state (HLA-DR+) [29, 152, 170]. The reduction of 
CD8+CD28+ expressing cells in HH patients was inversely correlated with transferrin 
saturation, which does not rule out the role of circulating iron as a modulator of T cell profiling 
[172]. But the HFE itself could also influence T cell homeostasis by acting over the MHC-I 
antigen presentation pathway. In 2005, Rohrlich et al described that HFE deletion in mice is 
associated with a decreased number of T cells expressing αV6 TCRs [173]. Also, by using 
transgenic mice they observed a direct cytolytic recognition for human HFE by mouse TCR, 
which occurs independently of HFE-bound peptides. These observations are in agreement 
with the previous finding that TCR-delta knockout mice develop hepatic iron overload, 
suggesting that cellular iron status might be transmitted to lymphocytes through HFE 
engagement with TCR [174]. This p.C282Y mutation is known to prevent HFE association 
with β2m leading to the accumulation of the misfolded protein in the endothelial reticulum 
(ER) with consequent induction of an unfold protein response (UPR).This UPR activation 
results in a significant down-regulation of MHC-I cell surface expression [175]. Moreover, 
inhibition of the ER stress response in cells expressing the HFE p.C282Y mutant protein 
leads to the restoration of MHC-I levels [176]. These observations point to an effect of the 
p.C282Y mutation in the HFE gene beyond the strict iron regulation and suggest the 
importance of HFE at the interplay between the two systems of iron homeostasis and 
immune responses. 
 
Iron and lymphocytes: evidence from the immune deficient mouse 
models 
 
A good insight into the question of the impact of immune cell abnormalities on iron 
homeostasis is given by animal models. The first hereditary hemochromatosis animal model 
preceded the discovery of the HH gene. It was described by De Sousa et al. when they 
demonstrated that β2m(-/-) deficient mice, that are almost depleted in CD8+ T cells due to a 
severe decrease in the expression of MHC-Class I molecules, develop a severe hepatic iron 
overload phenotype mainly observed in liver parenchyma cells, without accumulation in 
kupffer cells [23]. Moreover, β2m(-/-) mice were not able to reduce intestinal iron absorption in 
response to an iron overload condition and displayed an abnormally high transferrin 
saturation values (>80%) recapitulating the human model of HH [24]. After the discovery of 
the non-classical MHC-class I  HFE gene, the knockout mouse was generated confirming 
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that the Hfe(-/-) mice display liver iron deposition, and increased TfSat mainly due to an 
increase in iron absorption. The knock in mice for the p.C282Y mutation were shown to 
display a less severe phenotype liver iron phenotype than the Hfe(-/-) and even less iron 
deposition when in compound heterozygosity with the p.H63D mutation [177]. Moreover, the 
Hfe(-/-) mice do not show any immunological abnormality in terms of lymphocyte numbers. In 
order to address the synergistic effect of HFE and MHC-class I dependent lymphocyte 
defects, the knockout mice for mature lymphocytes was generated by depletion of the 
recombination activating gene 1 (Rag1). Multiple combinations of gene defects provide 
evidence that, , although the absence of lymphocytes alone does not predispose to an iron 
overload phenotype [174], the lack of both Hfe and lymphocytes (Hfe(-/-)Rag(-/-) and β2m(-/-) 
Rag(-/-)), led to a more severe liver iron phenotype with the last model showing a specific 
deposition of iron in the heart and pancreas [28, 35]. These mice models constituted 
important support to strengthen earlier clinical observations in HH patients where 
lymphocytes act as modifiers of the primary iron overload condition. 
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Background 
Hereditary Hemochromatosis (HH) is the most common genetic disorder of iron 
overload [178]. Most HH patients are homozygous for the p.C282Y mutation in the HFE 
protein, encoded by HFE, a non-classical MHC-class I gene located at position 6p21.3, near 
the HLA locus [179]. The exact mechanism underlying the involvement of HFE in HH is still 
not clarified. 
 Immunological abnormalities have been consistently described in HH in association 
with the iron overload phenotype, particularly in the number of peripheral blood CD8+ T 
lymphocytes [30, 33, 180]. There is presently strong evidence that the numbers of CD8+T 
lymphocytes are genetically transmitted in association with genes at the MHC-class I region. 
[41-43, 181]. The question remains if a putative MHC-class I-linked gene involved in the 
setting of CD8+T lymphocyte numbers is an important modifier of the clinical expression in 
HH. 
The mechanism(s) underlying the participation of lymphocytes in iron homeostasis 
remain mostly unknown. A recent study using human peripheral blood lymphocytes revealed 
that these cells are able to sense elemental iron and respond by modulating the expression 
of the central effector protein in iron metabolism: hepcidin [40]. However, it is not known what 
is the modifier effect of lymphocytes in systemic iron homeostasis and whether there are 
abnormalities in lymphocyte gene expression/regulation in HH. Also, a complete lack of 
information exists on the involvement of other lymphocyte proteins in iron cellular/systemic 
homeostasis as well as on the iron handling capabilities of these cells.  
 
Aims and outline of the thesis 
The general objective of this thesis is to clarify the role of lymphocytes in iron 
homeostasis, using Hereditary Hemochromatosis (HH) as a model. With this approach it is 
expected that the work will contribute to elucidate (1) the genetic contribution of the MHC-
class I region to the setting of lymphocyte numbers and (2) the mechanisms how 
lymphocytes may act as modifiers of the clinical expression in HH. 
 
The specific objectives of the thesis are: 
1. To evaluate the predictive value of MHC markers known to be associated with CD8 
T cells numbers in Portuguese HH patients 
The inheritance of certain HLA alleles are known to be associated with the genetic 
transmission of lower numbers CD8+ T lymphocytes as also a SNP microhaplotype 
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named A-A-T, was recently found to be associated with a more severe phenotype and 
also with the “low CD8 phenotype” in HH Portuguese population [44]. We present the 
results of a genomic approach analysing the MHC genetic region and its association with 
the CD8+ T-cell phenotype in HH patients. More specifically, in Chapter 3.1 we aimed to 
test whether the predictive value of the A-A-T microhaplotype remains in other 
populations’ settings. For that purpose, we analysed HH patients from 3 geographically 
distant populations (Porto, Portugal; Alabama, USA and Nord-Trøndelag, Norway), where 
the A-A-T extended haplotypes were determined and the association with CD8+ T-
lymphocyte numbers was evaluated. 
 
2. To refine the genetic region between HFE and HLA-B in HH patients and controls 
In Chapter 3.2 we aimed to better characterize the HLA-HFE haplotype structure of the 
HH Portuguese patients by performing a high density mapping with coverage of 63 SNPs 
markers within this region. With this approach we were able to gain a better insight into 
the recombination history and founder effects of HH associated haplotypes in our 
population, as well as their association with the “low CD8 phenotype”. 
 
3. Evaluate the in vitro cellular response of lymphocytes and monocytes to changes 
in non-transferrin-bound iron (NTBI) in HH patients versus normal healthy blood 
donors. 
As one of the major cellular components of peripheral blood, T lymphocytes can be 
exposed to circulating NTBI and have been for a long time proposed to act as a first 
physiological barrier against iron-mediated toxicity in situations of systemic iron overload 
[179]. Until now little was known about the capacity of T lymphocytes to take up NTBI. In 
Chapter 3.3 we aimed to address the ability of CD8+ T lymphocytes to store iron 
acquired as NTBI. For that purpose we performed in vitro studies addressing the kinetics 
of NTBI uptake (Results 1) and export (Results 3) by human CD8+ T lymphocytes after 
exposure to iron citrate. The hypothesis that CD8+ T cells may act as NTBI “buffers” and 
modify the disease outcome was tested by comparing NTBI retention ability by CD8+ T 
cells isolated from peripheral blood of HH patients and normal subjects (blood donors) 
(Results 4). 
 
4. Characterize the response of CD8 T lymphocytes to iron overload in terms of gene 
expression, using a wide-genome Affymetrix microarray approach. 
In Chapter 3.4 we aimed to address the transcriptional profile of peripheral CD8+ T cells 
in the biological context of Hfe absence. To avoid the MHC genetic diversity found in 
patients, we first looked in the HH mouse model (Hfe-/-) which has a homogenous genetic 
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background. Using a wide-genome microarray approach, we addressed the 
transcriptional response of CD8+ T lymphocytes from the HH mouse model and the 
respective genetic background control (C57BL/6) and compared them either in iron 
normal conditions and after induce systemic iron overload by an iron-rich diet. The results 
obtained in the HH mice model, were further tested in the human disease context by 
analysing the most differently expressed genes found in the Hfe-/- context in human CD8+ 
T cells isolated from HH patients and normal subjects. 
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3.1 Effects of highly conserved major histocompatibility complex (MHC) extended 
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3.1 
Effects of highly conserved major histocompatibility complex 
(MHC) extended haplotypes on iron and low CD8+ T 
lymphocyte phenotypes in HFE C282Y homozygous 
hemochromatosis patients from three geographically distant 
areas 
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Abstract 
Hereditary Hemochromatosis (HH) is a recessively inherited disorder of iron overload 
occurring commonly in subjects homozygous for the C282Y mutation in HFE gene localized 
on chromosome 6p21.3 in linkage disequilibrium with the human leukocyte antigen (HLA)-A 
locus. Although its genetic homogeneity, the phenotypic expression is variable suggesting 
the presence of modifying factors. One such genetic factor, a SNP microhaplotype named A-
A-T, was recently found to be associated with a more severe phenotype and also with low 
CD8 +T-lymphocyte numbers. The present study aimed to test whether the predictive value of 
the A-A-T microhaplotype remained in other population settings.  
In this study of 304 HH patients from 3 geographically distant populations (Porto, 
Portugal 65; Alabama, USA 57; Nord-Trøndelag, Norway 182), the extended haplotypes 
involving A-A-T were studied in 608 chromosomes and the CD8+ T-lymphocyte numbers 
were determined in all subjects. Patients from Porto had a more severe phenotype than 
those from other settings. Patients with A-A-T seemed on average to have greater iron stores 
(p=0.021), but significant differences were not confirmed in the 3 separate populations. Low 
CD8+ T-lymphocytes were associated with HLA-A*03-A-A-T in Porto and Alabama patients 
but not in the greater series from Nord-Trøndelag.  
Although A-A-T may signal a more severe iron phenotype, this study was unable to 
prove such an association in all population settings, precluding its use as a universal 
predictive marker of iron overload in HH. Interestingly, the association between A-A-T and 
CD8+ T-lymphocytes, which was confirmed in Porto and Alabama patients, was not observed 
in Nord-Trøndelag patients, showing that common HLA haplotypes like A*01-B*08 or A*03-
B*07 segregating with HFE/C282Y in the three populations may carry different messages. 
These findings further strengthen the relevance of HH as a good disease model to search for 
novel candidate loci associated with the genetic transmission of CD8+ T-lymphocyte 
numbers. 
 
Keywords: Hereditary Hemochromatosis, HFE, MHC, CD8+ T lymphocytes, Iron, C282Y 
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Introduction 
The major histocompatibility complex (MHC) region on chromosome 6p21.3 
constitutes the most dense gene region of the human genome. It has been estimated that 
40% of classical MHC genes are expressed in the immune system [182]. These genes are 
physically clustered, possibly reflecting functional relationships, and are characterized by 
high polymorphism levels and strong linkage disequilibrium. These characteristics make the 
MHC region a paradigm in many aspects of genomic research, particularly in disease 
association studies. Genetic variation in the MHC is associated with more disorders than any 
other genomic region, the majority of which are immune-related. Nevertheless, fine mapping 
of those disease associations and the identification of specific functional variants remain 
difficult. Both structural and regulatory variants are important in disease associations and 
may operate in tandem [182]. 
 A classic example of disease association with extreme linkage disequilibrium at the 
MHC region is Hereditary Hemochromatosis (HH), an autosomal recessive disorder of 
primary iron overload characteristically found in Caucasians and associated with 
homozygosity for the HFE p.Cys282Tyr mutation (C282Y) in the vast majority of cases. HFE 
encodes a non-classical MHC class-I molecule and is localized 4Mb telomeric to HLA-A [27], 
in very strong association with an ancestral haplotype carrying the human leukocyte antigen 
(HLA) antigens A*03 and B*07 [183, 184]. By applying several types of linkage-disequilibrium 
calculations to analyze the HH locus, Ajioka and co-workers found very high disequilibrium 
values over a large region from 150 kb centromeric to 5 Mb telomeric of HLA-A, partly due to 
an unusual low recombination rate of approximately 28% of the expected value [185]. In the 
same study, a haplotype phylogeny for HH chromosomes suggested that the origin of HFE 
C282Y is recent. These observations also provided a plausible explanation for previous 
difficulties in localizing the HH gene [186, 187]. 
 Despite the genetic homogeneity at HFE among HH patients, their iron phenotypes 
are highly variable. Consequently, possible environmental and genetic modifiers of iron 
phenotypes in hemochromatosis have been intensively investigated. Among others, genes 
within the MHC class I region, inherited in linkage with the ancestral C282Y-containing 
haplotype, have been implicated in the clinical heterogeneity of HFE-associated HH [188]. 
However, conflicting results obtained by different authors have still not solved this question. 
Earlier independent studies in geographically different populations have shown that the 
number of copies of the common ancestral haplotype HLA-A*03-B*07 was associated with 
the expression of iron phenotypes. Patients with two copies of the ancestral haplotype were 
shown to have more severe iron overload phenotypes than those with one or no copy of the 
ancestral haplotype in studies performed in Australia, Italy and Alabama, USA [189-192]. 
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Moreover, Pratiwi et al. showed by extended linkage disequilibrium analysis in patients from 
Australia that there are two distinct peaks of association separated by 2 Mb in the region of 
HFE, a pattern not expected for a single gene disorder [193]. This suggested that a gene 
modifying the phenotype of C282Y homozygotes could be localized around the area of 
D6S105. More recent studies did not support the previous observations [194-197]. In a 
review of the origin and spread of the hemochromatosis mutation, Distante and co-workers 
[194] reported that although associations of HLA haplotypes with the severity of iron overload 
were described, no such relationship was found in patients from the UK (R.Raha-Chowdhury, 
A. Bomford and M. Worwood, unpublished data). In another study of 8 HH families from 
Britanny, France, Sachot and co-workers analyzed C282Y homozygous relatives with no 
clinical signs of the iron overload in comparison to the respective probands who had 
abnormal iron phenotypes. They found no evidence that either HFE polymorphisms or 
variants in 10 microsatellite markers surrounding HFE could explain phenotypic variability in 
the respective kinships [195]. Barton and co-workers extended their study of 
genotype/phenotype correlations to a population of 141 C282Y homozygous probands from 
Alabama, USA, and did not reproduce the previous observations that were based on a 
relatively small number of probands [196]. Finally, in a study of HLA haplotypes of HH 
patients in a rural population from a former Norwegian province in Central Sweden, Olsson 
and co-workers could not find an association of the HLA-A*03 with the iron phenotype. 
Interestingly however, they found that males with double copies of the very common A*01-
B*08 haplotype expressed a milder phenotype, supporting again an association of iron 
overload with the MHC region, but in the setting of a different haplotype [197]. 
Altogether the above described studies demonstrate that associations between the 
HH phenotype and the classical HLA markers vary among different cohorts from 
geographically distinct populations (who naturally diverge due to genetic drift or 
recombination events) and point to the necessity to look for novel markers at the MHC region 
that may help explaining the phenotypic variability in HH patients. One such factor could be a 
new 500 kb microhaplotype localized between HFE and the HLA-A locus as described by 
Cruz and co-workers [44]. This haplotype was associated with a more severe phenotype in 
its carriers and also with low CD8+ T lymphocyte numbers, which in previous studies from 
Portugal have predicted a more severe iron overload [21, 22, 30, 32]. Low lymphocyte 
numbers were also associated with a more severe phenotype in patients from Alabama in 
particular those with HLA-A*01-B*08 [171]. However, this same haplotype reported in a 
former Norwegian province seemed to be associated with a milder phenotype [197]. 
Unfortunately, no data are available regarding CD8+ T lymphocyte numbers in this population 
from Central Sweden.  
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  In the present study we sought to test whether the predicting value of the 
microhaplotype described by Cruz et al. [44] could be reproduced in other settings, i.e., in 
different populations from geographically distant regions.  In this context, we explored the 
degree of conservation of the reported HH-associated haplotypes in relation to their effect on 
the low CD8+ T lymphocyte phenotype or the clinical expression of iron overload. Our data 
indicate that although the same haplotypes are observed in distant geographical regions, 
their relative frequencies are variable, which may explain differences in genotype/phenotype 
associations among different populations. 
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Methods 
Ethics Statement 
The study was approved by the Ethical Committees of Centro Hospitalar do Porto, 
Porto; Institutional Review Board of Brookwood Medical Center, Alabama and The Regional 
Committee for Medical and Health Research Ethics, REC Central, Trondheim. Written 
informed consent was obtained from participants according to the Helsinki declaration. 
 
Study Populations & clinical data 
Three different populations of Hereditary Hemochromatosis patients from 
geographically distant regions were included in this study. The only inclusion criteria for the 
purpose of the study were the confirmation of homozygosity for the C282Y HFE mutation and 
to be an adult, because the CD8+ T lymphocyte phenotype is stable in adults. The first group 
included 65 unselected, unrelated HH patients from the north of Portugal, mainly from the 
Porto district area, consecutively identified between 1985 and 2011 in non-screening settings 
and regularly followed up at the Hemochromatosis Outpatient Clinic of Santo António 
Hospital, Porto and Predictive and Preventive Genetic Centre, Porto. This group of patients 
is designated as Porto patients. The second group of patients included 57 unrelated HH 
patients diagnosed in non-screening settings from central Alabama, USA, diagnosed 
between 1988 and 2010 and treated at Southern Iron Disorders Center, Birmingham, 
Alabama. These probands were selected for the present study only because they presented 
for diagnosis or treatment in a consecutive mode. This group of patients is designated as 
Alabama patients. The third group of patients included 182 patients from the Nord-Trøndelag 
County, Norway, who were diagnosed with HH as part of a population screening study 
(HUNT2) between 1995 and 1997, and were followed up at St. Olav Hospital, Trondheim. 
This group of patients is designated as Nord-Trøndelag patients. Most of the clinical and 
laboratory information about all patients were already available and described elsewhere [41, 
43, 44, 188, 198-200]. Previously available information included, in all patients, the iron 
parameters at diagnosis: transferrin saturation (TfSat) and serum ferritin (SF); HFE genotype 
(all homozygous for the C282Y mutation); and HLA class I alleles (A and B) as determined 
by low-resolution DNA-based techniques (PCR/sequence-specific oligonucleotide probes, 
Dynal RELI™ SSO, Dynal Biotech Ltd, UK). Values of total body iron stores (TBIS) estimated 
by quantitative phlebotomies were available from 104 patients (34 from Porto, 32 from 
Alabama and 38 from Nord-Trøndelag). 
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Immunophenotyping 
Blood counts of T-CD8+ lymphocyte subpopulation were available for all study 
participants. T-lymphocyte subpopulations were determined by FACS analysis using anti-
CD3 and anti-CD8 monoclonal antibodies as previously described in detail [41]. We defined 
as a “low CD8 phenotype” the finding of CD8+ T lymphocyte numbers below the 25% 
percentile in controls. This value was 310x103/ml in Porto and Alabama patients and 
319x103/ml for Nord-Trøndelag patients. Mean values (± standard deviation) in controls were 
433(±168) x103/ml in Porto and Alabama and 490(±234) x103/ml in Nord-Trøndelag. 
 
Genetic markers at the MHC region 
In addition to HFE and HLA genotyping, genetic information on three single 
nucleotide polymorphisms (SNPs) localized in the region between HFE and HLA-A was 
obtained in all patients included in this study. These SNPs were localized in the genes: 
piggyBac transposable element derived 1 (PGBD1, rs1997660), zinc finger protein 193 
(ZNF193, rs7206) and zinc finger protein 165 (ZNF165, rs203878), and defined a SNP 
microhaplotype of 500 kilobases (kb). These were the SNP microhaplotypes previously 
described in Porto patients [44] and were determined “de novo” in patients from Alabama by 
gene sequencing as described in [44] and in patients from Nord-Trøndelag by hybridization 
probe melting curve analysis on the LightCycler, Roche Diagnostics. Details on primer and 
probe sequences in addition to PCR conditions for SNP analysis can be provided by request. 
 
Generation of phased chromosomes and haplotype construction 
HLA A-B haplotypes, and the SNP microhaplotypes defined by the genes PGBD1, 
ZNF193 and ZNF165, were defined in HH patients by family segregation whenever 
informative family members were available. Otherwise they were inferred by the PHASE 
program. 
 
Statistical methods 
Associations of HLA alleles and haplotypes in chromosomes carrying the C282Y 
mutation in HFE were tested by the Chi-square test by comparison of their frequencies in HH 
patients from the 3 different regions of Porto, Alabama and Nord-Trøndelag with those of the 
respective reference normal populations. For the purpose of statistical analysis, only alleles 
or haplotypes with frequencies respectively higher than 10% and 7% in any of the tested 
population were considered. Information about HLA allele and haplotype reference 
frequencies in the normal populations from Porto (north Portugal) was obtained at the 
“Allele*Frequencies in worldwide populations” database. Frequencies for the Alabama 
control population were reviewed from the data previously analyzed by Barton and co-
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workers [198]. Frequencies in the non-Sami population from Norway were obtained from the 
data described by Harbo et al. 2009 [201], also published at the “Allele*Frequencies in 
worldwide populations” database [202]. In order to eliminate the artificially lowered 
frequencies in HH chromosomes of other alleles and haplotypes that were due to the 
relatively high frequencies of alleles A*03 and B*07 and the haplotype A*03-B*07, we 
estimated (in patients and respective controls) “corrected” allele and haplotype frequencies 
by subtracting from the denominator respectively the sum of A*03 and B*07 alleles or the 
number of A*03-B*07 haplotypes. These corrected frequencies allowed a more meaningful 
comparison between frequencies in HH and control chromosomes, as originally described by 
Marcel Simon and co-workers [184]. To analyze the relative strength of HLA allele or 
haplotype associations, the etiological fraction delta () was calculated as described 
according to the formula =(FAD-FAP)/(1-FAP) where FAD is the allele frequency in HH 
chromosomes and FAP the allele frequency in control chromosomes [203-205]. In the case 
of multiple comparisons we used the Bonferroni correction to test for the significance of 
differences. 
To investigate the association of CD8+ T lymphocyte numbers with particular 
genotypes, we assigned to each chromosome the value of CD8+ T lymphocytes of the 
respective carrier. Differences in mean CD8+ T lymphocyte values among groups were 
tested by the Student’s T-test or the One-Way analysis of variance (ANOVA) as appropriate. 
In addition, patients with CD8+ T lymphocyte numbers below the 25% percentile of the 
respective controls were selected and their chromosomes assigned as “low CD8 phenotype” 
cases. Differences in the relative frequencies of “low CD8 phenotype” cases among groups 
were tested by the Chi-square test.  
Quantitative measures of iron parameters were also compared among the 3 
populations of HH patients from Porto, Alabama and Nord-Trøndelag. Because of skewness 
in the distribution of serum ferritin and total body iron stores, for statistical purposes the 
logarithmic transformation was applied to those values. For representation in table and 
figure, however, the non-transformed values were used. Differences in means among groups 
were tested by One-Way analysis of variance (ANOVA) or the Student’s T-test as 
appropriate. 
Data were analyzed by Statgraphics software (Statgraphics Graphics System, version 
7.0). Values of P <0.05 were defined as significant. 
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Results 
1 - Clinical heterogeneity among the HH populations from Porto, Alabama and Nord-
Trøndelag 
A summary of the iron-related parameters of the HH patients from Porto, Alabama 
and Nord-Trøndelag is provided in Table 1, where values are given according to gender. 
Significant differences among the 3 populations of patients were observed in males for TfSat, 
SF, and TBIS, with P values < 0.00001 in all cases. These differences were explained by a 
more severe expression in patients from Porto and a milder expression in Nord-Trøndelag 
patients. In females, SF (P<0.00001) and TBIS (P<0.04) were also significantly different 
among the 3 populations, with Porto and Nord-Trøndelag patients having respectively the 
highest and lowest values. The HH cohort from Nord-Trøndelag was the only one in which 
patients were identified in screening programs. Moreover, previous studies in the same 
population showed that, in general, Nord-Trøndelag patients have a low prevalence of 
clinical symptoms and less severe iron overload [199, 200]. 
 
Table 1 Iron parameters (at diagnosis) in HH patients from Porto, Alabama and Nord-
Trøndelag 
 
N TfSat (%) SF (ng/ml) TBIS (g) 
HH male patients from: 
    
Porto 43 90 ± 14 (63-123) 1750 ± 295 (163-7685) 7.93 ± 0.78 (2.19-17.40) 
Alabama 32 73 ± 17 (41-100) 815 ± 82 (123-2119) 3.66 ± 0.50 (0.40-10.40) 
Nord-Trøndelag 103 81 ± 9 (58-100) 541 ± 63 (27-3511) 3.23 ± 0.47 (1.12-15.32) 
P value 
 
<0.00001 <0.00001 <0.00001 
HH female patients from: 
    
Porto 22 81 ± 18 (55-111) 543 ± 286 (67-3954) 3.20 ± 1.33 (1.10-13.80) 
Alabama 25 74 ± 20 28-100) 433 ± 78 (65-1892) 1.93 ± 0.27 (0.40-5.60) 
Nord-Trøndelag 79 73 ± 12 (51-97) 172 ± 27 (16-1151) 1.65 ± 0.30 (0.89-4.32) 
P value 
 
n.s. <0.00001 0.040 
Transferrin saturation (TfSat) is presented as arithmetic mean  standard deviation; serum ferritin (SF) and total 
body iron stores (TBIS) are presented as geometric mean ± standard error. Minimum-maximum values are in 
parenthesis. TBIS was available in 34 males from Porto, 32 from Alabama and 38 from Nord-Trøndelag and in 13 
females from Porto, 23 from Alabama and 12 from Nord-Trøndelag. Statistically significant differences (P value 
indicated) were tested among groups using One-way Anova. 
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2 - Analysis of genetic markers between HFE and HLA-B in the HH populations from 
Porto, Alabama and Nord-Trøndelag  
From the study of 304 HH patients with C282Y homozygosity from three 
geographically distant regions, namely Porto, Portugal (n=65), Alabama, USA (n=57) and 
Nord-Trøndelag, Norway (n=182), we obtained respectively 130, 114 and 364 chromosomes 
carrying HFE C282Y. These were genetically characterized with 5 different markers including 
HLA-A alleles, HLA-B alleles, and SNPs in the genes PGBD1, ZNF193 and ZNF165. HLA A-
B haplotypes and SNP microhaplotypes were assigned by family segregation, or generated 
by PHASE in patients without available informative family members (see Methods). 
HLA-A and HLA-B allele frequencies were first analyzed in HH chromosomes from 
the three populations. Results are summarized in Table 2 (uncorrected data are shown in 
Table S1). As expected from all previously published studies of HLA associations in HH, the 
most common HLA-A and B alleles in chromosomes from all the three HH populations from 
Porto, Alabama and Nord-Trøndelag were A*03 (respectively 0.408, 0.474 and 0.420) and 
B*07 (respectively 0.238, 0.307 and 0.288); these frequencies were significantly different 
from those of the corresponding controls (Table 2). The strength of these significant 
associations was measured by estimating the etiological fraction delta (see Methods) being 
similar in all populations (Table 2). After correcting for the strong effect of A*03 and B*07 on 
other allele frequencies (see Methods), other significantly associated HLA alleles were found 
in the populations from Porto (A*01, B*08 and B*40) and Nord-Trøndelag (A*11, B*14 and 
B*44). In Alabama patients, the only additional HLA allele with a statistically significant 
association was B*14, suggesting that Alabama patients represent a genetically more 
conserved population. 
 The most prevalent HLA A-B haplotype in the three populations from Porto, Alabama 
and Nord-Trøndelag was A*03-B*07, the proportion of its carriers being 0.169, 0.272 and 
0.214, respectively (see also Table 2). Although these haplotype frequencies do not differ 
statistically among the different populations (shown in Supplementary Table 1), the strength 
of their associations to HH, as measured by the etiological fraction delta, is stronger in 
Alabama (=0.247) than in Nord-Trøndelag (=0.164) or Porto (=0.158), suggesting a more 
recent founder effect in Alabama HH patients. This interpretation is also consistent with our 
observation that the prevalence of HLA-A and -B alleles and haplotypes is less diverse in 
Alabama patients than in Porto or Nord-Trøndelag patients. After we corrected for the 
predominance of A*03-B*07 haplotypes on other haplotype frequencies (see Methods), the 
next most common HLA haplotype found in patients from all populations was A*01-B*08, 
although the respective frequencies of A*01-B*08 did not differ significantly from those in the 
respective control populations. The A*03-B*14 haplotype also occurred in hemochromatosis 
chromosomes from Alabama and Nord-Trøndelag patients. The significance of this 
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association could be defined only in the Alabama population due to lack of sufficient 
available information about control subjects in Porto and Nord-Trøndelag. Nevertheless, its 
significance might be supported by the very low frequencies found in controls from 
Scandinavia [206]. The haplotype A*02-B*44, a very common haplotype in normal Caucasian 
populations, was found at similar frequencies in all non-A*03-B*07-carrying chromosomes 
from the three present populations. These respective frequencies did not differ significantly 
from those in the respective control subjects. 
We next analyzed the SNP microhaplotypes defined by the SNPs in the genes 
PGBD1, ZNF193 and ZNF165 in the three populations (results shown in Table S1). Previous 
studies in HH patients had revealed that the most conserved of these SNP microhaplotypes 
was the one designated as A-A-T and that this microhaplotype is also transmitted in 
association with a more severe iron phenotype of HH [44]. This microhaplotype was the most 
prevalent in all the populations studied here but its relative frequency differed significantly 
among them (P=0.0003). Porto patients had the highest A-A-T frequency (0.908) and Nord-
Trøndelag patients the lowest (0.765). Among the non-A-A-T SNP microhaplotypes, the most 
common was G-G-G, the frequency of which also differed significantly among the three 
populations (P=0.003). G-G-G frequency was highest in Nord-Trøndelag patients (0.160) and 
lowest in Porto patients (0.062). 
In summary, the observation of differences in the relative frequencies of the 
described HLA and SNP markers among the three geographically distant populations of HH 
patients support the postulate that evolutionary histories among populations differ due to 
differences in genetic drift and recombination of the HH founder chromosomes in the 
respective geographic regions. 
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Table 2 HLA allele and haplotype associations in HFE C282Y carrying chromosomes of HH patients from three populations 
 
Porto Alabama Nord-Trøndelag 
 
HH Patients 
(n=130 
chromosomes) 
Controls* 
(n=15874 
chromosomes) 
  
 
HH Patients 
(n=114 
chromosomes) 
Controls* 
(n=830 
chromosomes) 
  
HH Patients 
(n=364 
chromosomes) 
Controls
 * 
(n=1152 
chromosomes) 
  
HLA- allele frequency P value δ allele frequency P value δ allele frequency P value δ 
A*03 0.408 0.101 0.000 0.330 0.474 0.166 0.000 0.369 0.420 0.155 0.000 0.310 
B*07 0.238 0.060 0.000 0.180 0.307 0.130 0.000 0.203 0.288 0.148 0.000 0.160 
  corrected allele frequency
**
     corrected allele frequency 
**
     corrected allele frequency 
**
     
A*01 0.208 0.124 0.026 0.096 0.283 0.214 ns 
 
0.223 0.180 ns 
 
A*02 0.299 0.295 ns 
 
0.300 0.328 ns 
 
0.360 0.406 ns 
 
A*11 0.052 0.078 ns 
 
0.067 0.068 ns 
 
0.137 0.052 0.000 0.090 
A*24 0.065 0.117 ns 
 
0.067 0.082 ns 
 
0.100 0.061 ns 
 
B*08 0.131 0.079 0.053 0.057 0.165 0.152 ns 
 
0.127 0.143 ns 
 
B*14 0.051 0.072 ns 
 
0.139 0.040 0.0001 0.103 0.100 0.032 0.000 0.071 
B*15 0.020 0.061 ns 
 
0.025 0.005 ns 
 
0.085 0.130 ns 
 
B*35 0.162 0.126 ns 
 
0.051 0.094 ns 
 
0.077 0.107 ns 
 
B*40 0.101 0.035 0.000 0.068 0.013 0.014 ns 
 
0.135 0.132 ns 
 
B*44 0.162 0.162 ns   0.203 0.163 ns   0.228 0.159 0.000 0.082 
  haplotype frequency     haplotype frequency     haplotype frequency     
A*03B*07 0.169 0.013 0.000 0.158 0.272 0.033 0.000 0.247 0.214 0.060 0.000 0.164 
  corrected haplotype frequency 
**
     corrected haplotype frequency
 **
     corrected haplotype frequency 
**
     
A*03B*14 0.019 n.a. 
  
0.096 0.009 0.000 0.089 0.077 n.a. n.a 
 
A*01B*08 0.065 0.034 ns 
 
0.108 0.069 ns 
 
0.098 0.096 ns 
 
A*02B*44 0.037 0.038 ns   0.096 0.062 ns   0.080 0.075 ns   
Comparisons between patients and controls were done using the Chi-square test (P values indicated) and the strength of the associations was estimated by the etiological 
fraction delta (δ). 
* HLA allele and haplotype frequencies in the controls populations from Porto (north Portugal) were obtained at the “Allele Frequencies in worldwide populations” database 
(Gonzalez-Galarza et al.(2011) Nucleic Acids Res 39:913-919), from Alabama were reviewed from previous data reported by Barton et al. (2002) BMC Med Genet 3:9; and 
from Norway were obtained in the study by Harbo et al. (2009) Tissue Antigens 75:207-217.  
** Corrected allele and haplotype frequencies (see Methods) were calculated by subtracting from the denominator, respectively, the sum of A*03 and B*07 alleles and the 
number of A*03B*07 haplotypes. 
n.a.=data not available; ns=not significant. 
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3 - Haplotype conservation in HH patients from Porto, Alabama and Nord-Trøndelag  
We analyzed the degree of haplotype conservation as a measure of their proximity 
from the ancestral HH founder chromosomes by selecting the HH chromosomes carrying the 
most commonly associated HLA-A alleles (A*01, A*02 and A*03) and calculating the degree 
of conservation (%) of the most common SNP microhaplotype A-A-T in those chromosomes. 
Results are shown in Table 3 and Figure 1. In general, a high degree of conservation was 
observed in cohorts from Porto, Alabama and Nord-Trøndelag for chromosomes carrying 
A*03 (respectively 94%, 98% and 97%), including the A*03-B*07-carrying chromosomes 
(respectively 91%, 100% and 99%). In contrast, significant differences occurred among the 
three populations regarding the conservation of chromosomes carrying A*01 or A*02 alleles 
(Table 3). 
 
Fig. 1 Conservation (%) of the SNP microhaplotype A-A-T according to HLA-A alleles in chromosomes 
from HH patients. A comparison of the percent haplotype conservation among the three groups of HH patients 
from Porto, Alabama and Nord-Trøndelag was done using the Chi-square test and significant results are indicated 
by a * (P<0.00001) 
 
These differences are illustrated in Figure 1, particularly visible for chromosomes 
carrying HLA-A*01. In the case of Porto patients, the SNP microhaplotype A-A-T is 
conserved in all HLA-A*01 carrying chromosomes (16/16), including all HLA-A*01-B*08 
carrying chromosomes (7/7). This was not observed in either Alabama or Nord-Trøndelag. In 
the case of Alabama patients, 53% (9/17) of HLA-A*01-carrying chromosomes (or 56%, 5/9, 
of A*01-B*08 carrying chromosomes) do not conserve the A-A-T microhaplotype. In Nord-
Trøndelag patients, 87% (41/47) of chromosomes carrying HLA-A*01 (or 86%, 25/29, of 
A*01-B*08 carrying chromosomes) do not conserve the A-A-T microhaplotype. In the Nord-
Trøndelag population the A-A-T microhaplotype was not conserved in 42% (32/76) of A*02 
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carrying chromosomes. In contrast, the percentage of conservation was 96% (22/23) and 
100% (18/18) in Porto and Alabama cohorts, respectively. 
 
Table 3 Comparison of the conservation of the SNP microhaplotype A-A-T in 
chromosomes of HH patients from Porto, Alabama and Nord-Trøndelag 
  
Percentage (n) of haplotypes 
 
Associated HLA 
alleles 
Associated SNP 
microhaplotype 
Porto Alabama 
Nord-
Trøndelag 
P 
*
 
A*01 
     
 
Conserved  A-A-T 100% (16) 47% (8) 13% (6) 2.52x10
-9
 
  Non conserved A-A-T 0 53% (9) 87% (41) 
 
A*02 
     
 
Conserved A-A-T 96% (22) 100% (18) 58% (44) 3.06x10
-5
 
  Non conserved A-A-T 4% (1) 0 42% (32) 
 
A*03 
     
 
Conserved A-A-T 94% (50) 98% (53) 97% (148) n.s. 
  Non conserved A-A-T 6% (3) 2% (1) 3% (5) 
 
Non A*01-A*02-A*03 
     
 
Conserved A-A-T 74% (28) 76% (19) 89% (78) n.s. 
  Non conserved A-A-T 26% (10) 24% (6) 11% (10) 
 
* 
Relative frequencies of conserved and non-conserved haplotypes among three populations were compared 
using the Chi-square test (P values are indicated). 
 
Taken together, the present results further suggest that the recombination histories or 
founder effects of the C282Y-carrying HH chromosomes differ in the three hemochromatosis 
populations studied. This may affect other traits encoded in the same chromosomal region, 
including determinants of CD8+ T lymphocyte numbers or other putative modifiers of iron 
overload. 
 
4 - Associations of the CD8+ T lymphocyte phenotype with MHC markers in HH 
patients 
We sought to investigate the association of CD8+ T lymphocyte numbers with 
particular MHC markers. First, we analyzed the distribution of CD8+ T lymphocyte numbers in 
the three populations of HH patients, each of whom had C282Y homozygosity. Low CD8+ T 
lymphocyte numbers were common in patients from each geographic region (Fig. 2), but the 
distribution of T lymphocyte numbers differed. Patients from Porto and Alabama had a more 
striking deviation to low numbers than patients from Nord-Trøndelag (Fig. 2). 
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We then analyzed the associations of 
the “low CD8 phenotype” with particular 
extended haplotype combinations among the 
three different populations. A “low CD8 
phenotype” was defined as CD8+ T lymphocyte 
numbers below the 25% percentile in the 
respective controls, i.e., 310x103/ml for Porto 
and Alabama, and 319x103/ml for Nord-
Trøndelag (see Methods). The extended 
haplotype combinations were chosen to reflect 
the degree of conservation relative to the most 
common ancestral haplotype, i.e., if the A-A-T 
microhaplotype was conserved or not and, 
within A-A-T conserved haplotypes, if HLA-A*03 
was conserved or not (Table 4). We estimated 
the frequencies of “low CD8 phenotype” cases 
for each haplotype combination. The results, 
illustrated in Table 4, demonstrate that there are 
differences among the three populations. The 
“low CD8 phenotype” was significantly 
associated with the most conserved haplotypes 
carrying A-A-T and the HLA-A*03 in the 
populations from Porto (P=0.045) and Alabama 
(P=0.012) but not in the population from Nord-
Trøndelag. These associations were also 
reflected on the mean CD8+ T lymphocyte 
counts. Values in Porto and Alabama patients 
were significantly lower than the expected 
values in controls (P=0.0017 and P=0.021, 
respectively). 
  
Fig. 2 Distribution of peripheral blood CD8
+
 T 
lymphocytes in HH patients from Porto, Alabama 
and Nord-Trøndelag The dash lines indicate the 
mean value observed in the respective control 
populations 
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Table 4 Correlations between haplotype conservation and the CD8+ T lymphocyte 
phenotype in chromosomes of HH patients from Porto (n=128), Alabama (n=112) and 
Nord-Trøndelag (n=362). 
 
Relative frequency of the  
“low CD8 phenotype” in HH patients 
Mean (±SD) of CD8+ T lymphocytes(x10
3
/ml) 
in HH patients 
Extended haplotype 
combinations 
Porto Alabama 
Nord-
Trøndelag 
P value Porto  Alabama  
Nord-
Trøndelag  
P value 
Conserved-A-A-T  
With HLA-A*03 
44.0%  
(22/50)* 
49.0% 
(25/51)* 
25.7% 
(38/148) 
0.0026 370 ± 179* 369 ± 233* 507 ± 251 0.0001 
Conserved-A-A-T  
Without HLA-A*03 
39.4%  
(26/66) 
31.1% 
(14/45) 
38.3% 
(49/128)** 
n.s. 393 ± 194 453 ± 263 458 ± 259 n.s. 
Non-conserved- 
A-A-T 
16.7%  
(2/12) 
43.8% 
(7/16) 
31.4% 
(27/86) 
n.s. 540 ± 207 430 ± 331 469 ± 216 n.s. 
The percentage (case/total numbers) of patients with CD8
+
 T lymphocytes below the 25% percentile (“low CD8 
phenotype”) are indicated followed by the mean (±standard deviation) of CD8
+
 T lymphocyte counts (x10
3
/ml) for 
each haplotype combination. (P) Statistical significant differences among the 3 populations of patients (using the 
Chi-square test or One-way ANOVA, as appropriate, see M&M). (*) Results significantly lower (p<0.05) than the 
respective control populations (using the Chi-square test or Student T-test, as appropriate, see M&M). (**) Result 
significantly lower than the respective control due to a small (n=5) founder group of HLA-A*01 patients. The 
statistical significance is lost if this group is excluded. 
 
Taken together, the different patterns of association of the “low CD8 phenotype” with 
particular extended haplotype combinations in the three populations of patients suggest a 
stronger founder effect in the patients from Porto and Alabama with fewer recombination 
events between a putative locus marking the “low CD8 phenotype.” In patients from Nord-
Trøndelag, genotype/phenotype associations were apparently lost. 
 
5 - Associations of the iron phenotype with MHC markers in HH patients 
In order to analyze the effect of associated SNP microhaplotypes on the clinical 
expression of iron overload, HH patients were divided in two groups, according to the 
presence, in homozygosity, of the ancestral SNP microhaplotype A-A-T. For statistical 
purposes, males and females were analyzed separately. Results are presented in Table 5 
and Figure 3. No significant differences were found in females and no significant differences 
were found for TfSat in both males and females (Fig.3). In general, the average SF and TBIS 
values in male patients were significantly higher (respectively P=0.027 and P=0.021) in those 
homozygous for the A-A-T microhaplotype than in those carrying one or more non-A-A-T 
microhaplotype. Even if the average SF and TBIS values in male patients appeared higher in 
those homozygous for the A-A-T, no significant differences were seen in the 3 separate 
populations (Table 5). 
In conclusion, these results may support a general prediction of a more severe iron 
phenotypes in patients’ populations carrying the conserved A-A-T microhaplotype in 
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homozygosity, but they also show that, for individual purposes, the microhaplotype A-A-T 
cannot be used as a universal marker of iron phenotype in HH. 
 
 
Fig. 3 Effect of the SNP microhaplotypes on the expression of iron overload. Comparisons of the iron 
parameters: transferrin saturation (TfSat), serum ferritin (SF) and total body iron stores (TBIS) between groups of 
HH patients divided according to the associated SNP microhaplotypes (A-A-T homozygous or non-A-A-T 
homozygous). Males are represented by solid circles and females represented by open circles. Significant 
differences in the mean values (by the Student´s T test) are indicated by an * (P=<0.027). 
 
Table 5 Average values of total body iron stores (TBIS) and serum ferritin (SF) of HH 
male patients according to the associated SNP microhaplotypes (A-A-T homozygous 
or non- A-A-T homozygous) 
  All HH patients HH patients from 
  
 
Porto Alabama Nord-Trøndelag 
Average of TBIS (g) in:  
    
A-A-T homozygous  
male patients   
4.98 [4.24-5.85] 
(n=77) 
8.08 [6.42-10.11] 
(n=29) 
3.83 [3.01-4.88] 
(n=24) 
3.62 [2.75-4.76] 
(n=24) 
Non-A-A-T homozygous 
male patients 
3.37 [2.43-4.69] 
(n=27) 
7.11 [3.07-16.48] 
(n=5) 
3.23 [1.34-7.75] 
(n=8) 
2.65[1.87-3.77] 
(n=14) 
P* 0.021 n.s. n.s. n.s. 
Average of SF (ng/ml) in:  
    
A-A-T homozygous  
male patients   
849 [718-1004] 
(n=124) 
1764 [1296-2400] 
(n=36) 
818 [670-999] 
(n=24) 
571 [461-707] 
(n=64) 
Non-A-A-T homozygous  
male patients 
602 [470-771] 
(n=51) 
1652 [576-4737] 
(n=5) 
806 [402-1616] 
(n=8) 
496 [381-646] 
(n=38) 
P* 0.027 n.s. n.s. n.s. 
TBIS and SF are presented as geometric mean and 95% Confidence Interval for Mean [Lower Bound - Upper 
Bound]; the numbers of patients in each group (n) are indicated in each case. *(P) Statistical significant 
differences using the Student´s T- test (with log transformed values, see methods) 
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Discussion 
The question of HLA haplotype conservation in HH has been a focus of scientific 
interest for a long time, and several interpretations about its role in the recent evolutionary 
history of chromosomes carrying the C282Y mutation have been largely discussed [183-187, 
194, 197, 207, 208]. Besides the well described A*03-B*07 ancestral haplotype [183-187], 
also the A*01-B*08 haplotype is very long and resistant against recombination, and appears 
to be derived from a single ancestor [194, 197]. The present study explored the implications 
of haplotype conservation on HH patient’s phenotypes. While not confirming the value of the 
A-A-T microhaplotype as a universal predictive marker of iron overload in HH, the study 
revealed important differences in both the genetic composition and the genotype/phenotype 
correlations among the geographically distant populations which may help explaining 
differences in phenotype and local penetrance of the disease. The most relevant questions 
raised by these results were: Why do all A*01-B*08 haplotypes from Porto patients carry the 
conserved A-A-T microhaplotype, but only 47% in Alabama and 13% in Nord-Trøndelag? 
Why don’t we see an association of the A-A-T microhaplotype with low CD8+ T lymphocytes 
in the Nord-Trøndelag population, as we observe in Porto and Alabama? Could the selection 
of “non-conserved” chromosomes in HFE C282Y homozygotes may help us in future to 
identify the individual loci contributing to the “low CD8 phenotype” and/or other novel 
associated modifiers of iron overload? Could the loss of A-A-T microhaplotype provide the 
explanation for the mild phenotype of A*01-B*08 carriers in particular populations, such as 
the one described in a former Norwegian province in Sweden [197]? 
In a recent study, Baschal and co-workers analyzed HLA data and genotypes for 
thousands of SNPs across the MHC complex in a large number of families, demonstrating 
the occurrence of multiple common “completely” conserved complex SNP haplotypes in the 
MHC region, several of them influencing disease susceptibility [209]. They suggested that 
such conservation could also occur in other genomic areas and proposed that this type of 
analysis of conservation versus sub-conservation of extended haplotypes may be an 
important tool for further positioning of disease-associated loci. In the present study, we took 
advantage of the known occurrence of highly conserved MHC-linked haplotypes in patients 
with HH and its known association with a phenotype of low CD8+ T lymphocyte numbers to 
study the distribution and composition of the HH-associated chromosomes and explain 
differences found in genotype/phenotype correlations among three geographically distant 
populations. Although high frequencies of the low CD8+ T lymphocyte phenotype were found 
in all HH populations, the pattern of association of this phenotype with particular haplotypes 
differed among patients from the three geographic regions, possibly reflecting diverse 
haplotype structures due to different recombination histories or founder effects. 
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Haplotype heterogeneity among populations 
The simple analysis of the distribution of HLA associated haplotypes (Table 2), in 
addition to the degree of conservation of the associated A-A-T SNP microhaplotype (Table 3, 
Fig. 1) in the three cohorts of patients from Porto, Alabama and Nord-Trøndelag, shows that 
the strong association of HH with the HLA-A*03-B*07 haplotype is the most consistent 
observation in all populations studied, confirming the existence of a common ancestral 
haplotype subsequently modified by recombination and geographical scattering due to 
migrations [184]. The diversity of associations with other haplotypes reveals differences 
among populations which agree with the expected differences in the history of their HH-
carrying chromosomes, taking into consideration particular founder effects or the time for 
recombination events. The most stricking differences are observed in chromosomes carrying 
HLA-A*01 (which include the ancestral HLA-A*01-B*08), in which the SNP microhaplotype A-
A-T was conserved in 100% chromosomes of Porto patients, while it was less conserved in 
patients from Alabama (47%) and much less conserved in or Nord-Trøndelag patients (13%) 
(see Fig.1), supporting the different founder effects or distinct recombination histories in the 
respective populations. The highest haplotype diversity observed in the Nord-Trøndelag 
population is also consistent with the high frequency of HFE C282Y in Norwegians [199, 200, 
210], possibly related with characteristics of rapid population growth that has occurred in 
northwestern Europe since the Celtic period [194]. On the contrary, patients from Alabama 
showed the lowest haplotype diversity, reflecting a more recent founder effect. A previous 
study showed that aggregate "British Isles" or Scotland indices of ancestry were significantly 
greater and the proportion of non-British Isles, non-Native American ancestry was 
significantly lower in Alabama hemochromatosis probands with HFE C282Y homozygosity 
than in population control subjects [211, 212]. These observations suggest that British Isles 
ancestry likely accounts for the relatively high C282Y allele frequency and association of 
HLA-A*03-B*07 and HFE C282Y in central Alabama whites. Therefore, the evidence of a 
recent founder effect in Alabama HH patients suggested by the present results agrees with 
the previous ancestry studies and with the predominance of English people among whites 
who migrated to and settled the geographic area of the present State of Alabama in the late 
18th and early 19th centuries [213, 214]. HLA-A*03-B*14 also occurred in hemochromatosis 
chromosomes from Alabama and Nord-Trøndelag patients. Although this haplotype is also 
described as a common HH ancestral haplotype in hemochromatosis populations in many 
northwestern European countries, particularly in Scandinavia [208], its appearance in 
Alabama HH patients is unlikely to be attributed predominantly to Norwegian or other 
Scandinavian founders because ancestry reports from these geographic areas of Europe are 
rare in Alabama hemochromatosis probands and population control subjects [211]. 
Nevertheless this haplotype could have a common ancestral Irish origin and be spread in 
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Norway by the close contacts between Ireland and Scandinavia through the Vickings’ 
movements [207, 208]. In the case of Porto patients, the relative low diversity of HH 
haplotypes could be attributed to the particular demographic characteristics of the 
Portuguese population in the north region namely the unipolar mode of migration and the low 
rate of mobility from other regions [215]. Significant regional differences were previously 
found in the distribution of the C282Y mutation in Portugal with the highest frequencies found 
in the north of the country [216]. In terms of historical population settlements, it is well 
recognized that there is a geographical and cultural boundary between the north and the 
south of Portugal documented by archeological, ethnographic and linguistic records [215], all 
favoring the notion that a stronger Celtic influence in the north could map the founder HH 
chromosomes in this region by the 6th century BC. The hypothesis that the later 
Nordic/Suevian occupation and settlement, which also occurred only in the north of the 
present country, could also contribute to the increased frequency of the mutation cannot be 
excluded. The present results of divergent patterns of haplotype conservation and 
genotype/phenotype associations in patients from Porto and Nord-Trøndelag do not favor a 
strong Scandinavian HH founder effect in north Portugal. 
 
Effect of haplotype conservation on the CD8+ T lymphocyte phenotype 
It is well known that the existence of different founder effects and different 
recombination histories at the MHC region affect the transmission of other genetic traits 
encoded in the same chromosomal region [182].The previously demonstration that CD8+ T 
lymphocyte numbers are transmitted in association with particular HLA haplotypes in 
Portuguese HH patients [41, 43] prompt us to analyze if the same association was also 
observed in the other HH populations. We confirmed that the phenotype of low CD8+ T 
lymphocytes was commonly observed in each of the three populations, but their respective 
distributions (Fig. 2) and their genotype/phenotype correlations (Table 4) varied. The “low 
CD8 phenotype” was significantly associated with the most conserved ancestral haplotype 
carrying A*03-A-A-T in the cohorts from Porto (n=50) and Alabama (n=51) but it was not 
associated in a much greater series from Nord-Trøndelag (n=148). This lack of association of 
the common ancestral haplotype with the “low CD8 phenotype” in Nord-Trøndelag patients is 
intriguing. One should stress however, that discrepancies in expected genotype/phenotype 
correlations can also be highly informative regarding the localization of genetic traits. That 
individual chromosomes with the same alleles (A*03, A-A-T) may or may not be associated 
with the “low CD8 phenotype” indicates that these alleles are not, by themselves, 
determinants of the trait, further supporting the hypothesis of another independent, still 
unidentified, genetic marker in the region. The time and place, during the evolutionary history 
of the HH chromosomes, when the association occurred remains unknown. Further studies 
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of genotype/phenotype correlations in other populations with different founder effects could 
clarify this question. As suggested by Olsson and co-workers [207], it would be of great 
interest to explore further the HLA haplotype/phenotype correlations in an extended 
population of patients from the Trøndelag region, because of its long historic close contacts 
with the British islands, the supposed origin of founders of the “Celtic” haplotypes in 
Scandinavia [207]. On the other hand, results from Porto and Alabama support the postulate 
that a major genetic determinant of CD8+ T-lymphocyte numbers is transmitted in linkage 
disequilibrium with HFE in this ancestral haplotype and suggest these populations as good 
targets to further position a candidate locus associated with the transmission of low CD8+ T 
lymphocyte phenotypes. The evidence that the association is lost not only in chromosomes 
without the A-A-T SNP microhaplotype but also, within the A-A-T conserved haplotypes, in 
chromosomes without the ancestral A*03 allele (Table 4), favors the localization of such a 
putative trait between HLA-A and PGBD1. Future studies in these populations should 
consider selecting “non-conserved” chromosomes, i.e., those with discontinuous regions of 
conservation to the consensus haplotypes, to facilitate the search for individual loci 
contributing to the trait. 
 
Effect of the SNP microhaplotypes on the iron overload phenotype 
In addition to its association with a ”low CD8 phenotype”, the conservation of the 
ancestral A-A-T microhaplotype had been previously shown to be associated with a more 
severe iron overload phenotype [44]. In the present study we showed that, although in 
general, the presence in homozygosity of the A-A-T microhaplotype was associated to higher 
values of serum ferritin and total body iron stores in male patients, this association was not 
significantly sustained at the individual populations’ level and therefore cannot be used as a 
reliable universal marker of the phenotypic expression in HH (Table 5). The lack of statistical 
power in individual populations could be explained by the low numbers of non-A-A-T 
homozygous patients found in each region together with a high phenotypic diversity in these 
patients (reflected in the high range of values shown in Table 5), but it could also be 
influenced by genetic differences among populations, namely the loss of association of the 
A-A-T microhaplotype with the putative ”low CD8 phenotype” marker in the Nord-Trøndelag 
patients. One should also note that these patients were mainly identified by screening of 
asymptomatic subjects, therefore unselected for clinical severity. On the contrary, Porto and 
Alabama, patients were mainly diagnosed on a clinical setting. Nevertheless, even using the 
same selection criteria, there are also great differences in iron loading between Porto and 
Alabama patients that could be related with different environmental factors or local life-style 
habits, including regular alcohol consumption. Therefore, further studies are still needed in 
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larger populations and with a higher density mapping of the region, in order to find a more 
specific and universal surrogate marker of iron overload severity in HH. 
 
Concluding remarks 
We conclude that the evolutionary history of long extended haplotypes on 
chromosome 6p21.3 could account for heterogeneity within the haplotypes and consequent 
differences in the phenotypic expression of persons with HFE C282Y related HH. These 
observations have important implications for the interpretation of genotype/phenotype 
association studies in HH such as in the case of MHC loci associated with the transmission 
of the phenotype of low CD8+ T lymphocyte numbers where differences occur among HH 
populations from geographically distant regions (namely in north Portugal, Norway and 
Alabama, USA) or the association of MHC markers with iron overload. The effect of 
haplotype conservation may also have implications for understanding differences in disease 
penetrance or the consequences of patients’ sampling according to different detection 
methods. Although no consistent evidence is given about the predictive value of the A-A-T 
microhaplotype for individual purposes, one may predict that, in general, any cohort of 
severe or symptomatic HH patients may contain a high frequency of this conserved ancestral 
haplotype associated with a “low CD8 phenotype”, such as we have consistently found in 
Portuguese patients. On the contrary, in populations where programs for screening of 
asymptomatic cases are implemented, such as in Norway, it will be more probable to find HH 
patients with non-conserved haplotypes that are not associated with low CD8+ T 
lymphocytes. It remains unknown whether the severity of iron overload depends directly on 
the “low CD8 phenotype” or whether another independent modifier of the iron phenotype is 
inherited in linkage disequilibrium. Naturally, future positional cloning of a long-sought major 
genetic trait in MHC associated with the transmission of CD8+ T lymphocyte numbers [181] 
should provide answers to this question. 
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Supplementary Data 
 
Table S1 - Comparison of the most common HLA allele, HLA A-B haplotype 
(uncorrected data) and SNP microhaplotype frequencies among three different 
populations of HH patients. 
 
 
Porto 
(n=130) 
Alabama 
(n=114) 
Nord-Trøndelag 
(n=364) 
P* 
 
HH chromosomes of 
patients from: 
 
HLA- A alleles [%(n)] [%(n)] [%(n)]  
     
HLA-A*01 12.3 (16) 14.9 (17) 12.9 (47) n.s. 
HLA-A*02 17.7 (23) 15.8 (18) 20.9 (76) n.s. 
HLA-A*03 40.8 (53) 47.4 (54) 42.0 (153) n.s. 
HLA-A*11 3.1 (4) 3.5 (4) 8.0 (29) n.s. 
HLA-A*24 3.8 (5) 3.5 (4) 5.8 (21) n.s. 
HLA-B alleles 
 
[%(n)] 
 
[%(n)] 
 
[%(n)] 
 
 
HLA-B*07 23.8 (31) 30.7 (35) 28.8 (105) n.s. 
HLA-B*08 10.0 (13) 11.4 (13) 9.1 (33) n.s. 
HLA-B*14 3.8 (5) 9.6 (11) 7.1 (26) n.s. 
HLA-B*15 1.5 (2) 1.8 (2) 6.0 (22) n.s. 
HLA-B*35 12.3 (16) 3.5 (4) 5.5 (20) .009** 
HLA-B*40 7.7 (10) 0.9 (1) 9.6 (35) .008** 
HLA-B*44 12.3 (16) 14.0 (16) 16.2 (59) n.s. 
HLA Haplotypes 
 
[%(n)] 
 
[%(n)] 
 
[%(n)] 
 
 
A1-B8 5.4 (7) 7.9 (9) 7.7 (28) n.s. 
A2-B44 3.1 (4) 7.0 (8) 6.3 (23) n.s. 
A3-B7 16.9 (22) 27.2 (31) 21.4 (78) n.s. 
A3-B14 1.5 (2) 7.0 (8) 6.0 (22) n.s. 
SNP microhaplotypes 
 
[%(n)] 
 
[%(n)] 
 
[%(n)] 
 
 
A-A-T 90.8 (118) 86.0 (98) 76.5 (276) 0.0003 
G-G-G 6.2 (8) 9.6 (11) 16.0 (59) 0.003 
Non A-A-T nor G-G-G 3.1 (4) 4.4 (5) 7.5 (27) n.s. 
*Comparisons among populations were done using the Chi-square test (P values indicated)
 
** not statistically significant after Bonferroni correction 
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Abstract 
Background: Genetic analyses in patients with Hereditary Hemochromatosis (HH) have 
shown that the relative frequencies of the most common MHC haplotypes and their 
associations with a phenotype of low CD8+ T lymphocyte numbers vary amongst distinct 
populations, reflecting different recombination histories or founder effects. 
Aims & Methods: To refine the region of interest to search for quantitative trait loci (QTL) for 
the inheritance of low CD8+ T lymphocyte numbers in HH, we performed a high-density SNP 
mapping of the 4 Mb genomic region between HFE and HLA-B in a cohort of 43 HH patients 
and in 105 control subjects from the same area in north Portugal. Haplotype genealogies 
were inferred by phylogenetic analyses and the distribution of CD8+ T lymphocyte numbers in 
HH patients was analyzed in relation to the inheritance of conserved or recombinant 
haplotypes. 
Results: Two major haplotype groups, defined by a block of 4 SNP markers, were identified 
in patients and controls. They were designated, according to the two flanking alleles, as the 
AA and CG haplotype groups. A remarkably higher genetic homogeneity is observed in 
haplotypes from the AA relative to the CG group, both in HH patients and controls, 
suggesting that recombination suppression is somehow favored in chromosomes carrying 
this particular combination of alleles. Accordingly, in HH the most common and conserved 
HLA-A*03-B*07 associated ancestral haplotype is included in the AA group, while the less 
common HLA-A*01-B*08 associated ancestral haplotype is included in the CG group. 
Haplotype genealogies confirmed the distribution of HH chromosomes in two opposite 
phylogenetic branches and genotype/phenotype distributions support the co-inheritance of a 
low CD8 phenotype with the more conserved haplotypes of the AA group.  
Conclusions: A high-density map of the HFE-HLA region in chromosomes from Portuguese 
HH patients highlights the remarkable conservation of ancestral haplotypes associated with a 
major QTL determining CD8+ T lymphocyte numbers, and provides evidence to support a 
selective suppression of recombination in the context of particular haplotypes in this region.  
 
Keywords: Hereditary Hemochromatosis, HFE, HLA haplotypes, CD8+ T lymphocytes 
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Introduction 
The Hereditary Hemochromatosis (HH) associated gene was first localized in 1976 
based on its strong association with HLA [162]. This was the first step towards the later 
positional cloning of the HFE gene in 1996 [27]. The 20 years’ delay in the discovery of the 
HFE gene is easily understood taking into consideration the extreme linkage disequilibrium 
known to occur in the 4 Mb region between HFE and HLA [207, 217-219]. The finding that 
one single HFE mutation (p.C282Y) in homozygosity explains the vast majority of HH cases 
[27] naturally concentrated all the attention on the HFE molecular defect as the single 
pathogenic player in HH, generally neglecting the possibility that other MHC linked players 
could be involved in the disease process. Nevertheless, this chromosomal region is 
extremely rich in other immune related genes transmitted in linkage disequilibrium with HFE 
which could concur for the disease expression. It is known that HH is clinically highly 
heterogeneous and this phenotypic variation was shown to be associated with the HLA 
haplotypes, independently of the HFE mutation [43, 190, 192]. Relevant to this concept is not 
only the demonstration of an iron overload phenotype in various MHC deficient animal 
models [23, 24, 28, 35] but also the consistent finding of abnormalities of CD8+ T lymphocyte 
numbers in HH patients, a phenotypic trait that what demonstrated to be inherited in 
association with the HLA markers [30, 41]. A recent genome wide association study in 
normal subjects provided more evidence to support the existence of a major quantitative trait 
loci (QTL) involved in the genetic control of CD8+ T lymphocyte numbers located in the class 
I cluster of the MHC region [181], thus reinforcing our interest to look for such QTL in HH. 
In 2008 Cruz et al. described a new 500kb haplotype (A-A-T) localized between HLA 
and HFE which was associated with the transmission of a low CD8 phenotype and a more 
severe expression of iron overload in Portuguese HH patients [44]. More recently we tested 
the predictive value of this microhaplotype as a putative useful marker in other 
geographically different populations by comparing the genotype-phenotype associations in 
HH patients from Porto, Portugal, Alabama USA and Nord-Trøndelag, Norway. The results 
(described in detail in chapter 3.1) showed that the A-A-T microhaplotype alone cannot be 
used as a universal marker of the CD8 phenotype since the genotype-phenotype 
associations varied significantly among the different HH populations, probably due to 
different recombination histories or founder effects[220]. 
In the present study we refined the mapping of the region between HFE and HLA with 
a total of 63 genetic markers analyzed in 43 HH patients and 105 normal controls from the 
same geographical region in north Portugal. Our choice to focus on Portuguese HH patients 
in this study was justified by the previously demonstrated stronger genotype/phenotype 
correlations in this population [220]. The results obtained allowed us to characterize the 
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structure and history of the two major conserved extended haplotypes associated with HH in 
this population, and better explore their associations with the transmission of a low CD8 
phenotype. 
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Material & Methods 
Study Populations  
HH Patients 
A group of 47 Portuguese HH patients (41 probands and 6 affected relatives) from 
north Portugal, mainly from the Porto district area, were included in this study. They had 
been diagnosed between 1985 and 2011 at the Hemochromatosis Outpatient Clinic of CHP-
Santo António Hospital, Porto. Most of the patients’ clinical information, including available 
genetic information, has been already described elsewhere [41, 43, 44, 188, 198-200]. The 
previously available genetic information included, in all cases, HFE genotype (all patients are 
homozygous for the p.C282Y mutation), HLA class I alleles (A, B and C) determined by low-
resolution DNA-based techniques (PCR/sequence-specific oligonucleotide probes, Dynal 
RELI™ SSO) and typing for the microsatellites D6S265, D6S2222, D6S105 and D6S2239. 
Information on the CD8+ T lymphocyte numbers was available from their medical records. 
Analyses of novel genetic markers were performed in stored DNA samples previously 
obtained with proper informed consent in the context of other studies (Cruz 2008, Costa et al 
2014) with the approval of the CHP- Santo António Hospital Ethical Committee. 
 
Controls 
For the purpose of comparative analyses, the same SNP markers were analyzed in a 
control population of 105 unrelated Portuguese healthy blood donors from whom we had 
available stored DNA collected with proper informed consent in the context of another 
genetic study [42]. Previous genotypic and phenotypic information of these controls included 
HFE, HLA A, B and C, ZNF305, PGBD1, ZNF193, ZNF165 genotypes as well as CD8+ T 
lymphocyte phenotypes.  
 
High-density mapping of the region between HFE and HLA-B 
A high density mapping of the region between HFE and HLA-B was performed 
including, besides the previously available information on HFE, ZNF305, PGBD1, ZNF193, 
ZNF165 and the microsatellites D6S265, D6S2222, D6S105 and D6S2239 (published in 
[44]), additional information on the following 46 selected SNP markers: rs10447393, 
rs10807035, rs10946940, rs12174753, rs12180820, rs12197514, rs13195291, rs13197633, 
rs13200462, rs13201308, rs13201411, rs13204012, rs13205211, rs13205911, rs13208096, 
rs13211507, rs13215560, rs13217162, rs13218430, rs16893666, rs16893741, rs16893817, 
rs16893827, rs16893889, rs16893892, rs16893917, rs16901846, rs17711344, rs17711801, 
rs17720293, rs17720687, rs17774663, rs4713207, rs4713211, rs6902687, rs6912843, 
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rs724078, rs7381993, rs7382112, rs7382146, rs7383248, rs9257425, rs9257816, 
rs9393920, rs9468217, rs9468344. 
The chromosomal physical localization of the analyzed markers region is shown in 
Figure 1. 
 
Fig. 1 Distribution of the 63 SNP markers in chromosome 6 along the region from HLA-B to the HFE gene. 
 
SNPs were typed using the iPLEX™ Gold technology (Sequenom MassARRAY) in 
the USC node of the Spanish National Genotyping Center (CEGEN). Genotyping call rates 
were 99% for all individuals included in the analyses. Additional quality control measures 
included SNP missingness >10% and the use of positive and negative controls. None of the 
SNPs failed the missingness threshold. More details for SNP analysis can be provided by 
request. 
 
Generation of phased chromosomes and haplotype construction 
HLA A-B haplotypes, as well as the microhaplotypes defined by the genes PGBD1, 
ZNF193 and ZNF165 were defined in HH patients by family segregation whenever there 
were available informative family members. Otherwise they were inferred by the PHASE 
program. For the generation of high-density SNP extended haplotypes, we used the PHASE 
program to infer haplotypes. In the case of HH chromosomes, whenever the phase 
assignment was known (this happened for the markers: HLA A, B and C, ZNF305, PGBD1, 
ZNF193, ZNF165 and for microsatellites D6S265, D6S2222, D6S105 and D6S2239), this 
information was incorporated in the program. In total, high-density extended haplotypes were 
defined in 86 HH founder chromosomes (these are the two chromosomes from each 
unrelated proband and the unshared chromosomes in first degree relatives) and in 210 
control chromosomes. 
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Definition of haplotype groups and haplotype conservation 
An initial search for groups of conserved haplotypes within HH founder chromosomes 
identified two groups of chromosomes with a specific consensus sequence defined by 4 
SNPs between rs7382112 and rs7383248, termed “haplotype group.” The same haplotype 
groups were also found in control chromosomes. Chromosomes within each group were then 
compared to the respective consensus sequences that were defined as the most common 
sequence with complete SNP identity between HFE and HLA-B (respectively in HH patients 
and controls). We defined “loss of conservation” when one or more SNPs did not match the 
consensus sequence. Chromosomes were aligned and compared at 5 consecutive blocks 
from HFE to HLA-B and the conservation pattern (conserved vs non-conserved) was defined 
for each block. 
 
Statistical methods  
SNP data from all chromosomes was analyzed with MEGA4 to create a neighbor 
joining tree. Input data consisted in 302 chromosomes (210 from controls and 86 from HH 
patients), 53 SNPs per chromosome and ID numbers encoding HLA data (neither HLA nor 
microsatellite data were used to create the tree). To create the tree we used a pair wise 
comparison option with pairwise deletion and the neighbor-joining method (a distance based 
method) implemented in MEGA4. 
To analyze the impact of haplotype conservation on the CD8+ T lymphocyte numbers, 
patients were classified in three classes according to the inheritance of conserved or non-
conserved haplotypes: class 1 patients were the homozygous for the ancestral haplotype of 
the AA group, class 2 and 3 patients were the compound heterozygous for the ancestral AA 
group haplotype with a non-conserved haplotype of the AA or the CG groups respectively. 
Distributions of CD8+ T lymphocyte numbers were fitted to a normal curve in each class. 
Values above 1,5 SD of the mean value in the whole group of patients were assigned as 
“CD8 expansions”. Because of sample size limitations in multiple comparisons, statistical 
inferences were not applied. Data were analysed by SPSS software for statistical Analysis 
(SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.). 
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Results 
1 -Two haplotype groups characterize the MHC region between HFE and HLA 
We generated extended haplotypes with genetic information of 63 markers in 
the region from HFE to HLA-B in 86 HH founder chromosomes (see Methods). These 
are illustrated in Figure 2 (left panel), where the extended haplotypes are aligned by 
allele similarity. A detailed observation of the region between HFE and HLA-A reveals 
that this region is composed of several spread blocks of complete allele identity 
(highlighted in Figure 2 by dark yellow boxes) alternated with other blocks of some 
variability. In one block, defined by 4 SNP markers from rs7382112 to rs7383248, 
there is a clear segregation of all (except one) HH chromosomes into two major 
groups, each maintaining its identity defined by the four selected markers (highlighted 
in Figure 2 by framed boxes, bold lettering and different colours). The two groups 
were designated, according to the two flanking alleles, as the AA and GC haplotype 
groups, respectively. Of the two haplotype groups, AA was the most common (66/86) 
and the CG group the less common (19/86). All chromosomes carrying the previously 
described classical HH ancestral HLA haplotype A*03-B*07 were contained in the AA 
group, whereas all chromosomes carrying the HLA haplotype A*01-B*08 were 
contained in the CG group. Analysis of the same SNP markers in a sample of 210 
control chromosomes derived from 105 normal subjects from the corresponding 
geographical regions as the HH patients showed that the same haplotype groups are 
also found in normal chromosomes. Results are illustrated in Figure 2 (right panel) 
where, for the purpose of comparisons with HH derived haplotypes, the same color 
coding was used. Such as in HH patients, the AA haplotype group was the most 
common (113/210) and the CG group the less common (91/210). A small proportion 
of chromosomes (6/210) could not be included in either of the two defined haplotype 
groups. Since these haplotypes were inferred using PHASE (see methods) we admit 
that wrong inferences could account for these few apparent exceptions. 
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27 2 136 32 G   A    G  T A G C A T C A A G T C T  A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G T C G T C T C T
44 136 32   G    A  A C G A T A T C A A G T C T  A G T T A A A C A C T G  A T A G G T C C G C G T C T 245 150 G G T C A C G G T C
41 2 148 33 G A A C G A T A T C A A G T C T A G T T A A A C A C T G A T A G G  T C C G C G T C T 247 150 G G C C G T C T C T
14 8 148 33   G  A G T A   G    C  A T C A A G T C T  A G T T A A A C A C T G  A T A G G T C C G C G  T C T 247 156 A A T G A C G G T C
47 66 G A G T G A T A T C A A G T C T A G T T A A A C A C T G A T A G G  T C C G C G T C T 247 150 G G C C G T C T C T
18 12 138 68   G    A  A C G A T A T C A A G T C T   A  G T T A A A C A C T G   A  T A G G T C C G C G T C C 245 160 A A T G G T C T C T
18 12 138 A A A C G A T A T C A A G T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
14 8 G A A T G A T A T C A A G T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
8 7 132 1 G   C    G    C  A A T C C T G A A C T G G G C T A A A  G C T G A G T A A A  T T T A G A C G C 249 160 A A T G G T C T C T
8 7 132 1 G   C  G T A A T C C T G A A C T G G G C T A A A  C C T G A G T A A A T T T A G A C G C 249 160 A A T G G T C T C T
8 7 132 1 G C G T A A T C C T G A A C T G  G G C T A A A G C T G A  G T A A A T T T A G A C G C 249 160 A A T   G  G T C T C T
8 7 132 1 G C G T A A T C C T G A A C T G G G C T A A A  G C T G A G T A A A T T T A G A C G C 249 160 A A T G G T C T C T
8 7 132 1 G C G T A A T C C T G A A C T G G G C T A A A  G C T G A  G T A A A  T T T A G A C G C 249 160 A A T G G T C T C T
44 15 132 1 G   C  G T A A T C C T G A A C T G G G C T A A A  G C T G A G T A A A  T T T A G A C G C 249 160 A A T G G T C T C T
44 15 132 1 G   C  G T A A T C C T G A A C T G G G C T A A A  G C T G A G T A A A T T T A G A C G C 249 160 A A T G G T C T C T
7 7 132 1 G C G T A A T C C T G A A C T G G G C T A A A   G  C T G A G T A A A T T T A G A C G C 247 160 A A T G G T C T C T
51 5 132 1 G   A    G  T   A  G C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
7 15 132 1 G A G T A G C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 132 1   G  A G T A G C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 5 132 1   G    A  G T A G C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 12 132 1   G    A  G T A G C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
35 4 132 1 G A G T A G C C C T G A   A  C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
7 6 132 1 G A G T A G C C C T G A A C C T A G T T A A A C A C T G  A T A G G T C C G C G T C T 249 146 G   G    T    C  G T C T C T
35 14 132 1   G    A  G T A G C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 148 G G   T  C G T C T C T
44 132 1 G A G T A G C C C T G A A C T G G G T C A G A C A C T G   G  T G G G T C C G C G T C T 249 150 G G T C G T C T C T
7 132 1 G   A    G  C A G C C C T G G A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
40 136 1 A C A C G A T C C T G G A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G   C  C G T C T C T
35 4 136 2 G A A   C    G  A T   C    C    T    G  A G T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 251 150 G G T C A C G G T C
136 2 G A A T G G C C C T G A A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 7 134 2 G A A   T  A A T C C T G A A T C T A G T T A A A C A C T G   G  T A G G T C C A G A C G C 249 150 A A T G A T C T C T
12 140 2 G A A T A A T C C T G A A T C T  A G T T A A A C A C T G  G T A G G T C C A G A C G C 251 170 A A T   C  A T C T C T
57 6 136 2 G A A T A A T C C T G A   G  T C T A G T T A A A C A C T G  A T A G G T C C G C G T C T 249 150 G G T C G T C T C T
58 7 134 2 G A A T A A T C C T G A A T C T  A G T T A A A C A C T G  A T A G G T C C G C G T C C 249 162 A A T G G T C T C T
51 7 134 2   G    A  A T A A T C C T G A A T C T A G T T A A A C A C T G  G T A G G T C C A G A C G C 249 150 A A T G A T C T C T
18 7 138 2 G A G T A G C C C T G A A  C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 247 150 G G T C G T C T C T
14 5 136 2   G    C  A C G A T   C    C    T    G  A   A  T C T A G T T A A A C A C T G  A T A G G T C C G C G T C T 247 160 A A T G A C G G T C
18 2 136 2 G C   A  C G   G    C  C C T G   G  A T T G G A T T A G G C A C T G G C A G G T C C A G A C G C 249 162 A A T G G T C T C T
38 134 2 G   C  A T   A  G C C C T G G A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
27 1 138 2 G C G T A A T C C T G A A C T G G G C T A A A   C  C T G A G T A A A T T T A G A C G C 247 160 A A T G G T C T C T
15 16 136 2 G C G T A A C C C T G  A A C T G G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
8 7 132 2 G   C  G   T  A G C C C T G G A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 152 G G T C G T C T C T
16 136 2 G C G T A G C C C T G G A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C A C G G T C
44 2 A C A   C  G A T C C T G A A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
35 4 132 2 A C A C G A C C C T G A A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
49 7 132 2 A C A C G A C C C T G A A C C T  G G T T A A A C C C T G  A T A G G T C C A G A C G C 253 150 G G C C A T C T C T
49 7 130 2 A  C A C G A C C C T G A A C C T  A G T T A A A C C C T G  A T A G G T C C A G A C G C 253 150 G G C C G T C T C T
45 2 A C A   T  G A T C C T G A A T T G G A T T G G A C A C T G G T A G G C C C G C G T C T 251 156 G A T G A C G T T C
58 134 2   A    C  A T A A T C C T G A A T C T  A G T T A A A C A C T G  G T A G G T C C A G A C G C 249 156   G  A T G A   T    C    T    C    T  
48 8 136 2   A    C  A T A A T C C T G A G T C T  A G T T A A A C A C T G  A T A G G  T C C G C G T C C 249 166 A A T G A T C T C T
51 16 2 A C   A   T A G C C C T G G A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
7 7 2   A  C G T A G C C C T G G A C T G  G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 2 128 3 G   A  A T A A T C C T G A A T C T A G T T A A A C A C T G  A T A G G T C C G C G T C T 249 150 G G C C G T C T C T
18 12 128 3   G    A  G   T  A G C C C T G A A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 152 G G T C G T C T C T
8 128 3   G    A    G  T A A T C C T G A A T C T G G T T A A A C A C T G G T A G G T C C G G A C G C 249 150 G G T C G T C T C T
15 2 134 3 G   C  A C G A T C C T G G A T C T  G A T T A G G C A C T G G C A G G T C C A G A C G T 251 160 A A T G A C G G T C
14 8 128 3 G C G  C A G C C C T G G A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 152 G G T C G T C T C T
15 3 128 3 G   C  G C A G C C C T G G A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 152 G G T C G T C T C T
50 6 3 A C A C A G C C C T G G A T T G G A T T A G G C A C T G G C A G G T C C A G A C G C 249 162 A A T G G T C T C T
14 15 128 3 A C A C A A T C C T G  A  A T T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G A T G G T C T C T
44 4 128 3   A    C  A C G A T   C    C    T    G  A   A  C C T   G  G T T A A A C   C  C T G   G  T A G G  T C C   A    G    A    C    G    C  251 150 G G C G A C G G T C
51 14 136 5 G A A T A A T C C T G A A T C T A G T T A A A C A C T G   G  T A G G T C C G C G T C T 249 150 G G T C G T C T C T
51 16 132 11 G A A   T  G G C C C T G G A T T G A A T T A G G C A C T G G C A G G T C C A G A C G C 249 160   A    A  T   G  G T C T C T
35 4 136 11   A    A  A T A A T C C T G A A T C T A G T T A A A C A C T G G T A G G  T C C A G A C G C 249 166 A A T G A T C T C T
3 138 11 A C   G  C   G  G C C C T G G A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
18 2 132 11 G   C    G    T  A G C C C T G G A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 249 156 G   G  T   C  A C G G T C
14 8 130 23 G  A G T A G C C C T G G A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 2 130 23 G   C  G T A G C C C T G   G  A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
44 4 132 23 G C   G  C G   A    T  C C T G   A  A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
50 4 132 23 A C G T A G C C C T G G A C T G  G G T C A G A C A C T G  G T G G G  T C C G C G T C T 251 130 G G T C G T C T C T
45 6 24 G A A T A A T C C T G A A T C T A G T T A A A C A C T G G T A G G  T C C A G A  C G C 249 160 A A T G G T C T C T
38 12 132 24   G    A  A T A A T C C T G A A T C T  A G T T A A A C A C T G  G T A G G  T C C A G A C G C 247 150 A A T G A T C T C T
37 6 132 24   G    A  A T A A T C C T G A A T C T A G T T A A A C A C T G   G  T A G G T C C G C G T C T 249 150 G G   T  C G T C T C T
55 3 132 24   G    A  A T A A T C C T G A A T C T  A G T T A A A C A C T G  G T A G G T C C   A  G A C G C 249 158 G A T G A C G G T C
35 4 132 24   G  C   G    T    G  G C C C T G G A C T G G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150   G   G   C    C  G T C T C T
27 134 24 A C A T   G  A T C C T G A A T   T    G    G    A  T T A   G  A C A C T G G T   A  G G T C C A G A C G C 249 162 A A T G G T C T C T
39 7 132 24 A C A   T  G A T C C T G A A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 249 150 G G C C G T C T C T
39 7 132 24   A    C  A T G A T C C T G A A T C T A G T T A A A C A C T G G T G G G T C C G C G T C T 247 148 G G   C  C G T C T C T
18 7 132 24 A C A   T  G A T C C T G A A T T G G A T T G G A C A C T G G T A G G C C C G C G T C T 251 156 G A T G A C G T T C
57 6 132 24 A C   G  C A G C C C T G G A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
38 12 26 A C G C A G C C C T G G A T T G  G G T T A G A C A C T G  G T A G G T C C G C G T C T 249 150 G G T G G T C T C T
44 4 138 29 G A A T A G T C C T G A A T C T A G T T A A A C A C T G  G T A G G T C C A G A C G C 249 150 A A T G A T C T C T
44 16 136 29   G    A  G T A G C C C T G A A T C T G G T T A A A C A C T G G T A G G T C C G G A C G C 249 158 G A   T  G A C G G T C
51 15 138 29 G   C    A  T A G C C C T G G A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
51 15 138 29 G C   A  T   A  G C C C T G G A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
15 128 29   G    C    G    C  A G C C C T G G A T C T A G T T A A A C A C T G A T A G G  T C C G C G T C T 247 150 G G C C G T C T C T
44 16 138 29 G   C    G    T  A  G T C C T G G A C T G  G G T C A G A C A C T G  G T G G G T C C G C G T C T 249 150 G G T C G T C T C T
7 15 152 29 A   C  A   T    A  A C C C T G A A C T G G G T C A G A C A C T G G T G G G T C C G C G T C T 249 146 G G T C G T C T C T
44 138 30 G A G T A G C C C T G G A C T G  G A T C A G G C A C T G  G C G G G T C C G C G T C T 249 150 G A T C G T C T C T
40 138 30 A C A T   A  A T C C T G A A T   C    T    A    G  T T A   A  A C A C T G G T   G  G G T C C G C G T C T 249 150 G G C C G T C T C T
18 7 132 30 G   C    A  C   G  G C C C T G G A T T G G A T T A G G C A C T G G C A G G T C C A G A C G C 249 162 A A T G G T C T C T
14 8 136 31   A    C  A T A A T C C T G A A T C T A G T T A A A C A C T G  G T A G G T C C A G A C G C 249 150 A A T G A T C T C T
14 8 148 33 G A G C G A T C C T G G G T C G A A T T A G G C A C T G G T A G G T C C G C G T C T 249 150 G G T C G T C T C T
4 148 33 G A G T G A T C C T G A G C C T  A G T T A A A C A C T G A T A G G T C C G C G T C T 247 148 G A T G A C G G T C
51 15 66 G C A C G G C C C T G A G C C G G G T T A A A C A C T G A T A G G T C C G C G T C T 249 160 A A T G G T C T C T
53 4 142 66 A C G T A G C C C T G G A C T G  G G T T A G A C A C T G  G T A G G T C C A G A C G C 249 148 A A T G A C G G T C
51 2 68 A C G C G A T C C T G A  A T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G C C G T C T C T
51 15 68 A C G   T  A G C C C T G A G T C T A G T T A A A C A C T G A T A G G T C C G C G T C T 247 150 G G T C A C G G T C
51 15 68 A C G C G A C C C T G  A  A T T G G G T T A G A C A C T G G T G G G  T C C G C G T C T 252 148 G A T G A C G G T  C 
15 3 G A A C A A T C C T G A G T C T A G T T A A A C A C T G A T A G G T C C G C G T C C 249 160 A A T G A C G G T C
15 7 148 33 A A G T A A C C T C G G A C T G  G G C T A G A C C C T G  G T A G G T C C A G A C G C 249 160 A A T G A C G G T C
44 16 138 29 G A G T A   G    C  A   C    C  A   G    A    C  C T A G T T A A A C A C T G A T A G G  T C C G C G T C T 247 152 G G C C G T C T C T
37 6 138 30 G A G T A   A    T  A   T    T  A   A    G    T  C T G G T T A A A C C T T G A T A G G  T C C A G A C G C 249 158 A A T G G T C T C T
14 8 148 33 G A G T A  G C A C T G G A C T G  G G T T A G A C A C T G  G T G G G T C C A G A C G C 249 162 G A T G G T C T C T
14 8 148 33 A C A C G A C C C T A A A C T G  G G T T A A A C A C T G  G T A G G T C C A G A C G C 249 160 A A T G G T C T C T
8 25 A C G T A G C C T C A G A C T G  G G C T A A A C C C T G  G T A G G T C C A G A C G C 249 160 A A T G G T C T C T
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Left panel: Consensus sequences of 86 extended haplotypes from HH founder 
chromosomes organized by haplotype group. Each raw represents the sequence from one HH 
founder chromosome (arbitrarily ordered by overall homology) and each column one genetic 
marker, ordered by relative physical position. Yellow boxes show that the allele matches the most 
common consensus sequence, whereas blue boxes represent the opposite (or alternative) alleles. 
Blocks of complete allele identity are highlighted by dark yellow boxes. A block defined by the 4 
SNP markers from rs7382112 to rs7383248, segregates all (except one) chromosomes in the two 
haplotype groups, assigned according to their flanking alleles as AA or CG. These two haplotype 
groups are highlighted by framed boxes, bold lettering and different coloring (dark yellow vs green). 
Right panel: Consensus sequences of 210 extended haplotypes from normal chromosomes 
organized by haplotype group. For comparisons with HH chromosomes, the same color coding 
was used. 
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2 - Two ancestral extended haplotypes predominate in HH chromosomes 
An identical SNP consensus sequence was observed between HFE and HLA-A in 
80% of the HH chromosomes of the AA haplotype group (53/66). This conservation extended 
in a centromeric direction to HLA-A (62% of these carrying the A*03 allele) and to HLA-B 
(52% of these carrying also the B*07 allele). For further analyses, this consensus sequence 
was defined as the “ancestral extended haplotype of the AA group”. An identical SNP 
consensus sequence was also observed between HFE and HLA-A in 32% of the HH 
chromosomes of the CG haplotype group (6/19). Each of these conserved extended 
haplotypes contained the HLA-A*01 allele and all but one carried HLA-B*08. For the purpose 
of further analyses, this consensus sequence was designated as the “ancestral extended 
haplotype of the CG group”. 
 
3 - Conservation patterns of AA or CG group haplotypes in HH patients and controls  
All chromosomes within each group were compared looking for their patterns of 
conservation or non-conservation, relative to the respective ancestral sequence, in five sub-
regions: from HFE to ZNF193; from ZNF193 to PGBD1; from PGBD1 to rs7382112; from 
rs7383248 to HLA-A; and from HLA-A to HLA-B. We defined, for each region, loss of 
conservation if one or more SNPs differed from the respective consensus ancestral 
sequence in HH patients (Figure 3 left panel) or in controls (Figure 3 right panel). In the case 
of controls we defined as the ancestral sequence the most common consensus sequence 
found among 210 control chromosomes. In general, haplotype conservation was much 
higher in HH than in normal chromosomes, as expected by their assumed recent common 
ancestry. Control chromosomes belonging to the AA haplotype group (but not to the CG 
group) also show a strong degree of conservation, but this is restricted to the region between 
ZNF193 and the SNP marker rs7383248, while in HH chromosomes it extends to the entire 
region between HFE and HLA. In spite of their presumed common ancestry, HH 
chromosomes display different patterns of conservation according to the different haplotype 
groups, suggesting that they had different recombination histories. While a progressive loss 
of conservation is observed from HFE to HLA in chromosomes from the CG group (probably 
reflecting historical recombination events), chromosomes from the AA group, in contrast, 
maintain a high degree of conservation at the entire region between HFE and HLA, diversity 
becoming apparent only centromeric to HLA-A. Considering the recent origin of the HH 
chromosomes, this result could suggest a more recent origin (founder effect) of the AA group 
chromosomes than of the CG group. Alternatively, considering that the stronger conservation 
of AA group haplotypes is also observed in normal chromosomes, the results may also 
suggest the existence of a selective stronger recombination suppression in this region for the 
particular haplotypic combination of alleles in the AA than for the CG haplotype group.  
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Fig. 3 Percent conservation of HH patients (left graph) and controls (right graph) chromosomes in 5 
consecutive regions from HFE to HLA-B. The percentages of conserved chromosomes from the AA haplotype 
group are represented in blue bars and the percentage of conserved chromosomes from the CG haplotype group 
are represented in red bars. 
 
4 - Haplotype associations with the low CD8 phenotype 
The distribution of CD8+ T lymphocyte numbers was analyzed and compared among 
groups of HH patients classified according to the inheritance of the most common ancestral 
or the non-conserved haplotypes as described in Methods. Results are illustrated in Figure 4 
where fitting curves are displayed without (dashed red line) or with (continuous black line) 
exclusion of CD8 expansions (see Methods). By simple inspection of the curves it is evident 
that HH patients carrying non-conserved CG group haplotypes do not display the 
characteristic left deviation of values (relative to the normal median) as seen in patients 
homozygous for the most ancestral AA haplotype and, to a lesser extent, in compound 
heterozygous for the ancestral with a recombinant haplotype of the AA group. Notably, CD8 
expansions were more common in the group of homozygous patients who carry a low CD8 
phenotype relative to the other groups. An interpretation of this finding is provided in the 
discussion below. 
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Fig. 4: Distribution of CD8+ T lymphocytes in HH patients according to the 
inheritance of two ancestral haplotypes (upper graph), one ancestral and 
one recombinant of the AA group haplotype (middle graph) or one ancestral 
and one recombinant of the CG group haplotype (lower graph). Dashed red 
lines represent the distribution fitting to normal with uncensored data. Continuous 
black lines represent the distribution fitting to normal excluding CD8 expansions. 
The vertical blue dashed line indicates the median value in the control population. 
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5 - Insight into the evolutionary history of HH carrying haplotypes  
Insight into the evolutionary history of a gene region can be gained by inferring 
haplotype genealogies. To address the hypothesis of different recombination histories in HH 
chromosomes belonging to the two distinct haplotype groups, we used the genetic 
information obtained to construct HH haplotype genealogies using the neighbor-joining 
method implemented in MEGA. In this method we did not use HLA allele information; this 
was only encoded in ID numbers and used for the tree illustration in Figure 4. In general, 
chromosomes from the two haplotype groups are distributed in opposite clusters in the tree 
(CG haplotypes on the left, AA haplotypes on the right). In the particular case of HH 
chromosomes, these are mainly clustered in two different branches: one integrating the AA 
haplotype group (including all the HLA-A*03-B*07 carrying chromosomes, highlighted in red) 
and another one integrating the CG haplotype group (including all the HLA-A*01-B*08 
carrying chromosomes, highlighted in green). Other HH-linked haplotypes localized in distant 
and spread branches of the tree could correspond to the result of more recent re-
combinational events or the result of wrong haplotype inferences by PHASE. Distances are 
shorter (and more distant from the tree origin) among the AA haplotypes carrying the HLA-
A*03-B*07 than in the CG haplotypes carrying the HLA-A*01-B*08. This result may support 
the hypotheses that the origin of the AA group chromosomes, including the ancestral HLA-
A*03-B*07, is either more recent or subject to a stronger selective advantage by selective 
recombination suppression. 
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Fig. 5. HFE-HLA neighbor joining tree. SNP data for 86 HH founder chromosomes and 210 control 
chromosomes was analyzed with MEGA4 and a neighbor joining tree using pairwise comparisons (see 
Methods). HLA data was not used to create the tree but it is encoded within the ID characters associated with 
each chromosome [analytic ID (case=HH, control=C)_HLA-A_HLA-B_haplotype group (AA in red or CG in  
green)]. For a better visualization, chromosomes from the two major haplotype groups (AA or CG) are marked 
with an additional mark (respectively ▒ or ▒). 
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Discussion 
Factors controlling the frequency and location of recombination events on human 
chromosomes are still not well understood. In this respect, studies of the MHC-class I are of 
particular interest. The more-localized variation in this region, including “hot” and “cold” spots 
[221] suggest the existence of localized structures or functional elements that affect 
crossover occurrence or product viability by means similar to those demonstrated in lower 
eukaryotes (reviewed by Lichten and Goldman [222]). In a study of the 6-Mb region between 
D6S265 (70 kb centromeric of HLA-A) and D6S276, Malfroy and co-workers demonstrated 
the existence of a nonrandom pattern of recombination throughout this region with a 
recombination rate of 0.19% within the 4-Mb interval centromeric to HFE , contrasting with 
the approximate 1% rate observed within the most telomeric two megabases [221]. In the 
present study we explored the haplotype structure and recombination history of the HFE 
p.C282Y carrying chromosomes, including their association with a quantitative trait for CD8+ 
T lymphocyte numbers, through a high-density SNP mapping of the 4 Mb region between 
HLA-A and HFE in 86 founder chromosomes from Portuguese HH patients and 210 
chromosomes from normal individuals from the same region. 
The overall haplotype analysis showed that most HH chromosomes in the 
Portuguese HH population seem to derive from two major ancestral haplotypes, one (more 
common) containing HLA-A*03B*07 and the other (more rare) containing HLA-A*01B*08. 
The pattern of haplotype conservation, however, was significantly different in the two cases. 
While haplotypes derived from the ancestral HLA-A*03B*07 branch were, in general, highly 
conserved in the whole region between HFE and HLA-A, the same was not observed in 
haplotypes derived from the ancestral HLA-A*01B*08 branch. These results showing a 
differential conservation of SNP markers in the two major ancestral haplotypes are in 
accordance with results of microsatellite markers in other populations, namely in the Swedish 
population, where the general conservation of A*03 carrying chromosomes was shown to be 
stronger than that observed in A*01 carrying chromosomes [207]. 
Although the two described ancestral haplotypes in Portuguese HH patients can be 
distinguished by a set of highly conserved unique SNP sequences (belonging respectively to 
the AA and CG haplotype groups), they also share a long and highly conserved region from 
HFE to the SNP marker rs7382112 (Fig. 2), suggesting a common ancestry. However, the 
observation that the two haplotypes cluster in two separate branches of a phylogenetic tree 
(see Fig. 5) seem to indicate that independent founder effects occurred at different times in 
the Portuguese HH population and that, apparently, the HLA-A*01B*08 carrying CG 
haplotypes have a more ancient origin (with higher diversity) than the HLA-A*03B*07 
carrying AA group haplotypes. This interpretation, however, does not fit with the current view 
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on the origin and spread of the HH-associated mutation (reviewed in Distante et al [194]), 
favoring the hypothesis that the most ancient HH founder chromosome should be the one 
carrying the HLA-A*03-B*07 from which all other haplotypes derive. This assumption is 
generally based on the high frequency and linkage disequilibrium of this haplotype in all 
populations studied throughout the world. Nevertheless, the fact that HLA-A*03B*07 carrying 
chromosomes, besides having the highest frequency in all worldwide spread populations, is 
also much more conserved than the HLA-A*01B*08 carrying chromosomes, favor an 
alternative hypothesis that the HLA-A*03B*07 could be maintained at a higher frequency due 
to a stronger selective pressure, as elegantly shown by Toomajian and co-workers [165]. In 
this context, it is worth mentioning that another HH-associated classical ancestral HLA 
haplotype, A*03B*14, described as having the strongest linkage disequilibrium in 
Scandinavian populations [207] does not occur in general at high frequencies among other 
HH populations. This suggests that either A*03B*14 results from more recent recombination 
events in some particular populations and/or that, in contrast to A*03B*07 carrying 
chromosomes, it was not favored by a putative selective pressure [184]. 
The observation of a reduced rate of recombination at the MHC region in a particular 
haplotype group not only in HH chromosomes but also apparent in normal chromosomes 
(illustrated in Figure 2) brings some new light to the question of the recombination 
suppression in this region. A selective suppression of recombination may be due to structural 
variations hampering proper meiotic pairing of homologous sequences and/or due to 
selective constraints depending on environmental factors. In this case, it could be related to 
immunity and iron status. The consistent observation that HLA haplotypes influence not only 
the inheritance of CD8+ T lymphocyte numbers in HH patients but also the severity of iron 
overload [43] together with the present demonstration that the inheritance of the most 
conserved ancestral haplotype impacts on the distribution of CD8+ T lymphocyte numbers, all 
point either to the existence of important selective forces acting upon immune responses or 
simply a bystander effect on the genetic transmission of a major QTL for CD8 numbers in 
this highly conserved chromosomal region. This hypothesis is favored by the previous finding 
that HH patients from Nord-Trøndelag, in Norway, do not display the same 
genotype/phenotype correlation. Further studies with complete covering of this genetic region 
with the use of High-throughput sequencing are still necessary to clarify this point, taking into 
account that recombination takes place more frequently in regions flanking conserved blocks 
than within them. 
A final comment should be given relative to the surprising observation that HH 
patients homozygous for the ancestral conserved haplotype, strongly associated with a low 
CD8 phenotype, were also the ones with a higher frequency of CD8 expansions (Fig. 4). A 
possible explanation for this finding derives from very recent evidence that CD8+ T 
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lymphocytes from Hfe deficient mice display an expression profile compatible with more 
activated cells in the peripheral blood [223], and that HFE acts “in vitro” as a suppressor of 
CD8+ T lymphocyte activation [224]. It is plausible to assume that, the same effect on T cell 
activation which may lead to the shifting and eventual exhaustion of the more mature effector 
memory cells in the periphery, could also, in particular conditions and in the context of 
particular antigen epitopes, lead to expansions of the CD8+ T lymphocyte pool. Whether 
these expansions are maintained throughout life or are eventually exhausted, this can only 
be clarified with appropriate long follow-up longitudinal studies in those patients.  
 
Conclusion 
In conclusion, this study of extended haplotypes in Portuguese HH patients reveals 
novel aspects of the haplotype nature and recombination history of HFE p.C282Y carrying 
chromosomes, and provides one more step towards the possibility of localizing a major 
quantitative trait for the setting of CD8+ T lymphocyte numbers in humans. 
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3.3  
In vitro response of T lymphocytes to iron and how they may act as 
modifiers of the clinical expression in HH 
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implications of NTBI uptake by T lymphocytes. Front Pharmacol 5: 24. 
 
 
 
 
 
 
Content 
Introduction 
Material and Methods 
Results: 
1. Quantification and pattern of NTBI uptake by T lymphocytes (Adapted from Arezes et 
al.2013) 
2. Characterization of the ferric citrate species taken up by T lymphocytes (Adapted from 
Arezes et al.2013) 
3. Quantification and pattern of NTBI export by T lymphocytes (Adapted from Pinto et al.2014) 
4. NTBI retention capacity by CD4
+
 and CD8
+
 T lymphocytes and CD14
+
 monocytes from 
healthy controls and HH patients (Unpublished results) 
5. Systemic NTBI retention capacity by total PBMCs distinguish two groups of HH patients 
with different re-accumulation pattern (Unpublished results) 
Discussion
 78 
 
 
In vitro response of T lymphocytes to iron, and how they may act as modifiers of the HH clinical 
expression 
79 
 
Introduction 
Iron is an essential nutrient in several biological processes such as oxygen transport, 
DNA replication and erythropoiesis. After intestinal absorption iron circulates in plasma 
bound to the plasma protein called transferrin. Circulating iron which is not bound to 
transferrin, heme or ferritin (here designated as non-transferrin-bound iron - NTBI) becomes 
important in iron overload disorders, in which plasma iron is present in excess of transferrin-
binding capacity [101, 102]. NTBI is responsible for the toxicity associated with iron-overload 
pathologies leading not only to formation of free oxygen radicals but also causing organ 
failure through cell death. NTBI is avidly taken up by the liver but this clearance mechanism 
has a threshold beyond which iron accumulation inside hepatocytes becomes toxic, leading 
to the development of liver pathologies such as fibrosis, cirrhosis and hepatocarcinoma. The 
chemical nature of NTBI is very diverse, the most common form is iron-citrate but the 
mechanisms by which the cells take up NTBI are not fully understood. Besides hepatocytes, 
a variety of other cell types have also been shown to take up NTBI [225]. The specific iron 
uptake kinetics displayed by distinct cell types [112, 226, 227], together with the observation 
of distinct patterns of affected organs in different iron overload diseases [228], all suggest 
that either the different cell types may differ in the expression of the same NTBI-carrier 
molecule(s) or that they possess different uptake systems capable of discriminating between 
the various circulating NTBI species. Until now little was known about the capacity of T 
lymphocytes to take up NTBI. Here we show for the first time that T lymphocytes are able to 
take up and accumulate NTBI. Moreover, we found that the iron-citrate specie preferentially 
taken up by T lymphocytes is the oligomeric Fe3Cit3 form, suggesting the existence of a still 
elusive selective NTBI carrier. Furthermore, we tested the hypothesis if there were 
differences in the NTBI retention capacity of the circulating immune cells between HH 
patients and if that could contribute to the heterogeneity of iron load in HH patients. Total 
NTBI retention showed a significantly different distribution between HH patients and controls, 
with a high proportion of HH patients showing values below the lower limit found in controls. 
NTBI retention was strongly negatively correlated with the TfSat of HH patients at the time of 
the experiment. Differences in plasma iron re-accumulation were also observed in patients 
when divided according to NTBI retention: patients with lower NTBI retention capacity had a 
faster and higher re-accumulation pattern (stabilizing TfSat values at an average of 70,6%) 
than patients with higher NTBI retention capacity, who had a slower and lower re-
accumulation pattern (stabilizing TfSat at values <50%). These preliminary results in vitro 
point out for biological differences between CD8+ T cells from HH patients and normal 
controls which are of great interest to be further addressed. 
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Methods 
Ethics Statement 
Peripheral blood samples were obtained from healthy blood donors and HH patients 
at Santo António General Hospital (Porto, Portugal), who gave their written informed consent 
to participate in this study, which was approved by the Santo António Hospital Ethical 
Committee. 
 
Isolation of human peripheral blood cells 
Peripheral Blood Mononuclear Cells (PBMCs) were obtained from buffy coat product 
processed at Santo António General Hospital. Cells were isolated by gradient centrifugation 
over Lymphoprep (Nycomed). After lysis of erythrocytes, cells were resuspended in RPMI 
(GibcoBRL) supplemented with 10% fetal calf serum (FCS; GibcoBRL) and plated. CD3+, 
CD4+ and CD8+ cells were purified from PBMCs using magnetic-activated cell sorting 
(MACS), after incubation with anti-CD4, -CD8 or -CD14 Microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany), following the manufacturer’s instructions. The purity of each 
cell population in the suspension was randomly assessed by flow cytometry and was always 
> 95%. 
 
Statistical analysis 
The results are expressed as mean values +/−1 standard deviation (SD). The 
existence of correlations between iron uptake and concentration of Fe-citrate species was 
assessed by simple regression analysis, performed with STATGRAPHICS Centurion XV 
(Statpoint Technologies). Statistical significance was set using Chi-square test for group 
comparisons between controls and HH patients. 
 
NTBI uptake by T lymphocytes 
Uptake of non-transferrin-bound iron (NTBI) was assessed using 55Fe- citrate [229]. 
55Fe- citrate stock solutions were prepared by mixing 55FeCl3 (PerkinElmer, Inc, USA) with 
unlabelled trisodium citrate, at different Fe:citrate molar ratios. The pH was maintained at 7.4 
and solutions were allowed to rest for 20 minutes before being diluted 33-fold in uptake 
medium and added to cells. Specific activity in the uptake medium was approximately 30 
counts.min−1.pmol−1 Fe. All Fe:citrate solutions were prepared immediately before use and 
discarded after each experiment. Unless otherwise indicated, cells were depleted of 
intracellular transferrin by incubation for 1 hour in serum-free/iron-free RPMI, washed and 
incubated with RPMI+20% HH plasma+5 µM 55Fe-citrate (as 5 µM 55FeCl3+100 µM citric 
acid), at 37°C. 5 µM is the typical NTBI concentration reported in sera from thalassemia 
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major patients [230] and 100 µM citric acid corresponds to the levels normally present in 
human blood plasma [229]. The pH of the uptake medium was maintained at 7.4. After 
incubation, cells were washed 3× with ice-cold buffer [20 µM desferrioxamine (DFO) in PBS, 
pH 7.4], lysed with 0.1% NaOH, 0.1% Triton X-100 and intracellular Fe was measured in a 
MicroBeta Trilux β-counter (Perkin Elmer), for 1 minute. No significant changes in cell 
viability with iron treatments was observed, using trypan blue exclusion and maintenance of 
proliferative potential following activation with anti-human anti-CD3 and anti-human anti-
CD28 for CD3+, CD4+ and CD8+T lymphocytes (Arezes et al. 2013).To distinguish between 
intracellular and membrane-bound Fe and citrate, cells incubated for 30 minutes with varied 
Fe:citrate ratios were washed four times with PBS, pH 7.4, at 4°C, and were then incubated 
with 1 mg/ml of the proteolytic cocktail Pronase (Sigma) for 30 min, at 4°C. The cell 
suspension was centrifuged at 12,000 g for 30 s, and the supernatant (containing 
membrane-bound radioactivity) transferred to new tubes. Cell pellets containing 55Fe 
radioactivity were solubilized as described above. 
 
Speciation plots for ferric citrate species 
Speciation plots were developed for Fe-citrate complexes formed under different 
ferric ion and citrate concentrations, using the Hyperquad simulation and speciation (HySS) 
program [231] and iron affinity constants previously described [232, 233]. The plots report the 
species present at equilibrium. 
 
NTBI export by T lymphocytes 
T lymphocytes were depleted of transferrin, as described above, and incubated, 
unless otherwise stated, in RPMI + 5μM Fe-citrate (or 5μM 55Fe-citrate) + 20% FCS for 2h. 
Cells were washed 2× with washing buffer and incubated for different time-periods in RPMI + 
20% FCS + 5μM DFO (for short-term experiments),to prevent re-uptake of exported iron, or 
in RPMI+ 20% FCS (for long-term experiments). At each time-point, the supernatants were 
collected and Fe was quantified as described in NTBI uptake. 
 
NTBI retention experiment in HH patients 
NTBI retention experiment was assessed in CD4+ and CD8+ T cells and CD14+ 
monocytes isolated from peripheral blood from normal healthy blood donors and HH patients 
(C282Y homozygous) regularly followed at the Santo António Hospital (CHP-HSA; Porto, 
Portugal) Hemochromatosis Clinic. HH patients were consecutively recruited into the study at 
the time of their visit for maintenance therapeutic phlebotomy. Transferrin saturation and 
haematological parameters were available for all individuals at the time of the experiment. 
Retrospective biochemical data were reviewed from clinical files by the clinician in charge. 
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55Fe- citrate stock solutions were prepared by mixing 55FeCl3 with unlabelled trisodium 
citrate, at Fe:citrate molar ratio (1:20) as previously described. Cells were depleted of 
intracellular transferrin by incubation for 1 hour in serum-free/iron-free RPMI, washed and 
incubated with RPMI +5 µM 55Fe-citrate (as 5 µM 55FeCl3+100 µM citric acid), at 37°C. The 
pH of the uptake medium was maintained at 7.4. Each experiment of NTBI uptake was 
performed in a normalized number of cells (1x105 cells). Cells were incubated in vitro with 
55Fe- citrate (5µM) for 3 hours. After incubation, cells were washed 3× with ice-cold buffer [5 
µM desferrioxamine (DFO) in PBS, pH 7.4], lysed with 0.1% NaOH, 0.1% Triton X-100 and 
intracellular Fe was measured in a MicroBeta Trilux β-counter (Perkin Elmer), for 1 minute. 
No significant changes in cell viability, using trypan blue, were observed with the iron 
treatments. Systemic NTBI retention capacity by PBMCs was calculated by the sum of NTBI 
retention (at 3 hours) of the CD8+, CD4+ T-lymphocytes and CD14+ monocytes multiplied by 
the respective cell numbers in each individual. 
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Results 
1 - Quantification and pattern of NTBI uptake by T lymphocytes 
Both CD4+ and CD8+ human T lymphocytes accumulate approximately 250 pmol of 
Fe/106 cells in vitro, when incubated with 5 µM of 55Fe-citrate (5:100) at 37°C (Fig. 1A). The 
rate of NTBI uptake is higher during the first 30 minutes of incubation (6.4 and 7.1 
pmol/min./106cells, respectively for CD4+- and CD8+-lymphocytes), followed by a second 
component in which uptake is maintained at a significantly lower rate (4×10−4 and 7×10−2 
pmol/min./106 cells, respectively for CD4+- and CD8+- lymphocytes) until the last time point 
analyzed (3 hours). A plateau in intracellular iron levels is reached after approximately 60 
minutes. The rate of uptake at 37°C during the initial 30 minutes was significantly higher than 
at 4°C (0.02 pmol/min./106cells). Treatment with pronase and trypsin following incubation 
with Fe-citrate did not significantly change cell-associated radioactivity in CD3+ T 
lymphocytes (representing total T lymphocytes), suggesting that the measured Fe is mostly 
intracellular (Fig. 1B). In contrast, at 4°C most of the NTBI is associated with the plasma 
membrane since cell-associated radioactivity was markedly decreased upon treatment with 
pronase (Fig. 1C). 
Fig. 1 NTBI uptake by T lymphocytes (A) NTBI uptake by human T-lymphocytes. CD4
+
 and CD8
+ 
human T-
lymphocytes were incubated with 5 µM of 
55
Fe-citrate (5:100) at 37°C and 4°C and intracellular iron quantified at 
each time-point. Each point = average (n≥3) ±1SD. (B–C) Specificity of NTBI uptake. CD3
+
 cells were incubated 
with 5 µM of 
55
Fe-citrate (5:100) for up to 90 min, at 37°C (B) or 4°C (C), and at each time point washed either 
with PBS (with or without pronase) or incubated for 15 min with serum-free RPMI with trypsin. Cell-associated 
55
Fe levels at each time point were measured. Each point is a mean value (n = 3) ± SD. The similar results 
obtained at 37°C together with the differences at 4°C suggest that most of the measured iron is intracellular. 
A B 
C 
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Statistical significance between samples at 37°C and controls at 4°C is indicated by * symbols (*p<0.01) (Arezes 
et al.2013) 
 
In addition to the previous time-dependent experiment a dose dependent experiment 
was performed by incubating CD3+ T lymphocytes with various concentrations of Fe-Citrate 
(ranging from 1 µM to 500 µM). We observed that Fe-citrate uptake in T lymphocytes 
reaches saturation at 200 µM, with a Michaelis constant (KM) of 92.6 nmol and maximum 
velocity (Vmax) of 0.4 nmol/min./106cells (Fig. 2). 
Fig. 2 Kinetics of NTBI uptake in T lymphocytes. Cells were incubated with different concentrations of 
55
Fe-
citrate (1 µM, 5 µM, 10 µM, 100 µM, 200 µM and 500 µM) at 37°C and intracellular iron quantified at various time 
points (0, 15, 30, 60 and 120 min) (n = 3). The values obtained during the first 30 min of incubation, when the 
transport system is not saturated, were used to calculate the rate of uptake for each concentration. CD3
+ 
cells 
reach saturation at 200 µM of Fe-citrate and present a maximum rate of 0.4 nmol/min/10
6 
cells (Arezes et al. 
2013). 
 
2 - Characterization of the ferric citrate species taken up by T lymphocytes 
Although it is commonly accepted that Fe-citrate is one of the most relevant NTBI 
forms in iron overload disorders, nothing is known regarding the selectivity for particular Fe-
citrate species by cells. Taking advantage of the recent development of a speciation model 
for Fe-citrate [232], we investigated iron uptake by T lymphocytes in the presence of various 
Fe:citrate ratios, for which the model predicts the formation of distinct Fe-citrate species. In 
the presence of 100 µM citrate, increase of Fe concentration from 0.1 to 100 µM is predicted 
to induce a shift from the FeCit2 species to the oligomeric Fe3Cit3, this latter species being 
essentially the only one present for iron concentrations equal or above 100 µM (Fig. 3A and 
Table 1). CD3+ lymphocytes were incubated with an equal volume of each of these Fe-citrate 
solutions, a dose-dependent increase in Fe uptake was observed up to 100 µM Fe (Fig. 3B), 
with a strong positive correlation observed between NTBI uptake and the presence of 
[Fe3Cit3] in the solution (Fig. 3C).  
In contrast, when CD3+ lymphocytes were exposed to media predicted to contain 
increasing concentrations of Fe3Cit3 and FeCit2 (Fig. 4A and Table 2), Fe uptake by T cells 
increased only while [Fe3Cit3] was increasing and stabilized or was inhibited when [Fe3Cit3] 
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remained stable (Fig. 4 A and B). Finally, a predicted 10-fold increase in [FeCit2] (with 
constant [Fe3Cit3]; Table 2) significantly inhibited Fe uptake by the lymphocytes, with no 
correlation found between [FeCit2] and NTBI uptake by these cells (P=0.15) (Figure 4C). No 
association was found between the concentration of any other Fe-citrate species predicted to 
be present and Fe uptake (data not shown). 
 
 
 
 
B C 
Fig. 3 Fe uptake by T lymphocytes correlates with [Fe3Cit3].(A) Speciation plots for Fe-citrate species were 
calculated for Fe:citrate ratios from 1:100–200:100 using the Hyperquad simulation and speciation (HySS) 
program. Predicted relative abundance (%) of the two most common Fe-citrate species, at pH 7.4, is marked by a 
blue vertical line and a red (Fe3Cit3) or blue (FeCit2) dot. (B) Fe uptake by T lymphocytes incubated with different 
iron:citrate ratios increases with the relative abundance of Fe3Cit3. Experiments were performed at least three 
times with three replicates per experiment. Each point represents the mean (n = 3) ±1SD. (C) Regression analysis 
showing a significant correlation between Fe uptake by CD3+ cells with predicted [Fe3Cit3] concentration at pH 
7.4 (Adapted from Arezes et al.2013). 
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Table 1 Calculated concentrations of Fe-Citrate (FeCit) species for increasing doses of 
Fe and 100uM Citrate. 
 
 
 
 
  
 
0.1µM Fe: 
100µM Cit 
1µM Fe: 
100µM Cit 
5µM Fe: 
100µM Cit 
10µM Fe: 
100µM Cit 
40µM Fe: 
100µM Cit 
100µM Fe: 
100µM Cit 
200µM Fe: 
100µM Cit 
Fe3Cit3 (µM) 2.37x10
-6
 2.44x10
-3
 2.40x10
-1
 1.12 10 29.6 33 
FeCit2 (µM) 9.3x10
-2
 9.22x10
-1
 3.95 6.09 8 1.65 0 
FeCit2H (µM) 3.92x10
-3
 3.89x10
-2
 1.67x10
-1
 2.57x10
-1
 NA 6.97x10
-2
 NA 
FeCitH (µM) 9.22x10
-6
 9.31x10
-5
 4.30x10
-4
 7.19x10
-4
 NA 2.14x10
-3
 NA 
FeCit2H2 (µM) 1.22x10
-5
 1.21x10
-4
 5.19x10
-4
 7.99x10
-4
 NA 2.17x10
-4
 NA 
Fe free (µM) 6.74x10
-12
 6.92x10
-11
 3.44x10
-10
 6.24x10
-10
 NA 2.04x10
-8
 NA 
Cit free (µM) 4.97x10
-6
 4.88x10
-6
 4.53x10
-6
 4.18x10
-6
 NA 3.81x10
-7
 NA 
H free (µM) 3.98x10
-2
 3.98x10
-2
 3.98x10
-2
 3.98x10
-2
 NA 3.98x10
-2
 NA 
Fig. 4 Fe uptake by T lymphocytes and hepatocytes does not correlate with [FeCit2]. (A) Speciation plots for 
Fe-citrate species, calculated for increasing Fe-citrate concentrations maintaining a constant Fe:citrate ratio of 
1:20 using the Hyperquad simulation and speciation (HySS) program. Predicted relative abundance (%) of the 
two most common Fe-Cit species at pH 7.4 is marked by a blue vertical line and a red (Fe3Cit3) or blue (FeCit2) 
dot. (B) Fe uptake by CD3
+ 
lymphocytes in the presence of increasing Fe-citrate concentrations, maintaining a 
constant Fe:citrate ratio of 1:20 (same conditions as in panel A). Experiments were performed at least three times 
with three replicates per experiment. Each point represents the mean (n = 3) ±1SD. (C) Regression analysis 
showing no significant correlation between Fe uptake by CD3
+ 
cells with predicted [FeCit2] concentration at pH 7.4 
(Adapted from Arezes et al.2013). 
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Table 2 Calculated concentrations of Fe-citrate (FeCit) species for increasing doses of 
Fe and a constant Fe:Citrate ratio of 1:20. 
 
0.1µM Fe:   
2µM Cit 
1µM Fe:    
20µM Cit 
5µM Fe: 
100µM Cit 
10µM Fe: 
200µM Cit 
100µM Fe: 
 2000µM Cit 
Fe3Cit3 (µM) 6.21x10
-7
 3.91x10
-2
 2.40x10
-1
 3.15x10
-1
 4.26x10
-1
 
FeCit2 (µM) 1.19x10
-3
 4.49x10
-1
 3.95 8.61 94.7 
FeCit2H (µM) 5.02x10
-5
 1.90x10
-2
 1.67x10
-1
 3.63x10
-1
 3.99 
FeCitH (µM) 5.90x10
-6
 2.35x10
-4
 4.30x10
-4
 4.71x10
-4
 5.21x10
-4
 
FeCit2H2 (µM) 1.56x10
-7
 5.90x10
-5
 5.19x10
-4
 1.13x10
-3
 1.24x10
-2
 
Fe free (µM) 2.16x10
-10
 9.04x10
-10
 3.44x10
-10
 1.89x10
-10
 2.11x10
-11
 
Cit free (µM) 9.95x10
-8
 9.44x10
-7
 4.53x10
-6
 9.02x10
-6
 8.97x10
-5
 
H free (µM) 3.98x10
-2
 3.98x10
-2
 3.98x10
-2
 3.98x10
-2
 3.98x10
-2
 
 
 
3 - Quantification and pattern of NTBI export by T lymphocytes 
In order to have a relevant role as a component of the iron storage compartment, T 
lymphocytes would need to selectively retain or, alternatively, export intracellular iron 
acquired as NTBI according to systemic signals. To test this hypothesis we analyzed the 
export of iron acquired as Fe-citrate by T lymphocytes. CD4+ and CD8+ T cells were exposed 
to 5μM Fe-citrate for 2h, a time point at which cells have reached the maximum iron content 
(Fig. 1A), and allowed to export iron into an iron-free medium for up to 6h. We observed that 
iron export by T lymphocytes follows a linear pattern, CD8+ cells export a little slower 
matching the CD4+ lymphocyte’s export rate after 60min of export (Fig. 5A). After 60min in an 
iron-free medium, iron export by T lymphocytes corresponds to approximately 3% of 
intracellular levels, demonstrating as low release of iron acquired as NTBI by these cells. 
This is confirmed by the quantification of intracellular 55Fe remaining in both T lymphocyte 
populations throughout time, which further shows that, after 72h of export, T lymphocytes 
maintain approximately 20% of the initial iron load acquired as NTBI (Fig. 5B). 
To test whether iron export by T lymphocytes is dependent on the extracellular NTBI 
concentration, cells were incubated with increasing ratio of Fe (5, 20, 40 and 100 µM) to 100 
µM citrate for 2 hours and allowed to export iron into an iron–free medium. We observed a 
dose-dependent increase in iron export with increasing NTBI concentrations (Fig. 5C).
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4 - NTBI retention capacity by CD4+ and CD8+ T lymphocytes and CD14+ monocytes 
from healthy controls and HH patients (Unpublished results) 
The potential of NTBI sequestration by PBMCs as a modifier of human systemic iron 
overload was then tested by the quantification of the ex vivo uptake of NTBI by T 
lymphocytes and monocytes obtained from Hereditary Hemochromatosis (HH) patients and 
from healthy blood donors. CD4+, CD8+ T-lymphocytes and CD14+ monocytes were isolated 
from peripheral blood and were incubated for three hours with 5 µM of Fe-citrate. The NTBI 
retention capacity was measured in a normalized number of cells (1x105) of each sub-
population. Results are presented in Figure 6 with transformed values of Log CPM. The 
average of NTBI uptake by CD4+ T cells was 3.83±0.12 in controls and 3.77±0.40 in HH 
patients, by CD8+ T cells was 3.70±0.11 in controls and 3.70±0.39 in HH patients and by the 
monocytes was 3.57±0.17 in controls and 3.65±0.37 in HH patients. Although the averages 
were very similar between patients and controls, the standard deviation denotes the 
existence of a remarkable higher variability in HH patients.  
All HH patients were in maintenance treatment and patient’s systemic iron status, as 
measured by the percentage of plasma transferrin saturation (TfSat) at the time of 
experiment, varied from 40 to 85%. These TfSat values were significantly correlated with the 
average TfSat levels measured serially during the previous 12 months (r=0.97; R2=57%; 
P=0.0299), reflecting the existence of highly stable individual profiles. 
 A 
Fig. 5 Iron export by T lymphocytes. A) Time-dependent iron export by T lymphocytes. Each point is a mean 
value (n=3) ± 1SD. B) Impact of iron export in intracellular Fe levels. Each point is a mean value ± 1SD of two 
experiments each with three replicates. C) Dose-dependent iron export by T lymphocytes. Each point is the mean 
of two experiments with two replicates each (Pinto et al.2014). 
B 
C 
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5 - Systemic NTBI retention capacity by total PBMCs distinguish two groups of HH 
patients with different re-accumulation pattern (Unpublished results) 
The systemic NTBI retention capacity by the PBMCs, estimated as the sum of NTBI 
accumulated by T lymphocytes and monocytes multiplied by total numbers of these cells in 
each individual, showed a significantly different distribution between HH patients and controls 
(Fig. 7A). In HH patients two groups could be identified, respectively with normal (in the 
same range of controls) and defective NTBI retention (Chi-square test 2=4.952; P=0.026; 
Table 3), with values correlating inversely with the TfSat levels at the time of each 
experiment (r=-0.76; R2=58%; P=0.017; Fig. 7B). This finding prompted us to analyze 
retrospectively if there were differences between the two groups of HH patients in the pattern 
of iron re-accumulation into the plasma transferrin pool following the completion of the iron 
depletion treatment (at this point all patients displayed similar TfSat values). The results 
clearly showed that patients with a lower NTBI retention capacity by PBMCs had a faster and 
higher re-accumulation pattern in comparison with patients with a normal NTBI retention 
profile (Fig. 7C). This set of results demonstrates in vivo the relevance of circulating immune 
system cells in the protection from systemic iron load. 
 
Table 3 Contingency table displaying the association between individual status (HH 
patient or control) and NTBI retention by PBMCs  
NTBI retention (Log CPM) Controls HH patients Statistics 
> 9.5 4 3 
2
=4.952 
P=0.026 < 9.5 0 6 
 
CD4+
 
CD8+ CD14+ 
Fig. 6 NTBI retention capacity by CD4+, CD8+ T lymphocytes and CD14+ monocytes isolated from 
healthy blood donors as controls (n=4)  and HH patients (n=9). Box-whiskers graph with minimum and 
maximum values represented. 
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Fig. 7 Impact of NTBI retention by PBMCs in iron parameters of HH patients 
(A) NTBI accumulation (Log CPM) by PBMCs (T lymphocytes + monocytes) of HH patients (n=9) and blood donor 
controls (n=4). Horizontal line signals the cutoff value (9.5) used for division of HH patients in high and low NTBI 
retainers. (B) Linear regression analysis (r=-0.76; R
2
=58%; P=0.017) of the correlation between TF saturation at 
the time of analysis and NTBI retention by PBMCs. Each dot represents one HH patient. (C) Profiles of iron re-
accumulation into the plasma TF pool for 24 months after completion of intensive treatment in the two groups of 
HH patients, divided as normal or low NTBI retainers (Log NTBI retention > 9.5 and < 9.5, respectively). Average 
of TfSat values for each time point ± maximum and minimum values are represented.  
 
Considering the average total numbers of T lymphocytes and monocytes in a healthy 
individual, those values correspond to a maximum NTBI retention potential ranging from 
45.1-149.9 µmol (for CD4+ cells), 22.5-82.5 (for CD8+) (Table 4), which is well above the 
physiological systemic NTBI levels commonly present in iron overload conditions. 
 
Table 4 Estimated maximum NTBI retention potential of human CD4+, CD8+ and CD14+ 
PBMCs. 
 CD4
+
 CD8
+
 CD14
+
 
Human Total cell number [min-max] [2.65 – 8.8 x10
9
] [1.5 – 5.15 x 10
9
] [1.05 – 4.60 x 10
9
] 
Maximum NTBI retention potential (µmol) [min-max] [45.1 – 149.9] [22.5 – 82.5] [18.9 – 82.8] 
 
In vitro response of T lymphocytes to iron, and how they may act as modifiers of the HH clinical 
expression 
91 
 
Discussion 
In this chapter, we address the reciprocal interactions between NTBI and 
lymphocytes which are among the first cell types from the circulating immune system to get 
in contact with this (and other) iron species, following its entrance into the blood circulation. 
The in vitro studies here performed aimed to address the kinetics of the interaction 
between NTBI specie, in the form of iron-citrate, and T lymphocytes. Fe-citrate uptake by 
CD4+ and CD8+ T cells show that both human T lymphocytes accumulate a maximum of 
approximately 250 pmol of Fe/106cells in vitro, when incubated with 5µM of 55Fe-citrate 
(5:100) at 37°C. A plateau in intracellular iron levels is achieved after approximately 60 
minutes. The maximum rate of 55Fe uptake by T cells is comparable to the described uptake 
rate of the hepatoma cell line HepG2 [234] and to what is described for primary hepatocytes 
[112] although T lymphocytes shown to be incapable to sustain this elevated rate of intake 
for more than 30 minutes. This difference leads to a lower capacity of each lymphocyte to 
accumulate NTBI when compared with hepatocytes which are able to increase intracellular 
NTBI accumulation in vitro for at least one week [235]. 
Several potential iron-binding ligands are present in plasma, including citrate, acetate 
and albumin. Albumin, the most abundant blood plasma protein [236], has been shown to 
bind iron both in the presence of citrate, as a ternary complex, or in its absence [237]. 
Nevertheless, May et al. [238], based on the relative concentrations of potential ligands, 
predicted that the dominant iron species present in plasma is ferric-citrate, the NTBI form 
used in the present study. Under the experimental condition of 5µM Fe:100µM Citrate at pH 
7.4, we observed a strong and exclusive association between Fe uptake and the predicted 
presence of the Fe3Cit3 oligomer in solution, in contrast with the lack of association with 
FeCit2 or with any other ferric-citrate species. We recognize that there are differences in the 
media composition used for the development of the speciation models (salt-buffered 
aqueous solution) and for the Fe uptake assays (RPMI medium). The simple aqueous 
solution used for model predictions may not hold several iron binding molecules that RPMI 
medium possess. However, significant changes in the predicted speciation between the 
aqueous solution and the uptake medium would only be expected if there is competition for 
Fe by those ligands. Under our conditions transferrin will not significantly compete with 
citrate, since it is 85% saturated (20% HH human plasma supplemented). Similarly, acetates, 
pyruvates and phosphates will not compete with citrate for Fe when the citrate concentration 
is ≥100 µM [238], as it is the case in our experimental conditions as well as in human 
plasma. Finally, albumin has been described to efficiently bind iron [237] but its ability to 
significantly modify citrate-bound iron is dependent on its glycation and oxidation [239]. 
Healthy individuals have approximately only 1% of their serum albumin glycated, and this 
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value increases up to 10% in diabetic patients [236]. Iron-overloaded individuals do not 
display higher levels than the healthy 1% baseline condition, suggesting that, at least on the 
absence of increased glucose levels, glycated albumin will not significantly compete for iron 
with citrate. Albumin oxidation, on the other hand, could have a relevant effect, in face of the 
pro-oxidant conditions expected to be induced by the iron overload. Previous studies have 
shown that fully oxidized albumin does not show increased iron binding capacities up to 5 µM 
of iron, but a 2.6- fold increase was observed for 10 µM of Fe [239]. Thus, in pro-oxidant 
conditions albumin may show an increased capacity to modify citrate-bound concentrations, 
although we predict that this will only be significant for very high NTBI concentrations and 
extensive albumin oxidation. 
The results here presented also show that the differences in Fe uptake in each 
experimental condition and the high correlation between Fe3Cit3 and Fe uptake are not due 
to a preferential uptake of membrane-bound Fe in particular conditions but instead may 
reflect a high specificity of a still unidentified putative receptor for the oligomeric Fe-citrate 
species. We anticipate that this finding may be instrumental in the search for the elusive Fe-
citrate transporter since it represents the identification of the ligand to which the transporter 
may respond, either at the level of transcription, translation or other form of modification. The 
high correlation between the presence of the oligomer Fe3Cit3 and Fe uptake may be 
surprising, as donation of Fe by smaller sized mononuclear Fe-citrate species might be 
expected to be easier, particularly if the uptake involves a channel transporter. However, 
predictions from models and from kinetics of NTBI chelation by DFO and deferiprone 
suggested that the dominant species under relevant concentrations of citrate are likely to be 
oligomeric forms, with a molecular mass around 3.5 kDa [232][240]. It seems thus 
reasonable to expect that, throughout evolution, cells have specialized in sensing and 
internalizing this particular species. Nevertheless, it is conceivable that particular tissues and 
cell types may be equipped with different cellular NTBI uptake systems, which would enable 
the discrimination between distinct NTBI species and could explain the different patterns of 
organ iron-loading observed in the various iron overload syndromes [9]. Particularly 
interesting would be to extend the present analysis to cardiomyocytes, a cell type in which 
NTBI accumulation has a particularly adverse effect [241, 242] and for which the involvement 
of specific NTBI transporters have been suggested [116]. Finally, the demonstration that 
Fe3Cit3 represents an important component of the NTBI taken up by hepatocytes and T 
lymphocytes could be used as a tool for optimization of chelator properties and of chelation 
regimens presently in use. 
Regarding CD4+ and CD8+ T lymphocytes ability to export/retain NTBI, the results 
show that these two cell types do not differ significantly in the export/retention of iron-citrate, 
which is in agreement with our findings of similar NTBI uptake by the two cell types. This may 
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indicated that both cell types are equally equipped to mobilize iron-citrate. These results are 
supported by previous observations in β2m
(-/-)Rag1(-/-) mice—deficient in CD4+ and CD8+ T 
lymphocytes and B lymphocytes that displayed higher severity in terms of iron overload than 
the β2m
(-/-) animals—deficient in CD8+ T lymphocytes alone [28]. 
From the observations in mice deficient in CD8+ T lymphocytes [23, 24, 34] and also 
from the recurrently inverse correlation only observed with CD8+ T lymphocyte numbers and 
the severity of iron overload in HFE-HH human patients [30, 32, 171] one may expect that 
CD8+ T cells, although not being the only cell type with NTBI retention ability, may have an 
important role in systemic iron homeostasis and the lack or a reduced number of these cells 
may affect the fine-tuning of iron homeostasis, namely NTBI distribution. 
After the demonstration of H-ferritin synthesis by human T and not B lymphocytes 
[243], the present demonstration of the T lymphocytes ability to take up and retain NTBI, is 
perhaps the strongest piece of evidence supporting the postulate put forward by de Sousa 
and co-workers that these cells could act as buffers to protect other tissues from iron-
mediated toxicity [3]. Our in vitro results estimate an elevated potential for the circulating 
populations of monocytes and T lymphocytes to influence the concentration of circulating 
NTBI. To address if PBMCs from HH patients had different NTBI retention capacity than cells 
isolated from healthy blood donors, we performed a NTBI retention assay with ex-vivo CD4+ 
and CD8+ T lymphocytes and monocytes isolated from peripheral blood from both groups. 
Despite the small sample size of the healthy control group, it should be noticed that 
each experiment was performed with cells isolated from randomly recruited blood donors and 
from these independent experiments we observed a very small variation as reflected in a low 
standard deviation. In contrast, HH patients show a high heterogeneity in the NTBI retention 
ability by T lymphocytes and monocytes. These results are extended by the observation that 
the individual profiles of iron re-uptake by HH patients, following the end of intensive 
treatments, strongly correlate with the NTBI retention potential of each individual’s cell types. 
Although in these patients, as in blood donor controls, the systemic levels of NTBI should be 
low, we interpret that circulating PBMCs, by sequestering a fraction of the newly exported 
iron, may modify transferrin saturation, in direct proportion to the retention potential of each 
individual. These results provide an explanation for the previous observation of spontaneous 
iron overload in CD8+- and total T lymphocyte-depleted animals [24, 28, 34, 35], as well as 
for the inverse correlation observed between CD8+ T lymphocyte numbers and the severity of 
iron overload in HH patients [30, 32, 171]. 
On a broader scope, our results provide a mechanistic support for the possibility of 
circulating T lymphocytes and monocytes acting in vivo as key partners in systemic iron 
homeostasis. However, a number of questions remain unanswered. Why only CD8+ 
lymphocyte numbers and not CD14+ or CD4+, have been associated with iron overload in 
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human HH patients? What is the fate, in the long term, of the NTBI sequestered by 
monocytes and T lymphocytes? What is the impact of the intracellular NTBI on the 
phenotype of each cell population (survival, activation potential, migration, etc.)? These 
questions prompted us for the following research objective where the CD8+ T cells phenotype 
and gene expression profile was addressed in the context of Hfe ablation. 
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3.4  
Lymphocyte gene expression signatures from patients and mouse 
models of hereditary hemochromatosis reveal a function of HFE as 
a negative regulator of CD8+ T-lymphocyte activation and 
differentiation in vivo 
This chapter is published in: 
Costa M, Cruz E, Oliveira S, Benes V, Ivacevic T, et al. (2015) Lymphocyte gene expression 
signatures from patients and mouse models of hereditary hemochromatosis reveal a function 
of HFE as a negative regulator of CD8+ T-lymphocyte activation and differentiation in vivo. 
PLoS One 10: e0124246. 
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Abstract 
Abnormally low CD8+ T-lymphocyte numbers is characteristic of some patients with 
hereditary hemochromatosis (HH), a MHC-linked disorder of iron overload. Both 
environmental and genetic components are known to influence CD8+ T-lymphocyte 
homeostasis but the role of the HH associated protein HFE is still insufficiently understood. 
Genome-wide expression profiling was performed in peripheral blood CD8+ T lymphocytes 
from HH patients selected according to CD8+ T-lymphocyte numbers and from Hfe-/- mice 
maintained either under normal or high iron diet conditions. In addition, T-lymphocyte 
apoptosis and cell cycle progression were analyzed by flow cytometry in HH patients. HH 
patients with low CD8+ T-lymphocyte numbers show a differential expression of genes 
related to lymphocyte differentiation and maturation namely CCR7, LEF1, ACTN1, NAA50, 
P2RY8 and FOSL2, whose expression correlates with the relative proportions of naïve, 
central and effector memory subsets. In addition, expression levels of LEF1 and P2RY8 in 
memory cells as well as the proportions of CD8+ T cells in G2/M cell cycle phase are 
significantly different in HH patients compared to controls. Hfe-/- mice do not show alterations 
in CD8+ T-lymphocyte numbers but differential gene response patterns. We found an 
increased expression of S100a8 and S100a9 that is most pronounced in high iron diet 
conditions. Similarly, CD8+ T lymphocytes from HH patients display higher S100a9 
expression both at the mRNA and protein level. Altogether, our results support a role for HFE 
as a negative regulator of CD8+ T-lymphocyte activation. While the activation markers 
S100a8 and S100a9 are strongly increased in CD8+ T cells from both, Hfe-/- mice and HH 
patients, a differential profile of genes related to differentiation/maturation of CD8+ T memory 
cells is evident in HH patients only. This supports the notion that HFE contributes, at least in 
part, to the generation of low peripheral blood CD8+ T lymphocytes in HH. 
 
 
Keywords: Hemochromatosis, HFE, iron, CD8+ T lymphocytes, S100a9, lymphocyte 
homeostasis 
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Introduction 
Hereditary hemochromatosis is a common genetic disorder of iron overload where the 
vast majority of patients are homozygous for the C282Y mutation in HFE, a non-classical 
MHC-class I gene localized on chromosome 6 in strong linkage disequilibrium with the HLA-
A locus [184, 244]. The conformational change introduced by the C282Y mutation impairs 
the association of HFE with β(2)-microglobulin and consequently its expression at the cell 
surface [27]. As an integral part of a membrane-associated protein complex in hepatocytes, 
HFE is involved in the regulation of hepcidin, a hormone that controls systemic iron levels 
[245]. Whether HFE is also involved in T-lymphocyte signaling, is still unresolved. 
Abnormalities in the pool of CD8+, but not CD4+, T lymphocytes have been 
consistently reported in HH patients [179]. Low numbers of CD8+ T lymphocytes in the 
peripheral blood [21, 22, 30] as well as in the liver [33] are associated with severe expression 
of iron overload. The low numbers of CD8+ T lymphocytes are mostly due to defects in the 
subpopulation of the effector memory T cells [31]. So far, functional studies have not been 
conclusive in terms of elucidating the nature of the CD8 defects in HH. Although decreased 
CD8-associated p56lck activity [170] and diminished cytotoxic activity [29] have been 
reported, other studies suggested a more activated profile of these cells namely a relative 
expansion of CD8+CD28- T-cell populations, a high percentage of CD8+HLA-DR+ cells and 
an increased production of IL-4 and IL-10 [29, 172]. A possible explanation for the activation 
profile of CD8+ T cells in HH may be found in a recent work where Reuben and co-workers 
propose that HFE has a role in antigen processing and presentation leading to an inhibition 
of CD8+ T-lymphocyte activation [224]. Their studies were based on several T-lymphocyte 
activation read-outs in cells transfected with wild type and mutated HFE molecules, but no 
evidence has been provided of an effect on antigen processing and presentation functions in 
vivo. 
The anomalies of CD8+ T-lymphocyte numbers in HH could be a consequence of iron 
overload or a direct effect of HFE on the homeostatic regulation of this cell population. The 
finding that young, early diagnosed asymptomatic HH subjects already display a low CD8+ 
phenotype similar to their clinically affected family members, favors the idea of a 
predominantly primary genetic effect linked to the HFE mutation [22]. On the other hand, the 
fact that some HH patients despite the same HFE defect do not display the low CD8+ 
phenotype indicates that environmental and/or genetic factors must compensate for the 
anomalies in the CD8+ T-cell pool independently of HFE. It is known that modifications in 
gene expression concur to define the different properties of CD8+ T cells at different 
differentiation stages and therefore their homeostatic equilibrium [157]. We have shown that 
particular HLA-A alleles and haplotypes are significantly associated with CD8+ T-cell 
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numbers in HH patients carrying the same HFE mutation [43, 44] but they do not constitute a 
universal marker in all patients analyzed [220]. Studies are still pending trying to localize 
other relevant markers in the same chromosomal region. Genomic based studies, however, 
are not sufficient to distinguish the functional effect of HFE from that of other MHC-class I 
genes in strong linkage disequilibrium in the same chromosomal region. 
In the present study we addressed the question whether HFE shapes the peripheral 
pools of CD8+ T lymphocytes. We applied two independent RNA-based genome wide 
approaches in isolated CD8+ T cells from HH patients homozygous for the C282Y HFE 
mutation and disease mouse models lacking the HFE gene (Hfe-/-). While studies in HH 
patients revealed the impact of HFE on the expression of genes associated with the 
differentiation and maturation of peripheral CD8+ T-lymphocyte subsets, the transcriptional 
profile of isolated CD8+ T lymphocytes from Hfe-/- mice revealed alterations in CD8+ T-cell 
activation-related genes, a result also confirmed in peripheral blood lymphocytes from HH 
patients. Altogether, our results support a mechanistic role for HFE as a negative regulator of 
CD8+ T-lymphocyte activation in vivo and provide formal evidence, at least in part, to explain 
the characteristic low CD8 phenotype of HH patients. 
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Results 
1- A genome-wide transcriptional profile of CD8+ T lymphocytes from HH 
patients is indicative of the subpopulations’ differentiation/maturation states  
A transcriptional gene profiling study of sorted CD8+ T lymphocytes from HH patients 
was performed to identify gene response patterns that may explain lower peripheral blood 
CD8+ T-lymphocyte numbers in patients with HH and severe iron overload. We took 
advantage of the known clinical and immune phenotypical variability in HH and selected 10 
patients stratified in two distinct groups: group 1 (n=6) shows a typical low CD8 phenotype 
(<300x103/ml) (see Methods) hallmarked by a severe clinical expression of iron overload; 
group 2 (n=4) shows normal/high CD8 phenotype (≥400x103/ml) (see Methods) and very mild 
clinical expression of HH. Gene expression analysis identified a signature of 16 genes (7 up-
regulated and 9 down-regulated) potentially associated with the CD8+ T-cell phenotype 
(Table 1). The magnitude of gene expression changes was small, generally less than 2-fold. 
Multiple variable correlation analysis among the 16 gene candidates identified two 
independent clusters of genes, which are functionally interlinked. One cluster contained the 
genes: chemokine C-C motif receptor 7 (CCR7), lymphoid enhancer-binding factor 1 (LEF1) 
and actinin alpha 1 (ACTN1), which are all down regulated in the group of patients with the 
low CD8 phenotype and are markers of CD8+ T-cell differentiation and/or maturation. The 
chemokine receptor CCR7 is a differentiation/maturation marker present in naïve (TN) and 
central memory (TCM) cells but absent in the effector memory (TEM) pool [246, 247]. LEF1 has 
been described as being down-regulated in naïve CD8+ T cells after antigen encounter and 
differentiation in vivo [248]. Of the three genes in this cluster, only ACTN1 (HS1) was not 
previously described as a differentiation/maturation marker, but it is known to be involved in 
cytoskeletal remodeling and calcium mobilization, a fundamental process for T-cell activation 
[249]. A very distinct picture was observed for the second cluster of functionally related 
genes which included: N(alpha)-acetyltransferase 50 (NAA50), purinergic receptor P2Y (G-
protein coupled, 8) (P2RY8) and FOS-like antigen 2, (FOSL2) that are all up-regulated in the 
group of patients with a low CD8 phenotype. This group of genes is involved in lymphocyte 
activation and expansion. Both P2RY8 and FOSL2 have been implicated as regulators of cell 
proliferation, differentiation, and malignant transformation [250, 251] and NAA50 is described 
as an anti-apoptotic molecule [252]. 
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Table 1 Summary of differentially expressed genes in total CD8 T-lymphocytes in HH 
patients with a low CD8 phenotype (n=6) relative to HH patients with a normal/ high 
CD8 phenotype (n=4). 
GeneBank 
accession # 
Gene Symbol Gene Description 
Fold Change 
(Profile A vs 
Profile B) 
NM_002123.3 HLA-DQB1 Major histocompatibility complex, class II, DQ beta1  Up 1.82 
NM_002124.2 HLA-DRB1 Major histocompatibility complex, class II, DR beta1  Up 1.82 
NM_005253 FOSL2
a)
 FOS-like antigen 2 Up 1.59 
BC096168 HIST1H1E Histone cluster 1, H1e Up 1.57 
NM_178129 P2RY8
a)
 Purinergic receptor P2Y, G-protein coupled, 8 Up 1.57 
BC009288 NR4A2
a)
 Nuclear receptor subfamily 4, group A, member 2 Up 1.52 
BC012731 NAA50
a)
 N(alpha)-acetyltransferase 50, NatE catalytic subunit Up 1.51 
NR_003330 SNORD116-15 Small nucleolar RNA, C/D box 116-15 Down 1.90 
BC038982 IGJ 
Immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 
Down 1.81 
NR_002907 SNORA73A Small nucleolar RNA, H/ACA box 73A Down 1.74 
BC035343 CCR7
a)
 Chemokine (C-C motif) receptor 7 Down 1.68 
DQ496098 ACTN1
a)
 Actinin, alpha 1 Down 1.65 
NR_003332 SNORD116-17 Small nucleolar RNA, C/D box 116-17 Down 1.57 
NR_001290 SNORD116-19 Small nucleolar RNA, C/D box 116-19 Down 1.57 
AF288571 LEF1
a)
 Lymphoid enhancer-binding factor 1 Down 1.56 
NM_019111.4 HLA-DRA Major histocompatibility complex, class II, DR alpha Down 1.52 
For definition of low CD8 phenotype and normal/high CD8 phenotype see Methods. 
a) Confirmed by custom designed real-time PCR primers 
 
Besides the above described genes, a significant up regulation of the MHC class II 
genes HLA-DQB1 and HLA-DRB1, as well as the histone cluster 1 gene HIST1H1e, was 
also observed in patients with a low CD8 phenotype, supporting the notion of an activation 
and cell cycle progression pattern of these cells [253]. 
In order to explore the significance of the results obtained in this screen, we analyzed 
the correlations of the expression levels of each gene with the clinical and immune 
phenotypic variables. These included the number of peripheral blood CD8+ T lymphocytes, 
including the differential pattern of CD8 TN, TCM and TEM cells as well as the iron overload 
profile, measured by the estimated total body iron stores (TBIS). The results are given in 
supplementary S1 Table. They strongly suggest that the differences observed in the gene 
expression of CD8+ T cells between the two HH groups reflect not only upon differences in 
the relative proportions of their CD8+ T-cell subsets but also upon differences in the 
activation profile of the cells. More specifically, the differentiation markers CCR7, LEF1 and 
ACTN1 correlated positively with the number of CD8+ TN and TCM cells in each patient, 
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reflecting a direct impact of the relative proportion of these subpopulations in the total CD8+ 
pool expression pattern. In contrast, the activation markers NAA50, P2RY8 and FOSL2 were 
negatively correlated with the total number of CD8+ TEM cells in each patient, indicating that 
subjects with a low CD8 phenotype show more activated effector memory cells. Curiously, 
variations in the mRNA expression levels of these activation genes had more impact on the 
total number of CD8+ T lymphocytes than the expression of the differentiation markers 
CCR7, LEF1 and ACTN1 (see data on S1 Table).  
In general, the TBIS was most significantly correlated with the differentiation markers 
CCR7, LEF1 and ACTN1 (see also data on S1 Table) therefore not excluding an effect of 
iron overload on the most immature CD8+ T lymphocytes or vice-versa. It should be noted, 
however, that due to the strict selection criteria applied in this screen, it was not possible to 
discriminate the confounding effects of the CD8+ T-cell numbers and of the iron overload 
phenotypes, because the two variables are highly correlated (R2=57%; r=-0.75, p=0.0187). 
In order to rule out the hypothesis of a bystander effect of systemic inflammation on 
the patients’ individual immunophenotypes, we retrieved historical measures of their C-
reactive protein (CRP) serum levels and compared them with the CD8+ T-lymphocyte counts 
determined on the same day. No significant correlation was found between the two 
parameters (R-squared adjusted for d.f.= -1.19185 percent; p=0.379), thus excluding any 
relevant effect of systemic inflammation on the patients’ immunophenotype. 
 
2 - Analysis of CD8+ T-lymphocyte subsets reveals the impact of HFE on the 
expression profile of central memory and effector memory cells  
As shown above, the transcriptional profiles of HH patients with low or normal/high 
CD8+ T-cell numbers not only highlight the differences in the relative proportions of their 
subsets but also reflect differences in the activation state of the cells. To understand if the 
gene expression profiles are informative beyond reflecting upon T-cell numbers, we next 
focused on the analysis of 6 genes (CCR7, LEF1, ACTN1, FOSL2, P2RY8 and NAA50) in 
the different CD8+ TN, TCM and TEM compartments. Cells were sorted according to the gating 
strategy illustrated in Fig. 1A, in blood samples from a group of 10 additional and unselected 
HH patients and 8 healthy control individuals. With this approach we aimed: i) to validate the 
results of the genome wide screen with independent HH samples ii) to test the impact of HFE 
on gene expression by comparing HH patients with normal healthy subjects and iii) to 
address if there was any additional impact of serum iron levels on the expression profiles in 
individual T-cell populations of HH patients, taking advantage of the fact that patients were at 
different stages of treatment and therefore showing a wide range of transferrin saturation 
values. 
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As illustrated in Fig. 1B, the mRNA expression levels of CCR7, LEF1 and ACTN1 
decreased from CD8+ TN to TEM cells, with the lowest values consistently observed in the TEM 
subset. Once CCR7 is a well-known maturation marker of T lymphocytes [246] it served as a 
non-anticipated positive control in our experiment. An opposite pattern was detected for 
FOSL2, which was up-regulated in the most differentiated lymphocyte subpopulation 
scrutinized, i.e. in TEM. P2RY8, in turn, showed the highest expression levels in TCM cells, 
while NAA50 was uniformly expressed in all CD8+ T-cell subsets. Of note, significant 
differences were observed in the profile of TCM cells between HH patients and controls, LEF1 
being significantly decreased (p=0.002) and P2RY8 significantly increased (p=0.019) in HH 
patients. In addition, LEF1 in HH patients was also significantly decreased in TEM (p=0.008). 
These differences between HH patients and controls in the gene transcription of central and 
effector memory cells, suggest that the HFE defect may affect the homeostatic equilibrium of 
Fig. 1 Gene expression analysis in CD8
+
 T-cell subpopulations 
A) Gating strategy used to discriminate the CD8
+
 T subpopulations of naïve, central memory and effector 
memory cells. B) Relative mRNA expression levels of CCR7, LEF1, ACTN1, FOSL2, P2RY8 and NAA50 in 
isolated CD8
+
 T subpopulations. Statistical significant differences were calculated by T-test between HH 
patients and controls in each subpopulation. 
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these particular populations without affecting the naïve T cells. Importantly, no significant 
correlations were found between the expression of any of the analyzed genes and the levels 
of circulating iron as measured by the transferrin saturation (data not shown) further 
supporting a primary effect of HFE on CD8+ T-lymphocyte signaling independently from 
circulating iron levels. 
 
3 - Apoptosis and cell cycle studies in CD4+ and CD8+ T lymphocytes from HH 
patients and controls 
The fact that the genes found up regulated in patients with the lowest CD8+ counts 
were genes involved in activation and proliferation suggests that, in spite of constituting a 
small pool, these cells must be constantly activated to proliferate. The next question to 
address was therefore to investigate whether an altered apoptosis/proliferation balance of 
peripheral blood CD8+ T lymphocytes in HH patients can account for these observations. 
Since this is the first study analysing apoptosis and cell cycle profiles in T lymphocytes from 
HH patients, the study was extended to both CD4+ and CD8+ subpopulations of T 
lymphocytes. 
 
3.1 Apoptosis in CD8+ T lymphocytes correlates with systemic iron levels 
In general, a highly significant difference was found between the CD4+ and CD8+ T-
lymphocyte subpopulations in terms of the percentages of apoptotic cells (T Test p=9.4x10-8, 
KS-Test p=0.000002), with the average apoptosis percentage being 21.8% ±9.9% in CD4+ T 
cells, and 47.3% ±21.8% in CD8+ T cells. Apoptosis in CD4+ and CD8+ T cells was not 
influenced by gender but it was influenced by age in CD8+ T cells only (R2=13.5%, r=0.37, 
p=0.0380). In general, apoptosis in each of these subsets (CD4+ or CD8+ T cells) was not 
statistically different between controls and HH patients and, in this later group, it was not 
influenced by the treatment status i.e. (intensive vs. maintenance treatment) (data not 
shown). In terms of association with total numbers, no significant correlations were found 
between apoptosis and either CD4+ or CD8+ T-cell total counts (cells/mm3) in both HH 
patients and controls, indicating that defective numbers in HH are not explained by increased 
apoptosis (data not shown). Nevertheless, the percentage of apoptosis in both CD8+ and 
CD4+ T cells in HH patients was significantly correlated with the systemic iron load 
parameters namely serum iron (respectively R2=34.6%, p=0.008 and R2=20.5%, p=0.046) 
and transferrin saturation (respectively R2=32.9%, p=0.006, and R2=20.4%, p=0.045). 
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3.2 Peripheral blood CD8+ T lymphocytes from HH patients show an increased 
proportion of cells in the G2/M phase  
Marked differences were observed between the populations of CD4+ and CD8+ T cells 
regarding the proportion of cells along the three phases of cell cycle, particularly in G2M and 
S (Table 2). Regarding the differences between HH patients and controls, some significant 
differences could be observed independently of iron status (Table 2). In general, there were 
more lymphocyte in S and G2/M and less in G0/G1 phase in HH patients than in controls, 
both in CD4+ and CD8+. These differences reached statistical significance in G2/M with 
values in patients being 2.5 and 11 times higher respectively in CD8+ and CD4+ cells, and in 
G0/G1 for CD4+ T cells only, although this difference is less than 0.2% of their absolutes 
levels, probably reflecting the space occupied by the increased numbers of cells in G2/M. No 
significant correlation was found between the percentages of cells in each cell cycle phase 
and the percentage of cells in apoptosis, showing that the increase of cells in G2/M observed 
in patients is not a direct consequence of apoptosis but rather an independent step, possibly 
related with increased cell activation. 
 
Table 2 Comparisons of CD4+ and CD8+ T-lymphocyte percentages in different cell 
cycle phases between HH patients and controls. 
Cell Cycle Phase Cell population % in Controls % in HH Patients KS test
1
 
G0G1 CD4
+
 T cells 99.65 ± 0.16 99.41 ± 0.33 P=0.0256 
 CD8
+
 T cells 98.86 ± 1.25 98.13 ± 1.69 n.s 
 KS test
2
 0.0337 0.0047  
S CD4
+
 T cells 0.34 ± 0.16 0.49 ± 0.23 n.s 
 CD8
+
 T cells 0.94 ± 1.00 1.39 ±1.09 n.s 
 KS test
2
 0.0337 0.0015  
G2M CD4
+
 T cells 0.01 ± 0.03 0.11 ± 0.14 P=0.0217 
 CD8
+
 T cells 0.20 ± 0.36 0.49 ± 0.74 P=0.0025 
 KS test
2
 <0.0001 0.0135  
1
 Kolmogorov-Smirnov Test comparing HH patients and controls 
2 
Kolmogorov-Smirnov Test comparing CD4
+
 T cells and CD8
+
 T cells 
 
In summary, results of cell cycle positioning of total peripheral blood CD8+ T 
lymphocytes from HH patients support the notion that those cells constitute a highly dynamic 
population in homeostatic equilibrium, compatible with the activation profile revealed before 
with the gene expression data. 
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4 - mRNA expression analysis in Hfe-/- and wild type mice supports the impact 
of HFE on the CD8+ T-lymphocyte activation profile 
All previous results in HH patients suggesting an impact of HFE on the expression 
profile of CD8+ T cells were still confounded not only by the known phenotypic heterogeneity 
among patients, possibly influenced by other MHC linked genetic determinants [44, 220] but 
also by the strong correlation between the CD8 phenotypes and the severity of iron overload 
[43]. In order to address the relative impact of HFE and iron overload on the CD8+ T-
lymphocyte gene expression profile in the absence of such confounding variables, we used 
the HFE deficient mouse model (Hfe-/-). We performed a differential genome-wide expression 
analysis comparing Hfe-/- and wild-type (wt) mice, in conditions of either normal or iron rich 
diet. Results showed that few genes were differently expressed in the CD8+ T cells of Hfe-/- 
mice, 66 in total: 37 up-regulated and 29 down-regulated under the standard normal iron 
condition. A few more genes were differently expressed under high iron diet, 78 in total: 67 
up-regulated and 11 down-regulated. Lists of the transcripts differentially regulated in Hfe-/- in 
comparison with wild type C57BL/6 mice are provided in S2 and S3 Tables. Functional 
clustering analysis was performed to define categories among the differentially regulated 
genes. The results are presented as supplementary material in S4 Table. 
From all differentially expressed genes, only thirteen were found in common in both 
normal and high iron diet conditions (Fig. 2a), suggesting an impact of HFE on the CD8 
expression of these genes regardless of iron levels. Nevertheless, an additional effect of iron 
cannot be excluded. 
 
Fig. 2 Genome-wide expression analysis of CD8
+
 T lymphocytes from Hfe
-/-
 and wild type mice A) Venn 
diagram with comparative analysis between the selected genes found to be differently regulated by the two 
genotypes under the same iron diet condition. B) Differential gene expression of Hfe
-/- 
mice with normal and high 
iron diet relatively to C57BL/6 mice under the same iron diet conditions. Fold Change of the genes found to be 
differently expressed (T-test, p<0.05) and with fold change >1.8 are represented. 
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As illustrated in Fig. 2b, the most striking differences were found for S100a8 and 
S100a9, two calcium-binding proteins (calgranulins) involved in the regulation of several 
cellular processes such as cell cycle progression and differentiation [254, 255]. These genes 
were increased in Hfe-/- mice under normal iron diet (fold-changes of 16.52 for S100a8 and 
12.96 for S100a9) but notably, the fold-change differences were even higher under high iron 
diet conditions (fold-changes of 34.58 for S100a8 and 29.21 for S100a9). 
 
4.1 Correlational analysis of the differential expressed genes between Hfe-/- 
and wild type mice 
In order to understand the putative interaction of the calgranulins S100a8 and S100a9 
with the other differentially expressed genes, we further analyzed expression data from all 
individual mice maintained in high iron diet conditions (the condition where differential gene 
expression was more marked) and performed multi-variable correlation analysis to identify 
the most significantly co-expressed genes. The results are given as supplementary material 
illustrated in S1 Fig. In general, correlations with S100a9 were stronger than those observed 
with S100a8. The gene whose expression was most significantly correlated with S100a9 was 
Tyrobp (r=0.9931; p=0.0001) which codes for the tyrosine kinase binding protein DAP12 
(DNAX activation protein 12). Interestingly, DAP12 has been shown by others to be a marker 
of self-reactive, non-MHC restricted activated memory-phenotype CD8+ T cells, in contrast to 
the conventional CD8+ T cells [160]. Two other genes, Retn1g and Fcer1g were found 
strongly correlated with DAP12 expression (r=0.9756; p=0.0009 and r=0.9701; p=0.0013, 
respectively) and, accordingly, they were the next most significantly correlated with S100a9 
expression (r=0.9693; p=0.0014 and r=0.9558; p=0.0029, respectively). Retn1g codes for a 
novel resistin-like molecule expressed in hematopoietic tissues and expected to have a 
cytokine-like role [256] and Fcer1g codes for the gama Fc membrane receptor (FcR) which, 
like DAP12, is a tyrosine kinase binding protein with a fundamental role in immune effector 
functions [257]. Two genes, Cd69 and Clec2d, were the only inversely correlated with 
S100a9 (r=-0.9764; p<0.0001 and r=-0.9421; p=0.0005, respectively). These are respectively 
the members C and D of the C-type lectin domain family 2, a family of co-stimulatory 
molecules recently recognized as markers of very early T-cell activation [258]. In particular 
Cd69 has been described as a marker of non-circulating resident (resting) memory CD8+ T 
cells, and characteristically absent in the recirculating central and effector memory CD8+ T-
cell populations [259]. The only gene from the initial list of 13 that was not significantly 
correlated with S100a9 at the individual level was CD79a. In summary, results of a 
significantly increased expression of S100a9 in CD8+ T lymphocytes from Hfe-/- mice 
positively correlated with DAP12 and negatively correlated with Cd69 suggests that the effect 
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of HFE on CD8 activation may target preferentially the central/effector memory cells, which 
are also the cells predominantly decreased in HH patients [31]. 
None of the genes found altered in HH patients with a low CD8 phenotype (LEF1 and 
P2RY8) were significantly associated with the up regulation of calgranulins S100a8 and 
S100a9, showing that the two models of differential gene expression are not equivalent. 
Hence the putative mechanisms involving HFE as a player in CD8+ T-cell activation in mice 
or those involving HFE as a player in the homeostatic equilibrium of CD8+ T-cell subsets in 
HH patients may be substantially different. 
 
4.2 Genes encoding proteins of iron metabolism are not altered in CD8 + T cells 
from Hfe-/- mice 
To assess whether iron impacts on the differential gene expression of Hfe-/- mice we 
analyzed the expression of genes related with iron metabolism in normal iron diet conditions, 
where the differences between the two mouse models in terms of iron loading were more 
marked (Fig. 3). The expression of most iron related genes was, in general, very low in CD8+ 
T lymphocytes and not significantly different between the two genotypes except for lipocalin 
2 (Lcn2) that was significantly up-regulated in Hfe-/- in comparison with wild-type (p=0.0016). 
Lcn2 is an antimicrobial protein that acts by capturing and depleting bacterial siderophores 
and is known to have chemoattractant properties [260]. These results are shown as 
supplementary material in S5 Table. No significant correlations were found between the 
expression of any of the 13 genes differentially expressed in Hfe-/- mice and the expression of 
the iron related genes (data not shown). 
 
Fig. 3 Hepatic iron concentration of Hfe
-/-
 and C57BL/6 mice under a normal or a high-iron diet. Values are 
expressed as mean ± standard deviation. Statistical significant differences were calculated between mice 
genotype groups under the same diet condition (T-test * P<0.05 and ***P<0.001). 
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5.  S100a9 mRNA and protein expression are increased in human peripheral 
blood CD8+ T lymphocytes from HH patients  
The previous findings that calgranulins are over-expressed in CD8+ T lymphocytes of 
Hfe-/- mice, prompted us to investigate these proteins in human patients with HH in 
comparison to normal controls. This was done first by accessing S100a8 and S100a9 
expression at mRNA levels with qRT-PCR without any previously activation step. As shown 
in Fig. 4A, S100a8 and S100a9 mRNA expression in isolated CD8+ T lymphocytes were 
significantly higher in HH patients than in controls with fold change of 2.4 for S100a8 and 3.4 
for S100a9 (Wilcoxon paired test, p=0.016 and p=0.027 respectively). Although in the Hfe-/- 
mouse model these two proteins were similarly expressed, in humans S100a9 gene 
expression was found to be 4.5x higher than S100a8. Due to this high expression, we next 
analyzed S100a9 protein level by flow cytometry. 
 
Fig. 4 S100a8 and S100a9 expression in CD8+ T cells from HH patients and controls A) S100a8 and 
S100a9 mRNA expression in isolated CD8+ T lymphocytes from HH patients and normal controls. Statistical 
significance was obtained with paired analysis of patient-control of the day using the non-parametric Wilcoxon 
test, *p<0.05. B) Median fluorescence intensity of S100a9 expression in CD8+ T cells from peripheral blood from 
HH patients and normal controls. Statistical significance was obtained with paired analysis of patient versus 
control of the day using the parametric T-test, *p<0.0001. 
 
The expression of S100a9 protein was evaluated by MFI (median fluorescence 
intensity) in total lymphocytes, CD8+ and CD4+ T subpopulations. In addition, the expression 
of S100a9 was also evaluated in neutrophils and monocytes that are known to express this 
protein and were used as positive controls (see Material and Methods). Paired T-Test 
comparisons of S100a9 MFI values in the several populations were performed between HH 
patients (n=30) and controls (n=13) tested in the same day under the same conditions. 
Neutrophils and monocytes had significantly (p=0.013 and p=0.005 respectively) higher 
S100a9 MFI values in HH patients (mean±SEM: 13090±1039 and 2947±181 respectively) in 
comparison with controls (mean±SEM: 10291±293 and 2435±80 respectively). The 
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expression of S100a9 in total lymphocytes was also consistently higher in HH patients than 
in controls (mean±SEM: 481±15 in HH and 418±10 in controls, p<0.0001), although at a 
much lower level. Regarding the T-lymphocyte subsets, the expression of S100a9 in CD8+ T 
lymphocytes was significantly higher in HH patients in comparison to controls (mean±SEM: 
481±17 in HH and 421±11 in controls, p<0.0001) (Fig. 4B). The same result was obtained for 
CD4+ T cells (mean±SEM: 469±17 in HH and 388±9 in controls, p<0.0001). S100a9 
expression in each cell type was not significantly correlated with the total numbers of the 
respective cells. 
Altogether, results in both animal and human models of HH support a direct effect of 
HFE on the transcriptional profile of CD8+ T lymphocytes, HFE deficiency inducing the up 
regulation of the calgranulin S100a9. As an HFE-dependent effect, it is not surprising that 
calgranulins have not been found differentially expressed in the first genome-wide screen in 
patients, where all subjects carry the same HFE mutation. Hence, results of calgranulin 
expression do not constitute an explanation for the heterogeneity found in HH patients 
regarding the numbers and subsets of CD8+ T lymphocytes. These were better explained by 
changes in the signaling pathways described above with the results of the differential 
expression profiles in CD8 subsets. 
  
CD8 gene expression analysis from HH patients and Hfe
(-/-)
 mice 
111 
 
Discussion 
In this paper we questioned whether or not HFE, a non-classical MHC-class I 
molecule, affects the triggering/signaling pathways of CD8+ T lymphocytes and if it 
contributes to the self-renewal and homeostasis of the three main CD8+ subpopulations of 
naïve, central memory and effector memory cells at the periphery. To do that, we used 
human and mouse models of HH, both lacking the cell surface expression of HFE. In a first 
step we analyzed the transcriptional profile of selected CD8+ T lymphocytes from HH patients 
homozygous for the C282Y HFE mutation. Because these patients share a common HFE 
defect but differ in the numbers of CD8+ T lymphocytes and subpopulations, this approach 
was expected to identify novel candidates associated with the CD8 phenotype independently 
of HFE. The signaling molecules CCR7 and LEF1, which are normally down regulated in 
naïve cells after activation [248], as well as ACTN1, a calcium dependent remodeling 
molecule, were significantly decreased in patients with a low CD8 phenotype. Conversely, 
the expression of FOSL2, P2RY8 and NAA50 molecules known to be involved in processes 
of activation/expansions of lymphocytes, were significantly increased in patients with low 
CD8 phenotype. By mRNA analysis in sorted populations we confirmed the expression 
patterns of these genes in naïve, central memory and effector memory cells. While CCR7 
and LEF1 were, as expected, mostly expressed in naïve cells we describe for the first time 
that and ACTN1 is also mostly expressed in naïve cells, that P2RY8 expression is 
preferentially observed in central memory and that FOSL2 is preferentially expressed in 
effector memory cells. This general pattern of subset specific gene expression was found 
both in HH patients and controls (see Fig. 1).Nevertheless, the expression of LEF1 and 
P2RY8 in central and effector memory CD8 subpopulations of HH patients differed 
significantly from controls, independently of their total cell numbers or serum iron levels. We 
interpret these results as evidence of an impact of HFE on the differentiation /maturation of 
CD8+ T lymphocytes, possibly in the conversion step of central memory into effector memory 
T cells described by Peixoto and co-workers with in vitro experiments [157]. The question 
remains, however, if a similar expression profile would be also observed in normal subjects 
displaying a low CD8 phenotype, in spite of a normal HFE. Amongst the healthy controls 
studied here (n=8), only one subject displayed a low CD8 phenotype (total CD8+ T 
lymphocytes=197x103/ml; total TEM T lymphocytes=0.058 x10
3/ml). But in contrast to HH 
patients, he had no evidence of a decreased LEF1 or increased P2RY8 expression in TCM or 
TEM subpopulations as compared to the other controls (data not shown), therefore not 
supporting a defect similar to that observed in HH. A formal proof to this concept, however, 
would imply an extended analysis of a large normal population, which was out of the scope 
of the present paper. 
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The observation that HH patients show an increased proportion of cells in G2/M 
phase in the periphery is compatible with the hypothesis of an increased activation state. In 
addition, the present study of apoptosis and cell cycle in human peripheral blood 
lymphocytes also brought into light a new aspect of lymphocyte biology which is the clear 
demonstration of marked differences in apoptosis and cell cycle progression between the 
subpopulations of CD4+ and CD8+ T lymphocytes. Although a higher percentage of apoptotic 
cells among the CD8+ relative to CD4+ T lymphocytes had been already observed in previous 
studies in the context of sepsis and pulmonary disease, its significance in normal 
physiological conditions had never been discussed [261, 262]. This is a relevant finding 
deserving fully consideration in future studies of lymphocyte activation and proliferation in the 
clinical setting. 
One pending question that could not be answered by the simple analysis of CD8 
expression data in HH patients was the clarification of the complex interaction between HFE, 
CD8+ T-lymphocyte numbers and the severity of iron overload. As mentioned in the results 
section, a limitation of the genome-wide screen experiment in HH patients was the fact that, 
due to the strict selection criteria used, i.e., patients grouped according to exclusive patterns 
of CD8 phenotypes (low or normal/high) which are significantly associated with the iron 
overload profiles, it was not possible to distinguish the relative interactions of iron overload or 
CD8 numbers with the expression profiles. Nevertheless, for the subsequent analysis of 
expression of the different genes in sorted CD8+ T-cell subsets we used a non-selected 
group of patients who were at different stages of treatment showing a wide range of 
transferrin saturation values not related to the CD8 phenotype. Although there was, in 
general, a higher variation in the gene expression of the different CD8+ T-cell subsets in HH 
patients than in controls (see Fig. 1B), we found no correlation with either transferrin 
saturation or total CD8 numbers, supporting the notion of a primary effect of HFE on CD8+ T-
cell signaling, independent of actual circulating iron levels. 
The above described impact of HFE on the CD8+ lymphocyte profile independently of 
iron levels does not exclude the hypothesis that CD8+ T lymphocytes may be equipped with 
some “sensing” system for iron. In this regard, it was interesting to observe a relationship 
between higher transferrin saturation and increased CD8+ T-cell apoptosis. Iron induced 
apoptosis had been already reported in human hepatocytes and rat neurons but it had never 
been described in human lymphocytes [263, 264]. It could be speculated that in this way iron 
overload could contribute to the decreased numbers of CD8+ T cells in HH. However, a direct 
relationship between apoptosis and cell numbers was not found. The most plausible 
explanation is a compensatory increased activation of CD8+ T cells contributing to a “more 
dynamic” pool of lymphocytes in HH as shown by an increase in the number of cells in G2/M. 
We should bear in mind, however, that an increased number of cells in G2/M is not 
CD8 gene expression analysis from HH patients and Hfe
(-/-)
 mice 
113 
 
exclusively due to an increased number of mitotic cells but may also reflect an increased 
number of cells arrested in G2 for DNA repair, eventually in response to iron-induced 
oxidative injury. Of note, in a previous study we have shown that HH patients´ lymphocytes 
had lower DEB-induced chromosome instability possibly due to an adaptive response of the 
HH lymphocytes with increased DNA repair [265]. 
Once the question of the relationship of iron overload and the expression profile of 
CD8+ T lymphocytes could not be clarified in the human model of HH, we decided to address 
this question in animal models where genetic and environmental variables are controlled. For 
that purpose, we analyzed the transcriptional profile of CD8+ T lymphocytes from mice Hfe-/- 
in comparison to normal mice of the same genetic background, experiments performed in 
either normal or high iron diet conditions. Because all mice share the same MHC 
background, any putative modifier effect of other MHC related molecules could not be a 
variable here. The results revealed a set of differentially expressed genes between the two 
strains and three features deserve to be mentioned. First, the differentially expressed genes 
identified were mostly clustered in functional types related to lymphocyte signaling and 
activation, supporting the suggested inhibitory effect of wild-type HFE on CD8 activation 
[224]. Secondly, most of these differentially expressed genes differed in conditions of normal 
or high iron diet. Nevertheless, the observed impact of a high iron diet is only a partial effect 
because Hfe-/- mice are already constitutively iron overloaded. Finally the genes previously 
found altered in HH patients with a low CD8 phenotype were not altered in the Hfe-/- mouse 
model indicating that the mouse model does not completely recapitulate the phenotype of HH 
in humans, which is not surprising taking into consideration the fact that abnormalities in 
CD8+ T-cell numbers have never been described in these mice. 
The most striking differences in Hfe-/- mice were observed for the expression S100a8 
and S100a9, belonging to the S100 family of proteins containing two canonical EF-hand 
calcium-binding motifs involved in the calcium dependent control of cell differentiation, cell 
cycle progression and growth [254, 255]. The fold-change values of differential expression of 
these calgranulins between Hfe-/- and wild type mice was superior in mice fed in a high iron 
diet than for mice under a normal diet. Interestingly, a previously published genome wide 
mRNA expression study aimed to assess the effect of iron loading in muscle cells from mice 
also revealed that, among others, S100a8 and S100a9 were over expressed in iron overload 
conditions [266]. Further studies are needed to clarify the putative modulatory role of 
systemic iron on CD8+ T-cell activation. 
Results of calgranulins expression in mice was next translated to the human clinical 
model of HH where patients with a non-functional HFE showed an increased expression in 
both the mRNA expression and intracytoplasmatic protein expression of S100a9 in CD8+ T 
lymphocytes. It should be reminded however that an HFE-dependent altered gene 
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expression in CD8+ T lymphocytes does not necessarily mean that HFE is exerting its effect 
on the surface of these cells. On the contrary, it is more plausible to assume that an HFE-
dependent alteration in antigen-presenting cells may indirectly affect the CD8+ T-cell 
signaling. In this context, it was interesting to observe that, at the protein level, an increased 
expression of S100a9 was also observed in other blood cell types which are known to 
express this protein in higher amounts, namely neutrophils and monocytes. The additional 
finding of a strong correlation between the expression of S100a9 and the adaptor protein 
DAP12 is also of particular interest and may open new avenues to better explore the 
pathways involved in the effect of HFE on CD8+ T-cell activation. 
The putative role of iron on CD8+ T-lymphocyte activation and differentiation deserves 
some additional considerations. For many years we have reported results of a negative 
correlation between the numbers of CD8+ T lymphocytes and the severity of iron overload in 
HH [21, 30, 32], supporting the postulate that they may act as systemic “buffers” to protect 
against systemic iron toxicity [2, 23, 34, 267, 268]. Following that hypothesis, we have 
recently demonstrated the capacity of peripheral blood lymphocytes to uptake and process 
NTBI [234] and in that way to protect against tissue iron accumulation [269]. The 
mechanisms involved in NTBI transport and signaling in lymphocytes are still elusive. It is 
well known that non-classical MHC I molecules display different features from the classical 
ones, namely in their capacity to bind non peptide ligands [270]. In the recent paper by 
Reuben and co-workers on the inhibitory effect of HFE on CD8+ T-lymphocyte activation they 
excluded the interaction with TfR1 as a necessary step for HFE-mediated inhibition of MHC I 
presentation. It would be interesting to explore if HFE could affect NTBI uptake and in that 
way somehow influence lymphocyte activation. 
The assumption of a mechanistic model of interactions between HFE, lymphocyte 
activation and S100a9 expression may have important implications for a better 
understanding of HH and its clinical consequences. We propose that the “low CD8 
phenotype” in HH is the result of a homeostatic equilibrium of cells constantly triggered to 
activate and differentiate into more mature effector cells. This hypothesis is compatible with 
the concept first advanced by Reuben and co-workers that HFE is a negative regulator of 
CD8+ T-lymphocyte activation and that the lack of HFE may render CD8+T lymphocytes less 
tolerant to constant stimuli and more susceptible to autoimmune phenomena [224]. Notably, 
calgranulins have been described as damage-associated molecular pattern molecules 
(DAMPs) highly up regulated in various autoimmune disorders [255]. Recently Loser and 
colleagues provided clear evidence, in both animal and human autoimmune disorder models 
that local calgranulin production is essential for the induction of autoreactive CD8+ T cells 
and the development of systemic autoimmunity, an effect mediated via Toll-like receptor 4 
(TLR4) signaling [255]. The idea that a normal surface HFE expression may help preventing 
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the development of autoimmunity in homeostatic conditions [224] would imply that HH 
patients should be also more susceptible to autoimmune disorders. Although these are not 
commonly described in HH, one may recall here the fact that one of the most perturbing 
clinical features of HH is a severe arthropathy of still unknown pathogenesis that is not 
prevented by iron depletion, suggesting that other HFE-related mechanisms should be 
involved. Considering the recently described effect of S100a9 as an inflammation 
orchestrator in rheumatoid arthritis [255] and lupus erythematosus [271], it is tempting to 
speculate that an increased expression of S100a9 could also contribute to the arthropathy 
process in HH. More studies are certainly needed to address this question and to understand 
if there is any impact of activated CD8+ T lymphocytes on the pathogenesis of HH 
arthropathy, what is the role of calgranulins in that process and if they could constitute a 
promising novel therapeutic target. 
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Methods 
Ethics statement 
Animal care and procedures were in accordance with institutional guidelines. 
Conducted experiments in mice were approved by the IBMC.INEB Animal Ethics Committee, 
in accordance with the Portuguese Veterinary Director General guidelines. Regarding human 
studies, they were approved by the Institutional Ethical Committee of Santo António Hospital 
– Centro Hospitalar do Porto and written informed consent was obtained from all participants 
in accordance with the Declaration of Helsinki. 
 
Mice 
Mice models used in this study were C57BL/6 supplied by Charles River and mice 
homozygous for the disruption of the Hfe gene (Hfe-/-) generated under the same genetic 
background as described elsewhere [272]. They were females maintained at the IBMC’s 
Animal Care Facility fed ad libitum with the standard local rodent diet (Teklan 2014 Harlan 
with 175ppm of iron) until 14-15 weeks of age. After this, four C57BL/6 wild-type and four 
Hfe-/- mice were fed with the same diet until they were 16-17 weeks old consisting in the 
“normal iron diet” group. Other four C57BL/6 wild type and four Hfe-/- mice were fed, during 
one week, with a mix of 50% Harlan 2014 and 50% Harlan Iron Rich (supplemented with 
2.5% carbonyl iron corresponding to 25000 ppm of iron) (TD.06700) following 100% Harlan 
Iron Rich one more week until they were 16 -17 weeks old, consisting in the “high-iron diet” 
group. To confirm the validity of the different diet conditions, non-heme iron concentration 
was determined in the liver of each mouse (n=16). As expected, significantly higher iron 
content was observed in the Hfe-/- mice in comparison with C57BL/6 under the same diet 
(Fig. 3). 
 
Human subjects 
 All patients included in this study were diagnosed and are regularly followed-up at the 
Hemochromatosis Outpatient Clinic of Santo Antonio Hospital (Porto, Portugal) by the same 
dedicated clinician. Patients are all unrelated, and genetically characterized as homozygous 
for the C282Y mutation of the HFE gene. They were recruited to participate in the study in a 
consecutive mode at the time of their regular consultations. Retrospective clinical and 
laboratory data from patients were obtained from the clinical files under the responsibility of 
the clinician in charge. These included a) the individual iron overload profile at diagnosis 
estimated by the total body iron stores measured by quantitative phlebotomies [273], b) the 
actual iron parameters at the time of experiment measured by serum iron and transferrin 
saturation; c) the individual immune-phenotype with determinations of total CD8+ T-
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lymphocyte numbers as well as measures of the CD8+ T subsets of naïve, central memory 
and effector memory cells, and d) measures of CRP as a marker of systemic inflammation. 
For the purpose of phenotypic grouping, HH patients were classified into one of these two 
types: “the low CD8 phenotype” defined as patients with absolute CD8+ T-lymphocyte 
numbers consistently lower than 300x103/ml in at least 5 serial determinations, and the 
“normal/high CD8 phenotype” defined as patients with CD8+ T-lymphocyte numbers 
consistently higher or equal than 400x103/ml. These limits were defined based on the normal 
distribution of values described in the Portuguese control population considering the limit for 
the low CD8 phenotype as the 25% lower percentile and the limit for a normal/high CD8 
phenotype the average value in controls [43, 220]. Clinical and laboratory data from the 
patients have been published previously [30-32, 34, 244]. 
 Healthy controls for the study were consecutively recruited amongst volunteer blood 
donors at the Blood Bank of Santo Antonio Hospital during their regular visits for blood 
donation. 
 
Experimental procedures  
a) Genome-wide expression analysis of CD8+ T lymphocytes from HH patients  
 Twenty-four HH patients were selected for the present experiment which comprised 
two parts: a genome-wide gene expression screening, followed by a gene profiling of 
selected CD8+ T-cell subpopulations. In the first part (genome-wide gene expression 
screening) 10 patients were selected and stratified into the two subgroups of “low” (n=6) or 
“normal/high” (n=4) as defined above. As expected from previously described data [30-32, 
34, 244] , patients in the low group had characteristically a severe iron overload while in the 
other group subjects were asymptomatic. In the second part, 14 previously unselected 
patients were consecutively enrolled for gene expression profiling of sorted CD8+ T-cell 
subpopulations, independently of their CD8 phenotype or iron status. They were at different 
stages of treatment which allowed us to obtain a sample with a wide range of transferrin 
saturation values. A group of 8 healthy blood donors were used as controls. 
 For the purpose of genome-wide screening, CD8+ T lymphocytes from HH patients 
were positively selected from peripheral blood mononuclear cells (PBMCs) that were isolated 
from whole blood or buffy coat samples by density separation over Lymphoprep 1.077g/ml 
density gradient (Axis-Shield). CD8+ T-lymphocytes were positively selected from PBMCs 
(3x107 cells) by Magnetic-Activated Cell Sorting (MACS; Miltenyi Biotec), following the 
manufacturer’s instructions. Total RNA of MACS-purified CD8+ T cells was extracted using 
Mini RNeasy Plus Kit Mini (Qiagen, Valencia, CA) as recommended by the manufacturer. 
RNA concentration and purity were determined using optical density (OD) measurements at 
260 and 280 nm. All the samples had an OD260/OD280 ratio of 1.95 or higher. In each 
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experiment time total RNA concentration was normalized between patients and controls and 
converted into cDNA with NZY First-Strand cDNA Synthesis kit (Nzytech) as recommended 
by the manufacturer. Transcriptional profile of CD8+ T lymphocytes was assessed using the 
GeneChip Human Gene 1.0 ST array (Affymetrix). The RNA processing and hybridization 
steps, carried out at the Genomics Core facility of the European Molecular Biology 
Laboratory (EMBL, Heidelberg), were performed as recommended by the manufacturer. 
Upon filtering and normalization of the raw data, samples were grouped according to the 
CD8 low or normal/high profiles and subjected to a between-group analysis using the 
GeneSpring GX software (Agilent). Genes which exhibited at least a 1.5-fold change in 
expression were considered as up- or down-regulated. Quantitate real-time PCR was used to 
confirm differential expression. 
 For the purpose of gene profiling experiments in separated CD8+ T-cell 
subpopulations, unprocessed peripheral blood samples were stained with the following 
fluorochrome-conjugated mouse anti-human monoclonal antibodies: anti-CD8a APC-eFluor 
780 (eBioscience), anti-CD45RA APC (eBioscience) and anti-CCR7 FITC (R&D System). 
After red blood cell lysis, the subpopulations of CD8+ T-lymphocytes were flow sorted in a 
FACS Aria (BD) instrument according to the gating strategy previously described [31] as: 
naïve (TN, CD8
+CCR7+CD45RA+), central memory (TCM, CD8
+CCR7+CD45RA-) and effector 
memory (TEM, CD8
+CCR7-CD45RA+/-). Samples were sorted until 3000 cells from each gated 
subpopulation were collected. Cells were sorted according to the gating strategy illustrated in 
Fig. 1A. In order to avoid the risk of low representativity after cell sorting, we did not further 
discriminate effector memory cells according to CD45RA expression as previously described 
[31]. This decision was supported by our previous observation that the cell subpopulation 
that mostly contributes to the variation in the total number of peripheral CD8+ T cells, both in 
HH patients and normal controls, is the entire effector memory population [31]. Total RNA 
was isolated from sorted cells using the RNeasy Plus Micro Kit (QIAGEN), according to the 
manufacturer’s guidelines. Gene expression in sorted CD8+ T-cell subpopulations: was 
assessed for a group of specific candidate genes: LEF1, ACTN1, CCR7; NAA50; P2RY8 and 
FOSL2. cDNAs resulting from the reverse transcription reaction with SuperScript First-Strand 
Synthesis System (Invitrogen) were subjected to a first round of PCR amplification with 
specific primers (S6 Table). To quantify the expression levels of all genes of interest in each 
CD8+ T-lymphocyte subpopulation, a second seminested real-time PCR was performed in an 
iCycler iQ5 (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) [274]. At the end of the 
PCR cycling, melting curves were generated to ascertain the amplification of a single product 
and the absence of primer dimers. Results were normalized to GAPDH as endogenous 
control. 
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b) Apoptosis and cell cycle studies in HH patients 
Twenty HH patients and 12 controls were used for apoptosis and cell cycle studies. 
These included 10 patients classified with the low CD8 phenotype and 10 patients classified 
as normal/high CD8 phenotype, as described above. During the study period, patients were 
evaluated at different stages of their treatment course. Four patients were under intensive 
phlebotomy treatment and the remaining 16 were receiving maintenance therapy. The 
inclusion of patients at different stages of iron load was also important in order to allow an 
analysis of cell cycle parameters in relation to a wide range of transferrin saturation values. 
For detection of apoptotic T cells, blood samples were collected into tubes containing 
sodium heparin and PBMCs were separated by centrifugation on the Lymphoprep 1.077g/ml 
density gradient (Axis-Shield) after 12 hour resting at 4ºC. Apoptotic T cells from HH patients 
were assessed through flow cytometry, using the Annexin V-FITC/7-AAD Kit (Beckman 
Coulter, BC), containing FITC conjugated Annexin V, 7-AAD staining solution and Annexin V 
binding buffer, following the manufactures’ instructions. Samples were acquired in a flow 
cytometer EPICS-XL-MCL (BC) using the System II software (BC). Data were analyzed 
using the System II software (BC). The percentage of viable (Annexin V negative/7-AAD 
negative), early apoptotic (Annexin V positive/7-AAD negative) and late apoptotic or already 
dead (Annexin V positive/7-AAD positive) CD8+ and CD4+ T cells was calculated. 
In order to analyze the distribution of CD8+ and CD4+ T cells throughout the cell cycle 
phases: blood sample was submitted to cell surface immunophenotyping with FITC-
conjugated mouse anti-human CD4 or anti-human CD8 IgG mAb followed by staining with 
FITC conjugated rabbit anti-mouse IgG polyclonal Ab and cellular DNA measurement using 
the DNA PREP Reagents Kit (BC) according to a protocol that was described in detail 
elsewhere [275]. After staining, samples were acquired in an EPICS-XL-MCL flow cytometer 
(BC) using the System II software (BC). Data were analyzed using specific software for DNA 
analysis Multicyle for Windows (Phoenix Flow System, PFS). The percentages of CD8+ and 
CD4+ T cells in each cell cycle phase (G0/G1, S and G2/M) were calculated. 
 
c) Genome-wide expression analysis of CD8+ T lymphocytes from Hfe -/- and 
wild type mice 
 Peripheral blood from each mice (n=16) was collected by heart puncture 
(approximately 500µl) and CD8+ T-lymphocyte population was isolated by FACS-ARIA I cell 
sorting using anti-CD8 APC antibody (BD Bioscience). The purities of isolated CD8+ T cells 
were measured by flow-cytometric analysis of cell markers (CD8) and in all samples >95% of 
purity was obtained. The maximum number of CD8+ T cells was sorted by each mouse blood 
sample. Total RNA was extracted with RNeasy Plus Micro kit (QIAGEN) according to the 
manufacture`s guidelines. Total RNA integrity was evaluated by Agilent 2010 Bioanalyzer 
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protocol. To overcome the low RNA concentration, we performed the Ovation Pico WTA 
system protocol by NuGEN to amplify the RNA samples followed by cDNA synthesis using 
the WT Ovation Exon module. 
Transcriptional profile of CD8+ T lymphocytes from mice was assessed using the 
GeneChip Mouse Gene ST 1.0 array (Affymetrix, Santa Clara, CA, USA). The RNA 
processing and hybridization steps, carried out at the Genomics Core facility of the European 
Molecular Biology Laboratory (EMBL, Heidelberg), were performed as recommended by the 
manufacturer. Data from the GeneChip were imported into GeneSpring GX 11.5 software 
(Agilent) and the expression value for each gene was normalized by using the Robust 
Multichip Average (RMA) 16 algorithm. Results were grouped according to mice genotype 
and iron diet conditions, i.e. wild type mice with normal or high-iron diet, and Hfe-/- with 
normal or high iron diet. Genes which exhibited at least a 1.8-fold change in expression were 
considered as up- or down-regulated. 
 
d) Human translational study of the candidate genes found differently 
expressed in Hfe-/- mice 
Subsequent studies were done for the most significantly different expressed genes 
found in mice study, calgranulin genes S100a8 and S100a9, consisting in mRNA and protein 
expression in HH patients and controls. 
Gene expression of S100a8 and S100a9 was assessed in sorted CD8+ T cells from 
HH patients and controls. For this, PBMCs were isolated from whole blood or buffy coat 
samples by density separation over Lymphoprep and CD8+ T-lymphocytes were selected 
MACS, as described above. Total RNA, of MACS-purified CD8+ T cells, was extracted as 
described above. In each experiment time total RNA concentration was normalized between 
patients and controls and converted into cDNA with NZY First-Strand cDNA Synthesis kit 
(Nzytech) as recommended by the manufacturer. Quantitative real-time PCR was performed 
in an iCycler iQ5 (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) using specific primers 
for each gene (S7 Table). At the end of the PCR cycling, melting curves were generated to 
ascertain the amplification of a single product and the absence of primer dimers. Results 
were normalized to 18S gene as endogenous control. In order to access the reproducibility of 
the technique, biological replicates were performed consisting in the analysis of different 
samples of the same patient in different days. This was always done against a different 
control for the experiment of the day (n=12). Since reproducibility of the replicates was 
achieved, all samples were included for analysis (n=12). Paired analysis of patient-control of 
the day was performed. 
Intracellular protein expression of S100a9 was accessed by flow cytometry in total 
peripheral blood samples from 30 HH patients and 13 controls. For this, peripheral blood was 
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collected into K3-ethylene-diamine-tetracetic acid (EDTA-K3)-containing tubes. The blood 
samples were stained with the following fluorochrome-conjugated mouse anti-human 
monoclonal antibodies: anti-human CD3 FITC (eBioscience) and anti-human CD8 PerCP 
(eBioscience). Leukocyte fixation and subsequent permeabilization of the cells was then 
performed using the Fix & Perm Cell Permeabilization Kit (Invitrogen). Anti-human IgG1 
S100a9 PE (sc-53187, Santa Cruz, CA) or the PE-conjugated isotype control was used for 
intracellular staining. Samples were acquired in FACS Canto v.2 flow cytometer (BD) under 
the same conditions, using the FACSDiva software (BD). In each experiment day at least a 
control sample was tested in parallel with patient’s samples. Data were analyzed in the 
Infinicyt software (Cytognos SL, Salamanca, Spain) and the median fluorescence intensity 
(MFI) of the S100a9 expression was determined in neutrophils, monocytes and lymphocytes 
defined according to SSC and FSC characteristics, in CD8+ lymphocytes defined by the 
CD3+CD8+ population after lymphocyte gating and in CD4+ lymphocytes defined as 
CD3+CD8- population after lymphocyte gating. Results were analyzed as a ratio of 
patient/control of the day. 
 
Statistical analysis  
Correlations among variables were analyzed by multiple-variable correlation analysis 
with calculation of various statistics, including covariances and partial correlations. 
Differences in group means or sample distributions were tested respectively by the Student’s 
t-test and the Kolmogorov-Smirnov (KS) two sample test as appropriate. For analysis of 
Affymetrix expression data we used the normalized values. For analysis of individual 
expression values in sorted CD8+ T-cell subsets, a systematic outliers’ exclusion was 
performed in HH patients´ data in order to permit comparisons with controls’ group means 
assuming equal variances. The non-parametric Wilcoxon test for paired samples was used to 
compare mRNA expression levels of S100a8 and S100a9 between patients and controls 
analyzed on the same day. The parametric paired T-test was used to compare protein 
expression of S100a9 by FACS (MFI) between patients and controls analyzed in the same 
day.  
Analysis of differentially expressed genes, resulting from genome-wide studies in 
mice, was clustered into biologically relevant categories using the bioinformatics resources: 
Database for Annotation, Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov/) and Web-based Gene SeT AnaLysis Toolkit (WebGestalt, 
http://bioinfo.vanderbilt.edu/wg2/). For Gene Ontology (GO) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways enrichment analysis, the minimum of two genes 
were required for identification of relevant biological pathway, with statistically significance. 
The p value of 0.05 was taken as the level of statistical significance. Affymetrix data were 
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analyzed in GeneSpring GX software (Agilent) and all other statistical analysis were 
performed with StatGraphics software (Statgraphics Statistical Graphics System, version 
16.0). 
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Supplementary Material 
Fig.1 Positive (A) and negative (B) correlations of S100a8 and S100a9 with the other 
differentially expressed genes. Results were obtained by multi-variable correlation analysis of 
the normalized gene expression values in individual mice on high iron diet conditions. The 
partial correlation coefficients and significance levels (P value in brackets) for the different 
gene combinations are shown. The relative strength of the correlations is highlighted by 
colour grading of blue (for positive correlations) or yellow (for negative correlation). Genes 
are ordered by the strength of their associations with S100a9. 
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Total CD8 T lymphocytes 
(0,09-0,73x106/ml)
naive + central memory 
(0,044-0,459x106/ml)
effector memory                
(0,060-0,403x106/ml) TBIS (1,5-17,4g)
CCR7 n.s. r=+0,95 R 2 =91% (p=0,0032) n.s. r=-0,78 R 2 =61% (p=0,0129)
LEF1 n.s. r=+0,79 R 2 =63% (p=0,0601) n.s. r=-0,70 R 2 =48% (p=0,0379)
ACTN1 n.s. r=+0,87 R 2 =75% (p=0,0249) n.s. r=-0,79 R 2 =62% (p=0,0115)
NAT13 r=-0,79 R 2 =62% (p=0,0070) n.s. r=-0,91 R 2 =84% (p=0,0108) n.s.
P2YR8 r=-0,86 R 2 =74% (p=0,0015) n.s. r=-0,88 R 2 =78% (p=0,0191) n.s.
FOSL2 r=-0,70 R 2 =49% (p=0,0243) n.s. r=-0,81 R 2 =65% (p=0,0525) n.s.
n.s.=not statistically significant
m
R
N
A
 e
x
p
re
s
s
io
n
 l
e
v
e
ls
CD8 T cell subsets
S1 Table: Clinical correlations of the genes identified in the genome-wide differential 
screen. Indicated are the correlation coefficient (r) R squared (R2) and significance level (p) 
values obtained by simple regression analyses between the mRNA expression levels for 
each indicated gene and the clinical variables reflecting the immune-phenotype (CD8 T 
lymphocyte and subset counts) and the iron overload profile defined by estimated total body 
iron stores (TBIS). For each clinical variable are indicated the ranges of values in the total 
HH patient population analysed. 
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S2 Table Genes up and down regulated in Hfe knockout CD8+ T lymphocytes in 
comparison with C57BL/6 mice under normal diet condition 
Transcripts 
ID 
Gene 
abbreviation 
Gene name 
Fold 
Change 
p-
value 
Gene ID 
10493831 S100a8 S100 calcium binding protein A8 (calgranulin A) 16,53 0,00 20201 
10499861 S100a9 S100 calcium binding protein A9 (calgranulin B) 12,96 0,00 20202 
10362674 Rnu3a U3A small nuclear RNA 5,31 0,00 19850 
10436100 Retnlg resistin like gamma 4,67 0,00 245195 
10456005 Cd74 
CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
4,62 0,01 16149 
10372648 Lyz2 lysozyme 2 4,33 0,01 17105 
10444291 H2-Ab1 histocompatibility 2, class II antigen A, beta 1 3,75 0,01 14961 
10493812 S100a4 S100 calcium binding protein A4 3,44 0,00 20198 
10450154 H2-Aa histocompatibility 2, class II antigen A, alpha 3,35 0,01 14960 
10570434 Ifitm1 interferon induced transmembrane protein 1 3,12 0,00 68713 
10551025 Cd79a CD79A antigen (immunoglobulin-associated alpha) 2,97 0,00 12518 
10468517 Mxi1 Max interacting protein 1 2,90 0,03 17859 
10512487 Rmrp RNA component of mitochondrial RNAase P 2,81 0,02 19782 
10444236 H2-DMb1/DMb2 histocompatibility 2, class II, locus Mb1 and Mb2   2,76 0,00 
15000 | 
14999 
10508465 Marcksl1 MARCKS-like 1 2,68 0,00 17357 
10551883 Tyrobp TYRO protein tyrosine kinase binding protein 2,63 0,02 22177 
10508721 Snora44 small nucleolar RNA, H/ACA box 44 2,59 0,03 100217418 
10550509 Pglyrp1 peptidoglycan recognition protein 1 2,50 0,00 21946 
10360070 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 2,49 0,04 14127 
10467979 Scd1 stearoyl-Coenzyme A desaturase 1 2,47 0,03 20249 
10429520 Ly6d lymphocyte antigen 6 complex, locus D 2,40 0,03 17068 
10538871 Gm4964 predicted gene 4964 2,37 0,04 243420 
10440576 Rnf160 ring finger protein 160 2,36 0,00 78913 
10392142 Cd79b CD79B antigen 2,20 0,01 15985 
10558769 Ifitm1 interferon induced transmembrane protein 1 2,19 0,01 68713 
10379727 Gm11428 predicted gene 11428 2,10 0,03 100034251 
10414262 Ear2 
eosinophil-associated, ribonuclease A family, 
member 2 
2,08 0,03 13587 
10349593 Faim3 Fas apoptotic inhibitory molecule 3 2,06 0,00 69169 
10548817 Plbd1 phospholipase B domain containing 1 2,04 0,05 66857 
10466172 Ms4a1 
membrane-spanning 4-domains, subfamily A, 
member 1 
1,99 0,05 12482 
10548535 Klra3 killer cell lectin-like receptor, subfamily A, member 3 1,97 0,03 16634 
10430818 Tnfrsf13c 
tumor necrosis factor receptor superfamily, member 
13c 
1,97 0,01 72049 
10556113 Rbm3 RNA binding motif protein 3 1,95 0,00 19652 
10481627 Lcn2 lipocalin 2 1,91 0,00 16819 
10535458 Zdhhc4 zinc finger, DHHC domain containing 4 1,89 0,03 72881 
10563338 Ppp1r15a 
protein phosphatase 1, regulatory (inhibitor) subunit 
15A 
1,87 0,03 17872 
10422227 Spry2 sprouty homolog 2 (Drosophila) 1,86 0,04 24064 
10398286 Mir342 microRNA 342 -4,69 0,01 723909 
10515694 Szt2 seizure threshold 2 -3,04 0,02 230676 
10503198 Chd7 chromodomain helicase DNA binding protein 7 -3,02 0,01 320790 
10405779 Mir23b microRNA 23b -2,78 0,03 387217 
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S2 Table Genes up and down regulated in Hfe knockout CD8+ T lymphocytes in 
comparison with C57BL/6 mice under normal diet condition (cont.) 
  
  
Transcripts 
ID 
Gene 
abbreviation 
Gene name 
Fold 
Change 
p-
value 
Gene ID 
10456490 Cep192 centrosomal protein 192 -2,66 0,02 70799 
10512827 Gm568 predicted gene 568 -2,50 0,03 230143 
10351043 Snord47 small nucleolar RNA, C/D box 47 -2,50 0,02 100217446 
10410311 Zfp456 zinc finger protein 456 -2,43 0,02 408065 
10447036 n-R5s65 nuclear encoded rRNA 5S 65 -2,39 0,04  
10523134 Pf4 platelet factor 4 -2,35 0,04 56744 
10503218 Chd7 chromodomain helicase DNA binding protein 7 -2,34 0,05 320790 
10434396 Abcf3 
ATP-binding cassette, sub-family F (GCN20), 
member 3 
-2,29 0,00 27406 
10412900 Nkiras1 NFKB inhibitor interacting Ras-like protein 1 -2,21 0,00 69721 
10502934 Rabggtb RAB geranylgeranyl transferase, b subunit -2,21 0,00 19352 
10531776 Fam175a family with sequence similarity 175, member A -2,10 0,00 70681 
10548333 Cd69 CD69 antigen -2,08 0,00 12515 
10457838 Zfp397os zinc finger protein 397 opposite strand -2,04 0,00 328918 
10586250 Dennd4a DENN/MADD domain containing 4A -2,03 0,02 102442 
10546706 Rybp RING1 and YY1 binding protein -2,01 0,02 56353 
10574141 Nlrc5 NLR family, CARD domain containing 5 -1,99 0,04 434341 
10442032 BC002059 
cDNA sequence BC002059, mRNA (cDNA clone 
MGC:6110 ) 
-1,90 0,01 213811 
10410530 Slc6a19 
solute carrier family 6 (neurotransmitter transporter), 
member 19 
-1,90 0,04 74338 
10542156 Clec2d C-type lectin domain family 2, member d -1,89 0,00 93694 
10525487 4932422M17Rik RIKEN cDNA 4932422M17 gene -1,89 0,03 74366 
10522009 Pgm1 phosphoglucomutase 1 -1,87 0,02 66681 
10515363 Mmachc 
methylmalonic aciduria cblC type, with 
homocystinuria 
-1,87 0,05 67096 
10443459 Sfrs3 splicing factor, arginine/serine-rich 3 (SRp20) -1,85 0,00 20383 
10492582 Mir15b microRNA 15b -1,85 0,05 387175 
10501048 Dennd2d DENN/MADD domain containing 2D -1,84 0,02 72121 
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S3 Table: Genes up and down regulated in Hfe knockout CD8+ T lymphocytes in 
comparison with C57BL/6 mice under high iron diet condition 
Transcripts 
ID 
Gene 
abbreviation 
Gene name  
Fold  
Change 
p-
value 
Gene ID 
10493831 S100a8 S100 calcium binding protein A8 (calgranulin A) 34,58 0,00 20201 
10499861 S100a9 S100 calcium binding protein A9 (calgranulin B) 29,21 0,00 20202 
10362674 Rnu3a U3A small nuclear RNA 9,10 0,00 19850 
10435497 Stfa2l1 stefin A2 like 1 6,49 0,05 268885 
10436100 Retnlg resistin like gamma 6,36 0,00 245195 
10456005 Cd74 
CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
3,71 0,05 16149 
10551883 Tyrobp TYRO protein tyrosine kinase binding protein 3,48 0,00 22177 
10399428 Snord118 small nucleolar RNA, C/D box 118 3,25 0,00 100216530 
10377429 Snord118 small nucleolar RNA, C/D box 118 3,25 0,00 100216530 
10383756 Ifitm2 interferon induced transmembrane protein 2 3,18 0,01 80876 
10569017 Ifitm3 interferon induced transmembrane protein 3 3,18 0,03 66141 
10379727 Gm11428 predicted gene 11428 2,89 0,02 100034251 
10444291 H2-Ab1 histocompatibility 2, class II antigen A, beta 1 2,77 0,03 14961 
10551025 Cd79a CD79A antigen (immunoglobulin-associated alpha) 2,74 0,04 12518 
10550509 Pglyrp1 peptidoglycan recognition protein 1 2,65 0,01 21946 
10539577 Spr sepiapterin reductase 2,60 0,04 20751 
10583286 Gpr83 G protein-coupled receptor 83 2,58 0,04 14608 
10545014 Vopp1 
vesicular, overexpressed in cancer, prosurvival 
protein 1 
2,51 0,03 232023 
10360070 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 2,46 0,00 14127 
10427908 Gm9948 predicted gene 9948 2,45 0,02 791293 
10553299 Ifitm2 interferon induced transmembrane protein 2 2,42 0,02 80876 
10344799 Cspp1 centrosome and spindle pole associated protein 1 2,42 0,02 211660 
10527638 Alox5ap arachidonate 5-lipoxygenase activating protein 2,40 0,01 11690 
10368508 2610036L11Rik RIKEN cDNA 2610036L11 gene 2,38 0,02 66311 
10397536 Gm4005 predicted gene 4005 2,37 0,02 100042747 
10588223 Anapc13 anaphase promoting complex subunit 13 2,36 0,01 69010 
10493820 S100a6 S100 calcium binding protein A6 (calcyclin) 2,36 0,00 20200 
10364293 Ube2g2 ubiquitin-conjugating enzyme E2G 2 2,28 0,04 22213 
10473250 Mrpl18 mitochondrial ribosomal protein L18 2,21 0,02 67681 
10569014 Ifitm2 interferon induced transmembrane protein 2 2,21 0,01 80876 
10437963 Fam128b family with sequence similarity 128, member B 2,19 0,00 72083 
10590298 Eif1b eukaryotic translation initiation factor 1B 2,18 0,01 68969 
10452110 2410015M20Rik RIKEN cDNA 2410015M20 gene 2,16 0,01 224904 
10603833 Usmg5 upregulated during skeletal muscle growth 5 2,14 0,02 66477 
10542156 Clec2d C-type lectin domain family 2, member d 2,14 0,01 93694 
10392142 Cd79b CD79B antigen 2,12 0,01 15985 
10412211 Gzma granzyme A 2,11 0,00 14938 
10514466 Jun jun proto-onogene 2,11 0,01 16476 
10575961 Usp10 ubiquitin specific peptidase 10 2,10 0,01 22224 
10356999 Prdx2 peroxiredoxin 2 2,09 0,04 21672 
10517336 Clic4 chloride intracellular channel 4 (mitochondrial) 2,08 0,02 29876 
10440918 Tmem50b transmembrane protein 50B 2,07 0,04 77975 
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S3 Table: Genes up and down regulated in Hfe knockout CD8+ T lymphocytes in 
comparison with C57BL/6 mice under high iron diet condition (cont.) 
 
 
 
  
Transcripts 
ID 
Gene 
abbreviation 
Gene name  
Fold  
Change 
p-
value 
Gene ID 
10362896 Cd24a CD24a antigen 2,05 0,01 12484 
10565081 Timm17a translocase of inner mitochondrial membrane 17a 2,03 0,00 21854 
10576391 Rab4a RAB4A, member RAS oncogene family 1,99 0,03 19341 
10416950 Mir18 microRNA 18 1,98 0,03 387135 
10605943 Pdzd11|Kif4 PDZ domain containing 11 | kinesin family member 4 1,97 0,01 
72621 | 
16571 
10604019 1810037I17Rik RIKEN cDNA 1810037I17 gene 1,97 0,05 67704 
10574151 Nlrc5 NLR family, CARD domain containing 5 1,96 0,02 434341 
10396862 Actn1|Strm actinin, alpha 1 | striamin 1,93 0,01 109711 
10468287 Usmg5 upregulated during skeletal muscle growth 5 1,92 0,03 66477 
10414958 Tcra-V8 T-cell receptor alpha, variable 8 1,92 0,04 100043322 
10450814 Ppp1r11 
protein phosphatase 1, regulatory (inhibitor) subunit 
11 
1,91 0,05 76497 
10487476 1500011K16Rik RIKEN cDNA 1500011K16 gene 1,91 0,01 67885 
10490221 Atp5e 
ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit 
1,91 0,02 67126 
10371002 Lsm7 
LSM7 homolog, U6 small nuclear RNA associated 
(S. cerevisiae) 
1,90 0,05 66094 
10430778 Phf5a PHD finger protein 5A 1,90 0,03 68479 
10345183 Cdk10 cyclin-dependent kinase 10 1,89 0,01 234854 
10349648 Ctse cathepsin E 1,88 0,04 13034 
10603837 Ndufb11 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 11 
1,87 0,02 104130 
10492757 Plrg1 pleiotropic regulator 1, PRL1 homolog (Arabidopsis) 1,87 0,02 53317 
10416199 Entpd4 ectonucleoside triphosphate diphosphohydrolase 4 1,86 0,04 67464 
10512901 Mrpl50 mitochondrial ribosomal protein L50 1,85 0,00 28028 
10450640 Mrps18b mitochondrial ribosomal protein S18B 1,85 0,00 66973 
10449356 AI413582 expressed sequence AI413582 1,83 0,03 106672 
10373577 Ormdl2|Dnajc14 
ORM1-like 2 (S. cerevisiae) | DnaJ (Hsp40) 
homolog, subfamily C, member 14 
1,83 0,02 
66844 | 
74330 
10366043 Dusp6 dual specificity phosphatase 6 1,81 0,04 67603 
10548333 Cd69 CD69 antigen -2,49 0,00 12515 
10396862 Actn1|Strm actinin, alpha 1 | striamin -1,93 0,01 
109711 | 
20904 
10542156 Clec2d C-type lectin domain family 2, member d -2,14 0,01 93694 
10345183 Cdk10 cyclin-dependent kinase 10 -1,89 0,01 234854 
10575961 Usp10 ubiquitin specific peptidase 10 -2,10 0,01 22224 
10574151 Nlrc5 NLR family, CARD domain containing 5 -1,96 0,02 434341 
10344799 Cspp1 centrosome and spindle pole associated protein 1 -2,42 0,02 211660 
10397536 Gm4005 predicted gene 4005 -2,37 0,02 100042747 
10583286 Gpr83 G protein-coupled receptor 83 -2,58 0,04 14608 
10416950 Mir18 microRNA 18 -1,98 0,03 387135 
10416199 Entpd4 ectonucleoside triphosphate diphosphohydrolase 4 -1,86 0,04 67464 
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S4 Table: Functional categories of the significantly different expressed genes between 
Hfe knockout and wild type  
Category Term Count P value Genes 
CLUSTER 1     
SP_PIR_KEYWORDS Immune response 8 3.41E-07 
Cd79a, Cd74, H2-Ab1, H2-Aa, Pglyrp1, Tnfrsf13c, 
Cd79b, Faim3 
GOTERM_BP_FAT 
Antigen processing and 
presentation of exogenous 
peptide antigen 
5 9.42E-07 Cd74, H2-DMb1, Fcer1g, H2-Ab1, H2-Aa 
GOTERM_BP_FAT 
Positive regulation of 
leukocyte activation 
4 1.95E-03 Cd74, Fcer1g, H2-Aa, Tnfrsf13c 
CLUSTER 2 
    
GOTERM_CC_FAT Late endosome 4 2.18E-04 Cd79a, Cd74, H2-DMb1, H2-Ab1 
KEGG_PATHWAY 
Intestinal immune network 
for iga production 
4 4.92E-04 H2-DMb1, H2-Ab1, H2-Aa, Tnfrsf13c 
KEGG_PATHWAY Graft-versus-host disease 4 5.85E-04 Klra3, H2-DMb1, H2-Ab1, H2-Aa 
CLUSTER 3 
    
GOTERM_BP_FAT 
Positive regulation of 
response to stimulus 
6 1.02E-04 Cd79a, Fam175a, Fcer1g, H2-Aa, Tnfrsf13c, Cd79b 
INTERPRO 
Phosphorylated 
immunoreceptor signaling 
itam 
3 1.31E-04 Cd79a, Fcer1g, Cd79b 
GOTERM_BP_FAT 
Immune response-activating 
signal transduction 
3 6.86E-03 Cd79a, Fcer1g, Cd79b 
GOTERM_BP_FAT 
Immune response-regulating 
signal transduction 
3 8.04E-03 Cd79a, Fcer1g, Cd79b 
CLUSTER 4 
    
GOTERM_BP_FAT Immune response 11 1.83E-07 
Pf4, Cd79a, Cd74, H2-DMb1, Fcer1g, H2-Ab1, H2-Aa, 
Pglyrp1, Tnfrsf13c, Cd79b, Faim3 
SP_PIR_KEYWORDS Disulfide bond 17 1.50E-04 
Lcn2, Pf4, Klra3, Tyrobp, Cd79a, Lyz2, H2-Ab1, H2-
Aa, Pglyrp1, Tnfrsf13c, Cd79b, Faim3, Cd74, Fcer1g, 
Ly6d, Clec2d, Cd69 
SP_PIR_KEYWORDS Signal 16 3.59E-03 
Lcn2, Pf4, Tyrobp, Cd79a, H2-DMb1, Lyz2, H2-Ab1, 
H2-Aa, Pglyrp1, Cd79b, Faim3, Retnlg, Gm11428, 
Fcer1g, Ly6d, Plbd1 
INTERPRO 
Ipr007110:immunoglobulin-
like 
5 3.44E-02 Cd79a, H2-DMb1, H2-Ab1, H2-Aa, Cd79b 
CLUSTER 5 
    
GOTERM_BP_FAT 
Positive regulation of 
immune system process 
6 1.67E-04 Cd79a, Cd74, Fcer1g, H2-Aa, Tnfrsf13c, Cd79b 
GOTERM_BP_FAT Go:0001775~cell activation 5 3.60E-03 Ms4a1, Pf4, Cd79a, Cd74, Fcer1g 
GOTERM_BP_FAT 
Go:0045321~leukocyte 
activation 
4 1.86E-02 Ms4a1, Cd79a, Cd74, Fcer1g 
CLUSTER 6 
    
UP_SEQ_FEATURE 
Calcium-binding region:2; 
high affinity 
3 4.23E-04 S100a8, S100a4, S100a9 
UP_SEQ_FEATURE 
Calcium-binding region:1; 
low affinity 
3 4.23E-04 S100a8, S100a4, S100a9 
PIR_SUPERFAMILY Pirsf002353:s-100 protein 3 4.73E-04 S100a8, S100a4, S100a9 
INTERPRO 
Ipr001751:s100/cabp-9K-
type, calcium binding 
3 1.54E-03 S100a8, S100a4, S100a9 
SP_PIR_KEYWORDS Ef hand 3 2.22E-03 S100a8, S100a4, S100a9 
SP_PIR_KEYWORDS Calcium binding 3 6.17E-03 S100a8, S100a4, S100a9 
CLUSTER 7 
    
GOTERM_BP_FAT Leukocyte chemotaxis 3 2.30E-03 Pf4, Fcer1g, S100a9 
GOTERM_BP_FAT Cell chemotaxis 3 2.30E-03 Pf4, Fcer1g, S100a9 
GOTERM_BP_FAT Chemotaxis 4 2.8E-03 Pf4, S100a8, Fcer1g, S100a9 
GOTERM_BP_FAT Locomotory behavior 5 3.09E-03 Pf4, S100a8, Chd7, Fcer1g, S100a9 
CLUSTER 8 
    
GOTERM_BP_FAT Defense response 6 5.11E-03 Cd74, Fcer1g, Lyz2, H2-Aa, Pglyrp1, Clec2d 
GOTERM_BP_FAT 
Defense response to 
bacterium 
3 3.04E-02 Fcer1g, Lyz2, Pglyrp1 
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S4 Table: Functional categories of the significantly different expressed genes between 
Hfe knockout and wild type (cont.)  
Category columm shows the original database/resource from which terms originate. The Term columm indicates 
the enriched terms associated with the gene list. The Count columm indicates the number of genes involved in 
the term. The P value was obtained with the modified Fisher exact test. BP, biological processes; GO, Gene 
Ontology Term; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular functions; PIR, Protein 
Information Resource; UDP, Uridine 5'-diphospho 
  
Category Term Count P value Genes 
CLUSTER 9 
    
GOTERM_MF_FAT Carbohydrate binding 5 7.02E-03 Pf4, Klra3, Pglyrp1, Clec2d, Cd69 
SP_PIR_KEYWORDS Signal-anchor 5 1.81E-02 Klra3, Cd74, Tnfrsf13c, Clec2d, Cd69 
UP_SEQ_FEATURE Domain:c-type lectin 3 2.21E-02 Klra3, Clec2d, Cd69 
INTERPRO 
Ipr018378:c-type lectin, 
conserved site 
3 2.82E-02 Klra3, Clec2d, Cd69 
INTERPRO Ipr001304:c-type lectin 3 3.50E-02 Klra3, Clec2d, Cd69 
INTERPRO Ipr016186:c-type lectin-like 3 4.01E-02 Klra3, Clec2d, Cd69 
SMART Sm00034:clect 3 4.16E-02 Klra3, Clec2d, Cd69 
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S5 Table: Expression levels of iron related genes in CD8+ T lymphocytes from Hfe 
knockout and wild type C57BL/6 mice. The relative levels of expression are highlighted by 
colour grading according to normalized expression values. The significance of the differential 
expression values is indicated by the p value of T-test. 
 
    Normal Iron Diet  
 Gene Protein Hfe
 -/-
 C57BL/6 p value 
Iron storage      
Ftl1 Ferritin L Chain   ns 
FtH Ferritin Heavy chain   ns 
Hmox1 Heme oxigenase   ns 
Iron transport      
Slc25a37 Mitoferrin   ns 
Slc11a2 Dimetal transporter1   ns 
Lcn2 Lipocalin2   0.0016 
Sfxn2 Sideroflexin2   ns 
Slc40a1 Ferroportin   ns 
Abcg2 Bcrp   ns 
Receptors      
Tfrc Transferrin receptor   ns 
Lrp1 LRP/CD91   ns 
Regulators      
Smad4 Smad4   ns 
Smad7 Smad7   ns 
Usf2 Usf2   ns 
Hamp2 Hepcidin 2   ns 
Fxn Frataxin   ns 
Ireb2 IRP2   ns 
BMP6 BMP6   ns 
BMP9 BMP9   ns 
Hamp1 Hepcidin 1   ns 
Hfe2 HJV   ns 
Hfe HFE   ns 
Oxidoreductases      
Cybrd1 Dcytb   ns 
 
      No expression (< 5normalized gene expression value) 
      low expression ([5 a 7[normalized gene expression value) 
      medium expression( [7 a 9[normalized gene expression value) 
      high expression( >9 normalized gene expression value) 
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S6 Table: Sequences of the oligonucleotide primers used for the first and second PCR 
experiments in CD8 T lymphocytes from HH patients. Primers on the top: forward 
primers; Primers on the bottom: reverse primers 
Gene 
Accession 
number 
1
st 
PCR primers 2
nd
 PCR primers 
LEF1 AF288571 
   5’-ATCCCGAAGAGGAAGGCGATT-3’ 
   5’-GCACCACGGGCACTTTATTTG-3’ 
   5’-CCGATGACGGAAAGCATCCAG-3’ 
   5’-GCACCACGGGCACTTTATTTG-3’ 
ACTN1 DQ496098 
   5’-TGAAGATGACCCTGGGCATGA-3’ 
   5’-CAACGATGTCTTCGGCATCCA-3’ 
   5’-GGAAGGATGGCCTCGGCTT-3’ 
   5’-CAACGATGTCTTCGGCATCCA-3’ 
CCR7 BC035343  
   5’-ACTTCCTCCCCAGACAGGGGT-3’ 
   5’-GCCCACGAAACAAATGATGGA-3’ 
   5’-TGGTGGTGGCTCTCCTTGTCA-3’  
   5’-GCCCACGAAACAAATGATGGA-3’ 
NR4A2 BC009288 
   5’-CCCGGTGAGTCTGATCAGTGC-3’ 
   5’-CAATCCATTCCCCAAAGCCAC-3’ 
   5’-GAGAAGATCCCTGGCTTCGCA-3’ 
   5’-CAATCCATTCCCCAAAGCCAC-3’ 
NAA50 BC012731 
   5’-AGCTGGGAGATGTGACACCACA-3’ 
   5’-GCCGACTCATTGCTGATCTGG-3’ 
   5’-GGCACCTTACCGAAGGCTAGGA-3’ 
   5’-GCCGACTCATTGCTGATCTGG-3’ 
P2RY8 NM_178129 
   5’-CCTTTGCAAGGTTGCTGGACA-3’ 
   5’-AGAGAAGAGGTTGCCCGGGAT-3’ 
   5’-TTCTGCCGCTGCTTCTGCA-3’ 
   5’-AGAGAAGAGGTTGCCCGGGAT-3’ 
FOSL2 NM_005253 
   5’-GCTCAGGCAGTGCATTCATCC-3’ 
   5’-TGCAGCCAGCTTGTTCCTCTC-3’ 
   5’-GCGTGATCAAGACCATTGGCA-3’ 
   5’-TGCAGCCAGCTTGTTCCTCTC-3’ 
GAPDH M33197 
   5’-GGTCGGAGTCAACGGATTTGG-3’ 
   5’-ATGGTGGTGAAGACGCCAGTG-3’ 
   5’-CAAATTCCATGGCACCGTCAA-3’ 
   5’-ATGGTGGTGAAGACGCCAGTG-3’ 
 
S7 Table: Sequences of the oligonucleotide primers used for S100a8 and S100a9 
expression studies in sorted CD8 from HH patients and controls 
Gene Primer forward  Primer reverse  
18S rRNA human 5`-CGCCGCTAGAGGTGAAATTC-3` 5`-TTGGCAAATGCTTTCGCTC-3` 
S100a8 human 5`-GTCTCTTGTCAGCTGTCTTTCA-3` 5`-CCTGTAGACGGCATGGAAAT-3` 
S100a9 human 5`-GGAATTCAAAGAGCTGGTGC-3` 5`-TCAGCATGATGAACTCCTCG-3` 
 
 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  
General Discussion 
Conclusions and future perspectives 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
134 
 
 
General Discussion 
135 
 
General discussion 
The general objective of this thesis was to clarify the role of lymphocytes in iron 
homeostasis, using the clinical model of Hereditary Hemochromatosis (HH). Due to some of 
its genetic characteristics, HH offers an excellent biological context to study the interactions 
between the immune system and iron. First, the gene implicated in this iron-overload 
disorder, HFE, is a non-classical MHC-class I gene, localized in the MHC genetic region, a 
cluster of highly related genes involved in immune responses [27]. HH patients are 
homozygous for the p.C282Y mutation in the HFE gene which is found in strong linkage 
disequilibrium with particular HLA-A alleles. Moreover, the inheritance of some specific HLA 
haplotypes predisposes HH patients to display a phenotype of low numbers of peripheral 
CD8+ T lymphocytes strongly associated with their clinical severity in terms of iron overload. 
These special features led to the definition of two specific goals in this thesis: i) to clarify the 
genetic contribution of the MHC-class I region to the setting of CD8+ T lymphocyte numbers, 
and ii) to elucidate the mechanisms through which lymphocytes may act as modifiers of the 
clinical expression in HH. 
 
HH and its MHC heritage 
The MHC genetic region is one of the most gene-dense and polymorphic regions of 
the human genome. It is also the genomic region most strongly associated with disease 
susceptibility, especially with autoimmune and infectious diseases [276]. This is a fact largely 
attributed to the high density of genes related with immune functions found in this region, in 
particular the human leukocyte antigen (HLA) class I and class II genes. In this context, it is 
interesting to note that HH provides one of the most remarkable examples of HLA-disease 
association. The finding of a very high frequency of the HLA-A*03 allele associated with 
hemochromatosis [19] constituted the first step leading to the later positional cloning of the 
HFE gene 4Mb distant from the HLA-A cluster. The finding that the vast majority of HH 
patients are homozygous for a single mutation (p.C282Y) that abrogates HFE function [27], 
and the evidence of iron overload in mouse models lacking Hfe, all constitute strong 
evidence to support a causal effect for this genetic alteration. Nevertheless, considering this 
strong association to the disease in the context of the MHC high gene density, the strong 
linkage disequilibrium and the extreme polymorphism and clustering of genes with related 
functions in so many diverse immune cell functions, it turns highly complex to determine the 
true causative effect of the disease-associated HFE allelic product. Relevant to this concept 
was the finding that a highly conserved microhaplotype (A-A-T) localized in the region 
between HFE and HLA was associated with both a phenotype of low CD8+ T lymphocyte 
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numbers and a more severe iron overload in Portuguese patients [44], suggesting that other 
genes in this region could also be involved in the disease process. 
One of the specific objectives of this thesis was to test if the previously found 
association of the A-A-T microhaplotype as a predictive phenotype marker in Portuguese 
patients was also observed in other geographically distant populations. The results, 
described in detail in chapter 3.1, clearly show that the predictive value of this haplotype 
cannot be generalized worldwide. We found that the low CD8 phenotype was associated with 
the most conserved haplotypes carrying A-A-T and the HLA-A*03 allele in the populations 
from Porto (Portugal) and Alabama (USA) but not in the population from Nord-Trøndelag 
(Norway). Because the low CD8 phenotype is generally associated with a more severe iron 
overload phenotype, we speculate that these genotype/phenotype differences could explain 
the presence of clinical symptomatology in Alabama and Porto patients while Nord-
Trøndelag patients are mostly asymptomatic [171, 197]. Assuming the existence of a major 
genetic determinant of CD8+ T-lymphocyte numbers that is transmitted in linkage 
disequilibrium with HFE in its ancestral haplotype, we considered that the population from 
Porto, by keeping the strongest genotype-phenotype association, would be the ideal 
population to allow further narrowing of the region of interest to look for a candidate locus 
associated with the transmission of the trait. With that purpose, 43 HH patients and 105 
normal individuals from north Portugal were genotyped for 63 markers in the chromosomal 
region between HFE and HLA-B. The results, described in detail in chapter 3.2, were 
somehow surprising in the sense that the inclusion of additional markers did not narrow the 
region previously defined by the A-A-T microhaplotype. Instead, a higher homology was 
found among patients with different phenotypes suggesting that either the putative major 
quantitative trait locus (QTL) is localized beyond the defined limits, or the coverage of the 
region was still insufficient to find better markers. One additional possibility is that the low 
CD8 trait may be defined by the combination of multiples genes in a more extended region. 
Although this study did not provide, as originally expected, a great advance in the positional 
cloning of a major QTL for CD8+ T lymphocyte numbers, it revealed, however, a novel 
important aspect of MHC genetics. This was the evidence that the long recognized 
recombination suppression found in this chromosomal region depends on the haplotype 
structure and allele combination in highly conserved haplotypes, observed in both HH and 
normal chromosomes. This finding not only helps explaining the evolutionary history of HH 
carrying haplotypes and its strong association with a low CD8 phenotype (in particular in 
HLA-A*03B*07 carrying haplotypes), but also suggests, for the first time, that the process of 
recombination suppression involves the combination of particular gene alleles in a restricted 
region close to HLA [277, 278]. 
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While providing new insights on the commonly reported phenotype of low CD8+ T 
lymphocytes in HH patients, the study described above followed a purely genomic approach 
and could thus not provide any indication of how lymphocytes may influence iron overload. In 
order to approach this question, a series of functional studies were performed, both in vitro 
and in vivo, which are referred to in the next paragraphs. 
The Lymphocyte pool: a new circulating iron storage compartment 
Iron homeostasis classically involves four major compartments: the uptake 
compartment (enterocytes), the functional compartment (erythroid precursors or other 
proliferating cells), the recycling compartment (spleen macrophages), and the storage 
compartment (hepatocytes and macrophages). Work performed in the context of this thesis 
placed, for the first time, the lymphocyte pool as a new “circulating storage compartment”. 
This was mostly based on the demonstration that circulating T lymphocytes are able to take 
up and retain iron acquired in the form of NTBI. Moreover, we identified Fe3Cit3 as the 
predominant oligomeric iron-citrate species in iron-overload physiological conditions, and the 
one that is preferentially taken up by T cells and hepatocytes (published in Arezes et 
al.2013)[234]. Whilst we argue that T lymphocytes are important players in systemic iron 
homeostasis, we appreciate that the remaining blood cell types, may also contribute to the 
fine-tuning of iron homeostasis. As previously described, the ability to take up NTBI was also 
observed in other circulating blood cells such as reticulocytes and erythrocytes [279, 280], 
monocytes, eosinophils, basophils, neutrophils and platelets [281]. The ability of these cell 
types to buffer the NTBI and keeping it away from target organs may depend on their 
retention capability and selectivity for the NTBI species that is present in circulation. 
The observation that T lymphocytes are able to take up and retain NTBI raised the 
following questions: what is the fate of the NTBI taken up by lymphocytes? What is the 
physiological implication of these findings in vivo? 
The fate of intracellular NTBI taken up by T lymphocytes was addressed in the paper 
published by Pinto et al in 2014 where we describe an increase in the labile iron pool (LIP) 
content in response to incubation with 5µM Fe-citrate. Besides using intracellular iron to 
proliferate, T cells also increase their iron-storage capacity in response to NTBI uptake by 
up-regulating ferritin levels [269]. Previous studies addressing the response of ferritin to NTBI 
in lymphocytes showed contrasting results [282-285] and this could be explained by the use 
of distinct iron donors and of non-physiological NTBI concentrations. We argue that the use 
of ferric citrate as iron donor, the maintenance of citrate concentrations between the 
physiological interval of 60–140 μM [286] and the use of iron concentrations within the range 
that is commonly found in iron overload situations [230] are the correct experimental 
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conditions and should become the standard procedure for future studies involving biological 
systems and NTBI. 
 
Fig.1 Proposed model of NTBI storage and further utilization for cell growth. NTBI is rapidly cleared from 
circulation by hepatocytes. Circulating T lymphocytes are the first cells in contact with the NTBI. NTBI in the blood 
stream is taken up by T lymphocytes, where it integrates the intracellular labile iron pool (LIP) and the ferritin 
stores (*). These cells, and possibly others, constitute the “circulating” iron storage compartment. When the 
circulating and liver NTBI clearance capacities are exceeded, other cell types, such as pancreatic beta cells or 
cardiomyocytes, also take up NTBI, with iron accumulation in the respective organs (pancreas, heart). Besides 
constituting a first line “safe” deposit of iron, T lymphocytes (and possibly other circulating cells) could also 
contribute to iron distribution and delivery to other cells and tissues, either in normal physiological (homeostatic 
erythroid/lymphoid proliferation) or pathological conditions (stress erythropoiesis, inflammation, tumor growth). T 
lymphocyte-derived iron uptake by target cells could occur as transferrin-bound iron (Tf-Fe) or as NTBI, which 
could be exported directly via ferroportin or, eventually, by ferritin secretion, as proposed earlier (Dörner et al., 
1980[287]). (Adapted from Pinto et al 2014) 
 
The physiological implications of the capacity of T lymphocytes to store NTBI was 
addressed in vivo, firstly in a mouse model deficient in T lymphocytes, the Foxn1null mouse, 
fed with an iron-sufficient or iron-rich diet (Pinto et al. 2014)[269]. Foxn1null mice fed with iron-
sufficient diet did not increase the liver iron stores, confirming that the deficiency of T 
lymphocytes alone is not the cause of iron overload. Under an iron-rich diet, however, 
Foxn1null mice displayed higher stores than the normal T cell phenotype (Foxn1+/-) under the 
same diet condition. To trace the NTBI, we have injected Foxn1null fed iron-rich diet with 
radiolabeled 55Fe -citrate and 55Fe was measured in the liver. By transferring T lymphocytes 
from Foxn1+/- into Foxn1null mice, we showed that the reposition of circulating T lymphocytes 
lowers the liver iron stores. This decrease in the liver iron content was directly proportional to 
the number of transferred CD8 T cells and this effect was not due to alterations in intestinal 
iron absorption since no changes in liver hepcidin mRNA levels were observed in response 
to T lymphocyte transfer. As a whole, these results support our hypothesis that T 
lymphocytes take up circulating NTBI preventing its accumulation within parenchymal cells, 
therefore protecting the liver, as well as other target organs, from tissue damage. 
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One important point addressed in this thesis was the extension of the above 
mentioned question to the human model. Taking the results obtained with the mouse model 
into consideration, we would expect patients with low numbers of CD8+ T lymphocytes to be 
more prone to develop a more severe iron accumulation, due to a lower remodelling 
potential. In fact, results of the in vitro human CD8+ T cells experiment (described in detail in 
chapter 3.3) corroborated the “remodelling hypothesis” observed in the Foxn1null iron-
overloaded mice. After assessing the NTBI retention capacity of HH CD8+ T cells, their 
systemic storage potential was estimated and shown to correlate strongly with the transferrin 
saturation at the time of the experiment. Moreover, the NTBI retention profile of each patient 
reflected the pattern of iron re-accumulation after depletion of the iron stores. 
It remains elusive whether the patients’ low retention capacity by T cells is under a 
systemic regulation by hepcidin or is only due to a hepcidin-independent higher iron export. 
The fact that, in spite of a deregulated hepcidin expression, the absolute levels of serum 
hepcidin in HH patients may be within the normal range supports the idea that an additional 
mechanism may be directly regulating the iron export by targeting ferroportin independently 
of hepcidin. A response to this question was, however, out of the scope of this thesis. 
 
HFE and CD8+ T lymphocytes: beyond the iron field 
Previous studies in HFE-HH patients consistently reported the existence of specific 
abnormalities in CD8+ T lymphocyte functions including defective lymphocyte-specific protein 
tyrosine kinase (p56lck) activity, decreased cytotoxic activity, decreased number of CD8+ T 
cells expressing the co-stimulatory molecule CD28, a higher number of CD8+ T cells lacking 
CD28, and an abnormally high percentage of HLA-DR-positive activated T cells [29, 152, 
170]. Based on this knowledge, one of the main objectives of this thesis (described in detail 
in Chapter 3.3) was to question if there was any direct impact of HFE on the differentiation 
and activation profile of CD8+ T lymphocytes. For that purpose, two gene expression 
microarray approaches were used. Firstly, we compared the transcriptional profiles of CD8+ T 
cells of HH patients with high or low numbers of these cells at the periphery. We observed 
that the fold-changes of the differently expressed genes between the two groups were lower 
than 2, suggesting that there were no major functional differences in CD8+ T cells from these 
two groups of patients. Nevertheless, we found a set of differentially expressed genes, which 
were significantly associated to the relative representation of specific CD8+ T subpopulations 
of naïve, central and effector memory cells. Genes derived from this screening were further 
validated in a larger number of HH patients and their expression compared between patients 
and normal controls. The most differentially expressed genes between these two groups 
were P2Ry8, which was increased in CD8 central memory cells (CD8CM), and LEF1, which 
was down regulated in CD8 effector memory cells (CD8EM) of HH patients in comparison to 
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controls. These results pointed to HFE as a potential player in the differentiation step of 
central-memory to effector memory which is in agreement with the previous observation of 
lower numbers of CD8EM reported in HH patients [31]. Interestingly, in this same study 
Macedo et al reported that the lower numbers of CD8EM cells in patients carrying the A-A-T 
haplotype in homozygosity when comparing with patients carrying the G-G-G haplotype is 
mainly due to reduced numbers of CD8EM CD27
-CD28- [31]. An effect of other MHC-linked 
genes on the differentiation process and setting of CD8+ T cells can thus not be discarded. 
In order to study the expression profile of CD8+ T cells without the confounding effect 
of MHC variability, which is seen in human patients, we further addressed the impact of HFE 
on the transcriptional profile of CD8+ T lymphocytes in the murine disease model of Hfe 
deficiency. One should bear in mind, however, that the Hfe-/- mouse model does not fully 
recapitulate the complete phenotype of HH patients, namely the defects in CD8+ T cell 
numbers. One of the characteristics of the Hfe-/- animal model is that all mice share a 
common MHC background, which may justify the homogeneity in CD8+ lymphocyte 
phenotypes. Our genome-wide expression profiling results in the Hfe-/- and wild-type mice 
revealed that the most enriched functional categories of differentially expressed genes in Hfe-
/- mice when comparing with wild-type mice were related with the signaling and activation of 
CD8+ T cells. Moreover, we identified calgranulins as the most differentially up-regulated 
genes in Hfe-/-, a result further confirmed in CD8+ T cells from human HH patients, which 
raises the possibility that these mediators may be players on a common pathway with HFE. 
The above mentioned results suggesting an activation state of CD8+ T cells in Hfe 
deficiency in vivo are supported by a recent in vitro study by Reuben et al, who describe that 
the co-transfection of APC cells with the full length gp100 melanoma antigen in combination 
with HFE WT inhibits the activation state of CD8+ T lymphocytes [224]. In contrast to the co-
transfection with p.H63D mutated HFE, p.C282Y mutated HFE or control HLA-A1 constructs 
were not able to reproduce the WT inhibitory effect and could not downregulate to the same 
extent the secretion of several soluble factors such as IL-13, MIP-1β, INF-Ƴ and sTNFR, 
leaving CD8 T cells in a more activated state. Moreover, Reuben et al identified the α1-2 
domains as the participants on the inhibitory effect of CD8+ T-lymphocyte activation. These 
domains are known to share specific chaperone binding sites with MHC Class I molecules. 
Considering the dual role of HFE as a monitor of circulating iron levels and 
simultaneously a controller of signalling and T cell activation discussed above, one has to 
consider its implications in two conditions where cells compete for iron in the context of an 
immune response: one is infection and another is cancer. Infection has been claimed as a 
potential driving selective force for the observed high frequency of the p.C282Y mutation in 
normal populations. In the context of epidemics, it is important to consider the putative 
impact of MHC related selection. It is plausible to accept that during the plague period 
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caused by Yersinia pestis, those individuals with the p.C282Y mutation would be better 
equipped to resist the infection since their macrophages, kuppfer cells and enterocytes 
display an iron depleted phenotype that may offer an additional protection against the growth 
of intracellular pathogens. Considering the possibility of a more activated immune system 
with increased recognition of MHC-I antigens by CD8+ T cells lacking surface HFE, this could 
be an additional advantage for pathogen clearance. 
In terms of the impact of HFE in cancer biology, it was recently shown that tumor cells 
increase HFE expression at cell membrane [288]. The same study also reported a reciprocal 
regulation where activated CD3 T cells were able to inhibit the HFE expression in tumor cells 
lines [288]. Down-regulation of HFE in tumor cells lines was shown to be mediated by CD4+ 
and CD8+ T lymphocytes through secretion of IFN-Ƴ and TNF [288]. The increased HFE 
expression is intriguing in the perspective of tumor growth and any interpretation is, so far, 
merely speculative. One possible reason why tumour cells increase HFE expression would 
be to down-regulate the MHC-I antigen processing and presentation, thus escaping immune 
surveillance. 
 
S100a9 a new mediator in the HFE-CD8 crosstalk 
From the clinical point of view, the finding that the S100a8 and S100a9 calgranulins 
were the most differentially regulated genes in CD8+ cells of Hfe-/- is of great relevance, 
especially since we confirmed that the expression of these calgranulins is also increased in 
peripheral blood cells from HH patients. This was the first description of up-regulated 
expression of these proteins in the context of HH, an iron overload disorder strongly 
associated with alterations in the immune system, particularly of CD8+ T lymphocytes. 
Previous studies in a mouse model of autoimmune disease suggested that S100a8 and 
S100a9 proteins function as TLR4 ligands on CD8+ T cells, which in turn upregulate IL-17 
expression and induce autoimmunity in mice and humans [255]. The same TLR4 and TLR3 
signaling pathways were shown to be able to down-regulate HFE protein and ferroportin 
expression in the spleen after activation with LPS and polyinosinic:polycytidylic acid, 
poly(I:C) treatments [289]. Although these studies did not address the eventual autocrine 
performance of calprotectins, they suggest, however, that the TLR4 signaling pathway may 
be a common target for both iron regulation and immune activation, and that S100a8 and 
S100a9 may somehow have an important role in the process. Although these two proteins 
are known to function as an S100a8/S100a9 heterodimer called calprotectin, they may also 
act independently. We reported a high expression of S100a9 in CD8+ T cells from HH 
patients, in contrast with a low expression of S100a8. Other authors have also stressed an 
independent role for S100a9. For example, local production of S100A9 has been described 
to induce monocyte production of pro-inflammatory cytokines like TNFα, IL-1β and IL-6, and 
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of chemokines like MIP-1α and MCP-1, which in turn could modulate the whole immune 
response [271]. Moreover, S100a9 autocrine activation stimulates the production of IL-6 and 
TNF-α production by T lymphocytes. Considering that, as previously referred, TNF-α 
production by T lymphocytes is able to down-regulate HFE expression in tumor cell lines 
[288], and the recent finding that S100a9 local production in breast tumor is associated with 
a reduced metastatic rate, and therefore a better prognostic [290], we may speculate that 
S100a9 and HFE could synergistically modulate the immune responses mediated by either 
iron or inflammation. 
 
Conclusions and future perspectives 
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Conclusions and future perspectives 
Altogether, the data presented in the different chapters of this thesis highlight and 
strengthen our view of lymphocytes as important players in iron homeostasis, and increase 
our knowledge of the interaction between CD8+ T lymphocyte anomalies in Hereditary 
Hemochromatosis (HH) and of its genetic background in the context of the MHC cluster 
genes. 
The extensive linkage disequilibrium at the entire 4Mb region between HFE and HLA, 
within the MHC class I cluster, naturally favoured the detection of several genotype-
phenotype associations in HH, starting from the historical HLA-disease association to the 
discovery of the HFE p.C282Y causing mutation, and to the most recently described 
association with a genetic trait involved in the transmission of CD8+ T lymphocyte numbers. 
Because, in general, recombination is assumed to be lower in the MHC than in other regions 
of the genome, this fact alone could justify the remarkable genotype/phenotype associations 
found in HH. The results we describe here, however, suggest for the first time that 
recombination suppression may be selectively favoured in the context of particular haplotype 
combinations in the region between HFE and HLA, and this interpretation offers a good 
explanation for the differences in genotype-phenotype associations found among 
geographical distant HH populations, who probably had different recombination histories or 
founder effects.  
Work presented in this thesis also brought into light some mechanisms that may 
explain how CD8+ T lymphocytes act as modifiers of iron overload. We demonstrated that 
CD8+ T cells are able to take up and retain NTBI and identified the specific oligomeric 
species Fe3Cit3, as the most physiological NTBI form that is preferentially internalized by 
these cells. Based on these findings, we hypothesized that the NTBI clearance from 
circulation by these cells avoids the accumulation within hepatocytes or other tissues where 
it may be toxic. Evidence is missing, however, on the mechanisms involved in NTBI uptake, 
transport and signaling by lymphocytes. From the transcriptional study of the CD8+ T cells in 
the context of Hfe deficiency (Hfe-/- mice) we concluded that Hfe impacts on their function by 
up-regulating several genes involved in T cell activation, signaling and differentiation. The 
observation that the most striking difference in the Hfe-/- mice was the higher expression of 
S100a9, and that its expression is also increased in CD8+ T lymphocytes from HH patients 
points for the first time to the importance of this calgranulin in the disease process.  
In terms of future perspectives, continuing work in this field may prove to be important 
to clarify some aspects of disease expression in HH that remain elusive. We plan to further 
characterize the S100a9 protein expression in CD8+ subpopulations and to measure the 
protein concentration in the serum of HH patients as a new marker to address the clinical 
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heterogeneity among patients. Based on the previously described role of S100a9 as a major 
player in autoimmune diseases such as rheumatoid arthritis, and its association with a CD8 
autoreactive phenotype, we will be particularly interested on its involvement in HH-related 
arthropathy. Another implication of our work in terms of future directions is the possibility of 
better approaching the positioning of a putative major genetic trait involved in the 
transmission of CD8+ T lymphocyte numbers. We are presently conducting a deep 
sequencing analysis covering the entire exonic region between HLA-DRB1 and HFE in 
samples from Portuguese HH patients. Sample selection for this study took into account the 
information obtained in our high-density mapping. In particular, we have chosen patients with 
a conserved haplotype structure despite divergent CD8 phenotypes, as well as patients with 
the highest haplotype heterogeneity despite a common low CD8 phenotype. With this 
strategy, we hope to effectively narrow the region of interest to look for major quantitative 
trait loci marking the CD8 phenotype in HH patients. 
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